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Abstract 
Our knowledge of the genetic contribution to Amyotrophic Lateral Sclerosis (ALS) is rapidly 
growing, and there is increasing research into how ALS spreads through the motor system and 
beyond. This thesis examines how genetic and non-genetic factors in ALS influence its spread. 
The genetic methods employed were PCR, genotyping, AFLP, DNA sequencing and gene 
expression. The methods to examine spread were H&E staining, clinical history, age of onset 
(AOO), survival and health utility. Statistical procedures applied included regression analyses of 
genetic and non-genetic factors, maximum likelihood estimation of genetic-phenotype variance 
and health utility, RNA-sequence analyses, and differential gene expression analysis. 
I found (A) that variation in the ATXN2 gene contributes to ALS, as does variation in C9ORF72 
after correcting for the known C9ORF72 pathological hexanucleotide repeat (HREM). (B) On 
comparing regions of the spinal cord, patterns of differential gene expression between ALS cases 
and controls appeared consistent with spread and pathology. Functional annotation clustering 
revealed these genes were mostly involved in blood vessel and angiogenin-like function, 
glycoprotein-based activity, and leukocyte activity. (C) A significant proportion of survival variance 
in ALS could be explained by genetic variance. There were SNPs that predicted survival and 
AOO, one showing epistasis with the C9ORF72 HREM. (D) When modelling ALS progression 
using staging and a clinical trial dataset, the time and duration of each stage was statistically 
predictable. Staging also predicted health utility and other functional and psycho- metrics. 
The spread and pathology in ALS spinal cord regions affected gene expression profiles, which is 
likely a consequence of genetic susceptibility in that region. Indicators of spread, AOO and 
survival, could be predicted using genotypes. Disease progression was predictable as measured 
by clinical staging and health metrics. In summary, ALS spread seems to occur at a fixed rate in 
an individual and is influenced by genetics. 
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Chapter 1 Introduction and Literature Review 
1.1 Introduction 
The cause and manifestation of Amyotrophic Lateral Sclerosis (ALS) is something we know little 
about, although in the last five years there have been accelerating advances in our understanding 
of the genetics, and interesting observations of how the disease seems to spread through the 
central nervous system (C.N.S.). This thesis examines both the genetics and the spread of ALS 
together, attempting to reconcile these two fundamental components of its pathology.  
We are confident that in ALS there is an orchestra of different genetic mutations that contribute 
to this pathology. Some share common disease mechanisms; some we see more prevalent than 
others; some are much more severe than others; but ultimately we do not know the means by 
which any of these mutations cause ALS. Ways to explain these various findings include 
computational network-modelling of genetic-cellular pathways, high-resolution exome 
sequencing, and increasingly powerful genome-wide association tests involving thousands of 
cases and controls. The literature review below shows that ‘older’ methods have been the 
dominant means of ALS genetic discovery in the last few years, more so than the more recently 
devised methods that are listed above. There are many reasons these “new tools” have not yet 
reached their full potential in ALS research.  It could be that these contemporary methods have 
yet to become useful for ALS in their development cycle, or that less contemporary methods are 
more useful for ALS because of the nature of the disease itself, which tend towards finding, in this 
case, more penetrant Mendelian mutations. Summating findings in western-dwelling Caucasians 
we find Mendelian mutations account for approximately 75% of familial ALS and 14% in those 
without a recognisable family history1. In addition we are beginning to see common functions 
among ALS genes, such as RNA processing2 and protein recycling3, which suggest they are of 
pathological importance in the disease. 
ALS is increasingly being viewed as an oligogenic disease4 and which genetic mutations are 
causal or modifiers of its phenotype are not yet clear. Why specific ALS genetic mutations 
correlate with a quicker disease progression is currently unknown; we hypothesise that perhaps 
- 18 - 
such genetic factors influence ALS progression by influencing disease spread through anatomy 
leading to a function of time. Nearly 150 years of clinical observations of ALS have informed 
research on the implicated neuroanatomy, but important questions are still left unanswered. For 
example, where does the disease begin (if anywhere), how does it spread in the C.N.S. and why 
is the disease highly variable in its duration and its presentation? Major obstacles stand in the 
way; for instance, symptomatological variability itself makes it difficult to study, the disease's wide 
pleiotropy with other neurodegenerative diseases is a confounding factor, and no convincing 
biomarkers are studiable as the patient is alive, and post-mortem proteomic and other biomarkers 
can be too profuse and too assorted to lead to clear hypothesis-generation. 
The characterisation of ALS disease spread has been a relatively neglected area in ALS research. 
What is known is that the disease seems to begin at a focal location and moves towards an end-
state, where ALS has engulfed the majority of upper and lower motor neural functionality. This is 
surprising because ALS is regarded as the result of a combination of genetic mutation and 
environmental exposure, and the idea that ALS is caused by ubiquitous aberrantly expressing 
genes and, at the same time, by an event at a specific anatomical location, which then 
progressively spreads throughout the motor system, is not immediately obvious. Clinical, 
neuropathological and neuroimaging studies show ALS focal-to-diffuse disease spread is evident; 
so then what is the contribution of the genetic mutations found in ALS?  
The main experimental section of this thesis begins by testing genes suspected to be involved in 
ALS. This is mainly performed using genotyping and bioinformatic analyses. Following this I use 
gene expression to examine differentially expressing genes stratified by anatomy and inferred 
disease location and stage. I then use the genotype data to examine ALS phenotypes that are 
hypothesised to affect disease spread; age of onset (AOO), survival and onset location. Survival 
is an obvious indicator of disease spread and progression, but I believe that AOO and onset 
location is also, as they both directly influence ALS survival. And the final chapter examines the 
progression of ALS using King’s ALS Clinical Staging, which standardises survival and onset 
location, to present a predictable model of disease progression measured using healthy utility, 
health-related quality of life and a psychometric measure of depression and anxiety. 
- 19 - 
My overarching aim is to present a round and wide exploration of the genetics and disease spread 
of ALS in the same conceptual framework.  
 
1.2 Literature review of genetic discovery in ALS 
1.2.1 Genetic Risk Factors 
ALS is commonly considered a condition that is inherited in 5% and otherwise sporadic5-7. 
Although there are families in which transmission is clearly autosomal dominant with almost 
complete penetrance, in many cases the situation is less clear cut, with second or third degree 
relatives affected 8. Because many do not know their relatives beyond such relationships, it is not 
clear whether a more distant family history is common or even relevant in ALS, but it is likely that 
at least some cases of sporadic ALS represent examples of familial clustering on a coarse scale 
that is not apparent to patients or medical staff. The risk to relatives in such families would 
therefore be greater than the background lifetime risk of 1 in 400 9. Thus the distinction between 
familial and sporadic ALS is to some extent artificial, although convenient for the purposes of 
research. There is now considerable evidence for a genetic contribution to familial and sporadic 
ALS. Several genes have been shown to be mutated in familial ALS, and these will be discussed 
here. Mutations of every such gene have also been identified in sporadic ALS, and while 
causation is more difficult to show in this situation, it seems reasonable to assume that a 
pathogenic mutation causing familial ALS is responsible for sporadic ALS when found in someone 
with no family history10-12. The heritability of sporadic ALS has been estimated as 0.61 (0.38 to 
0.78) 13 and there are now several robustly replicated genetic associations. Although, in common 
with many other diseases, much of the heritability remains to be explained, newer genetic 
techniques such as next generation sequencing and epigenetics are likely to find the genetic 
variation responsible. Because the list of ALS genes is frequently changing, a complete list is 
available with relevant literature and bioinformatics links at the ALS Online Genetics Database, 
http://alsod.iop.kcl.ac.uk14.  
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Several methods exist for gene identification. Family based methods generally rely on a statistical 
method known as linkage, although other techniques such as homozygosity mapping will work in 
specific circumstances. When family-based methods are not possible, association studies are 
usually the alternative, and these can either be based on study of a specific candidate gene or by 
an unbiased approach such as genome-wide association. 
 
1.2.2 Genes identified through family-based studies 
1.2.2.1 SOD1 
Inherited forms of adult onset motor neuron degeneration were recognised in the 1800s 15, and 
ALS was one of the first conditions in which linkage to a gene was observed. Mutations in SOD1, 
responsible for about 2% of all ALS10, were first identified in 199316, 17, and there are now more 
than 150 mutations of SOD1 known affecting all parts of this small, five exon gene 
(http://alsod.iop.kcl.ac.uk)18, 19. The pathogenic mechanism remains unknown despite intensive 
efforts although it is clear there is a gain of some toxic function. One of the major problems to 
understand is how mutations occurring almost anywhere in the molecule20 can result in the same 
toxic gain of function with the same mode of inheritance and the same specificity for motor 
neurons.  
The commonest SOD1 mutation in the US is A4V21, accounting for nearly 50% of those with 
SOD1 mutation22 and associated with an aggressive form of ALS with short survival23. The alanine 
at codon 4 is essential for the structural integrity of the SOD1 protein24, 25, but this is not 
necessarily the mechanism of action as other mutations with no such role can result in ALS as 
well. Efforts to classify SOD1 mutations by structural effect have not led to any obvious 
relationship between phenotype and mutation effect (http://alsod.iop.kcl.ac.uk).  
The D90A mutation is the commonest worldwide and is interesting in several respects. First, it is 
the only mutation that shows a clear recessive inheritance26. There are individuals with ALS who 
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are heterozygous for D90A12, 27, but it is likely that in these cases it is one of several contributors 
to the burden of disease liability. Second, the phenotype of those who are homozygous is 
characteristic, with slowly ascending symmetrical paresis. Third, the phenotype of those 
heterozygous for D90A is often more severe and aggressive than those with homozygous 
genotypes12. Fourth, because it reaches polymorphic frequency in parts of Scandinavia, the 
distinction between sporadic and familial disease is meaningless, as two carrier parents can occur 
by chance and the familiality of the disease is then a product of chance and sibship size, while in 
other cases, an affected homozygous individual having children with a carrier will generate an 
apparently dominant pattern of inheritance. Fifth, founder studies have shown a single worldwide 
founder based in Russia or Scandinavia about 50 generations ago27. In contrast to A4V, the D90A 
mutation does not appear to have much effect on any aspect of SOD1 function or structure26, 28. 
The G93A mutation has been the subject of extensive research through transgenic animal 
models29 but again, the mechanism of action is unclear but may include inducing apoptosis, 
mitochondrial dysfunction, and oxidative cellular damage30-33. 
 
1.2.2.2 ANG 
Angiogenin (ANG) on chromosome 14q11.2 was originally screened as a candidate gene in Irish 
and Scottish families with ALS because it shares a metabolic pathway with the vascular 
endothelial growth factor gene, VEGF34, which is implicated in ALS (see below). Furthermore, it 
is in linkage disequilibrium with the apurinic endonuclease gene, APEX1, which was associated 
with ALS in other studies35. ANG missense mutations have been identified in most Western 
European countries and the USA, in those with a positive family history and those with the 
sporadic form36 37. ANG mutations have also been found in patients other mutations, including 
FUS, TARDBP and SOD1, supporting an oligogenic bases for the cause of ALS 4, 38 
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1.2.2.3 TARDBP 
There remained no significant familial ALS genetic breakthrough for several years until a 
pathological clue led to the identification of the next familial ALS gene and a shift in our 
understanding of ALS. A major component of ALS pathology is the presence of ubiquitinated 
inclusions42, 43. Although it was known that neurofilamentous aggregates comprised at least some 
of these, the major component was unknown until discovered to be TAR-DNA binding protein 43 
(TDP43), a protein involved in the response to HIV infection and in RNA splicing, with a major 
role in cystic fibrosis44-48. Wild-type (WT) TDP43WT is believed to be multifunctional, influencing 
RNA splicing inhibition and exon skipping, hnRNPs binding, transcriptional regulation, mRNA 
genesis, apoptosis, as well as protein-protein interactions, mainly through the C-terminus44, 47, 49-
51. Linkage followed by sequencing of DNA from ALS families identified segregating mutations in 
the TARDBP gene on chromosome 1p36.22, coding for TDP43 52, and functional studies 
supported a role for the protein in motor neuron death. Subsequently many other studies have 
replicated the original findings, and mutations have also been found in sporadic ALS44, 45, 53. The 
mutations nearly all affect the C-terminus; of the six ALS-causing mutations, all but one (D169G) 
are in exon 6, and all but one (truncating mutation Y374X) are missense mutations54, 55. The 
mutations result in redistribution of TDP43 from the nucleus to the cytoplasm in neurons and glia 
49, 56 in the anterior horn of the spinal cord57. TARDBP mutations account for about 3% of familial 
and 1.5% of sporadic ALS53.   
 
1.2.2.4 FUS 
Shortly after the identification of the pivotal role of TDP43 in ALS, linkage of other ALS families to 
chromosome 16q12 resulted in the next major target for gene identification58. Of the many genes 
in the target locus, one was similar to TDP43, and screening of this candidate, Fused in Sarcoma 
(FUS) identified many mutations in two pivotal studies, one from the UK and one from the US59, 
60. Most mutations appear to be missense and based in exons 14 and 1561. These exons code 
for the C-terminus, with the commonest being R521C, which disrupts RNA binding and 
transcription processing, leading to a toxic-gain of function59, 62, 63. 
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FUS protein is 526 amino acids long and structurally, functionally, and proteinopathically similar 
to TDP4353. Indeed, it has been considered that they might be acting in concert in ALS 
pathology64, although current evidence points towards them being mutually exclusive. Inclusions 
immunoreactive for FUS have been located within nucleic and cytoplasmic regions in several 
studies65, 66. FUSWT is multifunctional, and has been implicated in alternative splicing67, genomic 
maintenance68, and transcription factor regulation69. 
Interestingly, mutations of exons 3, 5 and 6 account for about a third of the mutations identified 
so far, and may be commoner in sporadic than familial ALS70. This part of the gene codes for the 
glycine rich N terminal and may result in aberrant mRNA synthesis71. FUS mutation is estimated 
to account for 4.4% of familial and 0.7% of sporadic ALS59-62, 70, 72. 
 
1.2.2.5 OPTN 
Using homozygosity mapping in consanguineous families, a region of chromosome 10 was 
implicated in ALS in a Japanese study73. Mutation analysis of these and other samples from 
people with familial and sporadic ALS, revealed mutations in a gene known to cause primary open 
angle glaucoma, Optineurin (OPTN). Mutations have been found in both familial and sporadic 
ALS, one missense autosomal dominant (E478G), and two autosomal recessive, a deletion of 
exon 5 and a nonsense mutation on exon 12 (Q398X)73. In general, those with OPTN mutation 
had a slow progression of ALS. The mechanism through which the recessive and dominant 
mutations result in ALS may well be different, with a loss of function likely for the recessive, and 
a gain of function related to mislocalization of the OPTN protein possibly important for the 
dominant. The impact on OPTN protein of ALS and primary open angle glaucoma linked 
mutations is different, with different effects on localization and different effects on NFKb signalling, 
and this is likely to be the reason for the difference in phenotypic expression. 
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1.2.2.6 DAO 
The D-amino oxidase gene, DAO, was found to be mutated in a family linked to chromosome 
12q22-23. Functional studies support the pathogenic role of the mutation R199W, but other 
families have yet to be found harbouring mutations in this gene74. 
 
1.2.2.7 VCP 
The valosin-containing protein gene, VCP, on chromosome 9 is involved in frontotemporal 
dementia with Paget’s disease75. A study using whole exome sequencing in Italian families with 
ALS has identified mutation in VCP with supporting functional evidence, and it seems likely that 
such mutations will be confirmed as a rare additional cause of ALS76. 
 
1.2.2.8 C9ORF72 
A GGGGCC hexanucleotide repeat expansion mutation on Chromosome 9 open reading frame 
72 (C9ORF72) was found in 2011 through family linkage. The 9p21 locus was implicated via the 
same method in 200677, 78and was replicated in several families over four years. Genome-wide 
association analyses (GWAS) confirmed this region’s involvement in ALS in several western 
populations, narrowing it down to haplotype spanning three genes79-81, Mps One Binder kinase 
activator-like 2B (MOBKL2B), interferon kappa (IFNK) and an open reading frame, C9ORF72. In 
2011 a mutation linked with intron 1 of C9ORF72 was found tagging this haplotype82, 83.Although 
currently debated, it is believed the repeat mutation becomes pathogenic beyond 23 repeats, 
although it is mainly seen that expansion in ALS cases is much greater than this (so much so that 
it cannot be measured using regular PCR). Little is known how this causes ALS, however there 
are two dominant hypotheses, (a) nucleic RNA foci sequestration of RNA binding proteins and/or 
(b) cytoplasmic repeat-associated mutated proteins via non-ATG RAN translation.It’s prevalence, 
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 in a predominantly Caucasian population, is currently estimated to be 37.6% for familial 
ALS and 6.3% for without any obvious ALS inheritance84. This makes it is the most prevalent 
genetic mutation in ALS found to date. And evidence suggests that it significantly shortens 
survival (measured by duration) compared to more typical ALS presentation85.  
 
1.2.2.9 UBQLN2 
A single point mutation on the Ubiquilin-2 (UBQLN2) gene, which encodes for an ubiquitin-like 
protein, was found X-linked dominantly inherited in a five generational family3. In the same study 
also confirmed four additional UBQLN2 mutations in four other families showing no male-to-male 
inheritance. Consistent with X-linked inheritance AOO in males is much younger males because 
they are likely to be hemizygous for the mutation.  
UBQLN2 mutations are especially interesting because Ubiquilin-2 skein-like protein inclusions are 
a common feature of sporadic and familial ALS and ALS-FTD post-mortem pathology, suggesting 
that they point to a common pathway in ALS pathology. This is likely to be linked to autophagy 
and protein recycling and shares functional similarity with the diffuse ubiquitin and p62 inclusions 
commonly seen in ALS post mortem tissue. Supporting the oligogenic nature of ALS, Ubiquilin-2 
inclusions are seen in patients with known TDP-43, FUS, and ubiquitin ALS pathology.   
 
1.2.3 Genes causing atypical ALS identified through family based studies 
Mutations of several genes have been found to cause atypical ALS, including the vesicle-
associated membrane protein-associated protein B (VAPB)86, which usually causes a lower motor 
neuron predominant variant of ALS, alsin (ALS2), which usually causes a form of young onset 
hereditary spastic paraparesis6, 87, 88, and senataxin (SETX), which causes a juvenile form of 
slowly progressive lower motor neuron ALS known as ALS489. 
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1.2.4 Genes identified through candidate gene association studies 
1.2.4.1 NFH 
Many genes have been proposed to be ALS susceptibility factors on the basis of association with 
ALS of common or rare variants within the gene. One of the first such replicated findings was of 
indel mutations in the neurofilament heavy gene, NFH90 . Two studies found various deletions 90, 
91 and another study an insertion92, all in the NFH tail domain which contains a lysine-serine-
proline repeat that is highly phosphorylated and involved in neurofilament assembly and spacing. 
All the indels were found in people with no family history of ALS, except one in someone with 
familial ALS91, although segregation with disease could not be shown. Two other studies of 
familial ALS did not identify such variants93, 94, but this is consistent with the idea that NFH tail 
domain indels increase the general liability to ALS without being of sufficiently large effect to 
cause disease. A large study of familial and sporadic ALS examining all three neurofilament 
subunits did not identify any association of variants with ALS, but the NFH tail could not be 
amplified and was therefore excluded from the analysis95, 96. 
 
1.2.4.2 ATXN2 
Spinocerebellar ataxia type 2, caused by triplet repeat expansion in the ataxin 2 (ATXN2) gene is 
associated with motor neuron degeneration in some case reports97, 98. ATXN2 protein expression 
is elevated in ALS spinal cords and it interacts with TDP43 protein in a complex. Furthermore, 
TDP43 pathology is seen in spinocerebellar ataxia type 2, and ATXN2 is abnormally localized in 
ALS motor neurons97. Thus, the ATXN2 gene makes an excellent candidate for involvement in 
ALS. Expansions of the triplet repeat in ATXN2 are large in spinocerebellar ataxia type 2 (greater 
than 33 repeats), and normal in unaffected individuals (less than 27 repeats), whereas 
intermediate length polymorphisms increase the risk of ALS. The threshold at which repeats 
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become pathogenic are debated, and may be population-specific {Van Damme, 2011 
#955}{Ross, 2011 #954}. CAA PolyQ interruptions have been associated with the ALS-related 
ATXN2 repeat length and not with SCA2, and therefore may be more important than the repeat 
length itself {Yu, 2011 #956}. 
 
 
1.2.4.3 SMN1 AND 2 
The survival motor neuron genes, SMN1 and SMN2 are involved in the commonest childhood 
onset motor neuron disease, spinal muscular atrophy99. Homozygous deletion of SMN1 causes 
spinal muscular atrophy with a phenotype that can be ameliorated by increased copies of the 
SMN2 gene which produces a less functional product100. Copy number variation (CNV) of SMN1 
appears to be a risk factor for ALS in some studies101, although others do not find evidence for 
this102. 
Large-scale CNV analysis reveals a significant association of SMN1 duplications with ALS 
{Blauw, 2012 #1452}. Retrospective meta-analyses of ALS genome-wide copy number variation 
association studies help confirm this finding {Blauw, 2010 #431}{Cronin, 2008 #432}{Wain, 2009 
#814}. Copy number studies are particularly sensitive to biases caused by quantitative PCR, 
prone to false-positive results by differential errors {Barnes, 2008 #1453}, which could explain the 
multiple null findings surround the SMN genes in ALS. This cause of error could be particularly 
confounded in the analyses of SMN as there share high sequence homology. 
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1.2.4.4 VEGF 
The vascular endothelial growth factor gene, VEGF, was identified as an ALS gene 
serendipitously. VEGF is involved in the vascular response to hypoxia and is therefore important 
in ischaemic heart disease106-108. A mouse model of cardiovascular disease using knockout of the 
hypoxia response element of the VEGF gene had a phenotype with striking similarity to ALS106 
and a subsequent association study of the equivalent human single nucleotide polymorphisms 
(SNPs) found association in three of four populations studied, as well as in a joint analysis109. 
These SNPs have not been associated with ALS in genome-wide association studies or 
replication studies and the original finding in humans may therefore have been false positive110, 
111, although a second study suggested that the effect may be sex dependent112, 113.  In any case, 
the mouse model provides evidence of the importance of VEGF to motor neurons and the 
rationale for generating a VEGF-based treatment. 
 
1.2.5 Genes identified through genome-wide association studies of unrelated samples 
1.2.5.1 DPP6 
There have been several independent genome-wide association studies in ALS, several of which 
have used a second cohort for replication of top hits79-81, 114-117. The first replicated gene variant 
implicated through such studies and achieving genome-wide significance was of the dipeptidyl 
peptidase 6 gene, DPP6, identified through a two stage study of Dutch, Swedish, Belgian and US 
samples116. The same variant was the top hit in an Irish study but did not achieve genome-wide 
significance114. Although this finding has been confirmed in an Italian study 118, subsequent joint 
analyses have not confirmed this association, but this may be a product of the winner’s curse 
phenomenon119, where an initial finding shows a higher effect size than subsequent studies. 
Consistent with this idea, a weak signal not achieving genome-wide significance has been seen 
in association studies from samples of Italian120, 121, Polish117, and Chinese122 populations.  
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1.2.5.2 ITPR2 
Similarly, the ITPR2 gene, coding for inositol 1,4,5-triphosphate receptor type 2, was associated 
with ALS in a Dutch population115 and the finding confirmed within the same study on an 
independent population from Sweden, Belgium and Holland . Again, subsequent studies have not 
confirmed this121, 123. 
 
1.2.5.3 UNC13A 
A large study using samples from many groups and again, with an internal replication sample, 
identified variation in the unc-13 homolog A (C. Elegans) gene, UNC13A as strongly associated 
with ALS79. This finding showed strong association in a joint analysis with samples from a third 
independent data set80 and has been replicated in an East Asian study {Iida, 2011 #1454}. The 
UNC13A gene is interesting because of the role of unc13 proteins in neurotransmitter release and 
influences on glutamatergic transmission particularly124.  
 
1.2.6 Genes identified through other methods 
1.2.6.1 ELP3 
The elongation protein 3 gene, ELP3, is part of a complex involved in RNA processing through 
elongation of messenger RNA, histone acetylation and modification of tRNA wobble 
nucleosides125-128. A study using microsatellites to perform genome-wide association in three 
populations identified variation in intron 10 of the ELP3 gene associated with ALS129. An 
independent mutagenesis study of Drosophila studying genes involved in axonal guidance and 
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development, identified mutations of ELP3 as a cause of defective neuronal guidance and 
function. Knockdown of ELP3 in zebrafish resulted in defects of motor neuronal growth and 
branching. ELP3 is a good candidate as an ALS gene because, like TDP43, FUS, SMN and ANG, 
it is involved in RNA processing, and defects of ELP1 and ELP4 cause familial dysautonomia and 
Rolandic epilepsy, two other neurodegenerative diseases130, 131. Whether ELP3 is a causative 
gene or a disease modifier is yet unknown. 
 
1.2.7 Genes modifying Age of Onset 
1.2.7.1 Using linkage analysis 
1.2.7.1.1 SOD1 
Homozygosity for SOD1 mutations is known to cause earlier age of onset, although G114A G37R, 
I104F, and L38V SOD1 mutations have been associated with younger ALS onset132. There is also 
evidence that ALS age of onset (AOO) is approximately 29% hereditable for families with A4V 
and D90A SOD1 mutations132, but this is yet to be replicated.  
 
1.2.7.1.2 APOE 
Two studies have found an association between APOE genotype and age of onset of ALS133, 134. 
This was also supported by a transmission disequilibrium test using 508 families, which found 
APOE-2 to be protective in ALS leading to later AOO.  
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1.2.7.2 Using association analyses 
1.2.7.2.1 CHGB 
This gene was chosen as a candidate due to its functional relationship with SOD1 and it was 




TXNRD1 was chosen due to its redox functionality in ALS, again relative to the oxidative 
dismutase function of SOD1136. An intronic SNP rs6539137 of this gene was associated with 
earlier AOO, but only in males. 
 
1.2.7.2.3 1p34.1 
A locus modifying AOO, reducing it by up to over 2 years, was identified at 1p34.1 by an 
international association meta-analysis137. The two SNPs identified were rs3011225 and 
rs803675, in a population of 4243 cases and 5112 European controls.  
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1.2.8 Genes modifying survival 
1.2.8.1 KIFAP3 
A genome-wide study of ALS survival found variation in the kinesin-associated protein 3 (KIFAP3) 
gene associated with a 14 month survival advantage138. The study used clinic-based samples 
and a subsequent smaller study using population-based samples did not find evidence for the 
association139. However, clinic populations exclude short survivors and it may be that the 
population-based study was therefore underpowered. 
 
1.2.8.2 UNC13A 
SNP rs12608932 in intron 20 of the UNC13A gene was associated with survival140. rs12608932 
was then replicated in follow-up multi European population of 1767 cases and 1817 control within 





In 2012, EPHA4 was identified as a modifier of survival in a Zebrafish model{Van Hoecke, 2012 
#1455}. Genetic inhibition of EPHA4 rescues SOD1MT SOD1 Zebrafish, and increases survival in 
two murine models. In humans, increased EPHA4 expression worsens AOO and survival, with 
loss-of-function associating with increasing survival time. The proposed pathological mechanism 
is an EPHA4 gain-of-function which contributes to the axonopathy prevalent in ALS and modifies 
motor neuronal vulnerability to the disease. 
 
- 33 - 
1.2.9 Genes modifying onset site 
Bulbar onset is significantly more frequent in ALS cases with FUS and TARDBP mutations72, 141, 
with FUS generally associating with a shorter survival than TARDBP.  It is known that bulbar onset 
in men is also more frequent9, 142. Overall no direct genetic modifier of onset site has yet been 
found. 
 
1.2.10 Genes modifying sex ratio 
The prevalence and incidence of ALS is more in men by approximately 1.3143, although this ratio 
is dependent on AOO144. Furthermore sex influences site of onset with an increased incidence of 
bulbar-onset ALS in women and flail-arm presentation in men. 
 
1.2.10.1 Using linkage analysis 
1.2.10.1.1 SOD1 
There is evidence that genes  influence sex dependent penetrance in a four-generational family 
with an autosomal dominant SOD1 mutation (Phe20Cys) which reduced penetrance in the 
women145. SOD1 influence on sex differences is supported by mouse models, where disease 
initiates earlier in males with the G93A mutation, but an alternative explanation may be the lack 
of protective properties from the heightened oestrogen in females146. 
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1.2.10.2 Using association analysis 
1.2.10.2.1 VEGF 
A VEGF SNP allele from a haplotype associated with ALS has also been associated with 
increased incidence of ALS in women in Germany112.   
 
1.2.10.2.2 TTC7A 
An intron SNP (rs735888) allele found at TTC7A on Chromosome 2 associated with ALS and is 
found significantly more in Caucasian women for sporadic cases. This SNP did not associate with 
ALS for men exclusively147.  
 
1.2.11 Summary 
Genetic studies of ALS are beginning to shed light on the underlying pathways that lead to motor 
neuron degeneration. Axonal degeneration, synaptic signalling and RNA processing are themes 
that are emerging. For example, TDP43, FUS, ANG, SMN and ELP3 are all RNA processing 
proteins. After a decade of effort at understanding ALS with models based on just one gene, 
SOD1, we now have many genes to build a picture of the pathogenic process with several more 
on the way. The relationship between ALS and frontotemporal dementia is becoming clearer as 
genes common and genes distinct for the two diseases become apparent, and with our greater 
understanding comes the hope that a new treatment will be generated. 
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ALS presentation is heterogeneous and it is unsurprising that elucidating the genetic and 
characteristics of its progression over time has proven challenging. There are significant 
predictors of ALS survival using genetics that translate directly into either faster disease 
progression or indirectly through causing bulbar-onset, which will cause respiratory death quicker 
due to its early anatomical involvement, or causing earlier AOO which will prolong ALS duration. 
Outside of genetics, these factors are known predictors of ALS disease progression. And although 
the genetic basis of these is still largely unknown, research is advancing in characterising how 
the disease actually progresses over its course. This has introduced the idea of health states, 
referred to as ALS stages. It has been found that the disease stages of ALS can be predicted in 
populations, despite its heterogeneity, informing us deeply about how the disease progresses and 
also giving us scope to provide better healthcare.  
 
1.3 Literature review of disease spread and gene expression 
1.3.1 Disease spread 
The concept of how ALS spreads to degenerate motor neurons can be described by “dying-back” 
and “dying-forward”148, 149 axonal pathology. It is possible that either upper motor neurons (UMN), 
lower motor neurons (LMN), or neuromuscular junctions, spread ALS to each other in a specific 
direction. Dying-back refers to how cell-death begins in the cell body and works its way “back” to 
through the corticospinal motor axon (possibly from UMN to neuromuscular junctions). Dying-
forward refers to how the disease may begin at an axonal location (or perhaps junctions) and 
works itself towards the cell body. Much evidence points to UMN and LMN degeneration occurring 
separately in terms of progression and spread, but both UMN and LMN symptoms seem to share 
the same onset location, suggesting some kind of relationship between the two motor neuron 
types150, 151.  
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1.3.1.1 Imaging 
A reason why understanding disease spread in ALS has been so problematic is the disease 
situation and technology. ALS has a rapid progression rate with patients typically dying within 
three years of diagnosis. This does not leave much time for research, which in many cases can 
be regarded by the patient as undesirable due to the futility of the prognosis. The use of 
electromyography and motor unit number estimation (MUNE) techniques in the spinal cord, and 
functional neuroligand imaging and repetitive transcranial magnetic stimulation (rTMS) 
techniques in the motor cortex have had limited success. Comparing methods and qualitatively 
different neuroanatomical structures is also difficult. Spatial and temporal resolution is a problem 
in characterising cellular-level pathological changes into macro-level structural transformations. 
Although this may be slowly being overcome by technologies using advanced pixel, structural and 
diffusion tensor techniques152, and imaging genomics. And, as in genetic research, disease 
heterogeneity impedes a clear understanding of how ALS spreads. 
The extent of connectivity in the motor network has been described as a correlate of survival, 
suggesting that disease spreads through functional connections and this progression is caused 
by inter-neural transmission of a disease agent153. Another study has shown structural 
connectivity to become pathological at later disease stages as the disease goes on to progress 
to frontal and parietal regions154, further supporting a more probable rostral-caudal spread.  
 
1.3.1.2 Pathology 
Neuropathological examination of post-mortem brain and spinal cords can be another approach 
to learn about ALS spread. It is believed that disease onset location corresponds to motor neuron 
loss151 and that ALS directionality of spread is more frequently outward in a rostral-caudal 
direction for LMNs and a medial-lateral direction for UMNs, although findings have been mixed155. 
Pathological studies do show that motor neuron loss decreases gradually as you move away from 
the disease’s neuroanatomical epicentre151, and that the direction of spread influences survival155. 
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These findings correspond with the clinical features of the disease, with greater frequency for 
spreading ipsilaterally for LMN symptoms and contralaterally for UMN symptoms156, and with 
greater frequency moving bulbar to spinal rather than the converse150.  
The mechanism of pathology has been hypothesised to be caused by an initial, possibly 
stochastic156, insult at a motor corticospinal location where there is genetic susceptibility. This 
leads to misfolded proteins, a known pathological consequence of some genetic mutations in 
ALS157, 158. Spread can then occur like a prion disease, with misfolded proteins aggregating, then 
binding and sequestering functional proteins as degeneration moves into a new motor cell. In 
genetic and neuropathological research, there are multiple dysfunctional pathways in ALS that 
may facilitate this159 as protein aggregates are transmitted across cells160. 
 
1.3.1.3 Clinical symptomatology 
In most ALS patients, the disease seems to begin in one limb150 and over time become diffuse 
through the corticospinal motor neurons causing a heterogeneous clinical presentation156. Early 
studies of ALS found that it spreads contiguously more often and quickly, that this spread is 
uniform in its progression, and it was hypothesised that this was a positive sign of propagation161, 
162. The King’s clinical staging system, validated in Chapter 5, helps confirm the uniformity of 
disease progression nearer disease onset and greater clinical heterogeneity towards the end of 
the disease163.  
The direction of spread seems to influence survival, when comparing cases with a uni-focalonset 
which spreads caudal-rostrally, compared to cases with disease spreading or leaping to further 
anatomical regions155.   
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1.3.2 Disease-spread using health states 
Phenotypes such as AOO, bulbar or limb onset, and sex can help estimate the overall progression 
(or survival) of ALS, but do not inform us about how the disease progresses. Studying ALS 
progression through time has indicated that symptomatological accrual, statistically, is 
curvilinear164, in which you can use early symptom and diagnostic information to predict ALS 
prognosis165, 166 and survival167. However, the evidence also shows that progression of ALS in 
one individual may be linear but varies significantly between patients162, 168.  
The utility of rendering ALS disease progression predictable is vast. It provides a categorical 
context of which stage of ALS a patient is in. This can facilitate evaluative estimations in terms 
cost-effectiveness and efficiency of treatments, by for example using quality of life scores. 
Similarly, the health care needs of an individual can be addressed more effectively as we become 
more informed. It can also help facilitate clinical trial design and analyses, standardise trial data 
for better use in statistical methods, and similarly provide a framework in ALS longitudinal 
research. 
Although several staging systems for ALS have been suggested in the past, the first formal 
staging system that used health states to map ALS clinical milestones was published in 2012163.  
This found that ALS disease progression could be standardised across patients and that time to 
health states was predictable. The difference between ALS staging and ALS-FRS is that the 
former captures information about clinical-based pathological progression, whereas the ALS-FRS 
captures information regarding progressive motor function. Motor function can oscillate over time 
whereas pathology is made more uniform, categorical and progressive, using the staging system.  
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1.3.3 Gene expression analyses 
1.3.3.1 Mouse models 
Mouse models are beneficial as you can measure disease spread across time across anatomy. 
However, the main focus has been temporal capture of gene expression profiles in lumbar spinal 
cords. Gene expression profiles, typically taken at 3-4 different time-points throughout the 
disease's duration, vary radically.  
However, there is some replication between murine studies and between time-points169, 
especially for vimentin (Vim)170-176 and the cathespin gene family170, 172-178. Furthermore genes 
Cathepsin B and D, GFAP and SERPINA3 have been shown to differentially express in two or 
more mouse studies and two or more human studies179-182, bridging the gap across species. Gene 
ontological analyses of replicated ALS mouse genes involve immune response, lysosome, metal 
ion binding and mitochondrion function to be either significantly under or over represented169. 
Whether these functions are disease responses is unknown. For example immune, mitochondrial 
and lysosome responses could be due to the motor cell failing or being under attack by some 
conformationally changed protein. They may not be specific enough to provide convincing 
pathways of ALS pathology. Metal ion binding dysfunction may be specific to the SOD1 mutations 
studied in the murine cohort. 
How applicable mouse pathology is to human pathology in ALS is debatable, as most have, up 
to now, been based on the SOD1 mutation model. SOD1 is the third most prevalent genetic 
mutation known in ALS today, but can present with a different phenotype compared to TARDBP 
and C9ORF72 mutations carriers183. On the other hand, keeping the mutation constant may be 
beneficial as there is otherwise variance across microarray platforms in addition to variance 
caused by genetic-driven heterogeneity. Homogeneity is harder to achieve in humans. 
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1.3.3.2 Human C.N.S. samples 
Similarly to mouse models, the majority of human gene expression projects have focused on 
lumbar spinal tissue, although cortical, cervical, ventral horn, sensory cortical and grey matter 
samples have been analysed. The majority of ALS cases have been sporadic. On average most 
papers reporting human C.N.S. gene expression studies have analysed about eight cases and 
seven controls. Since 2005 the introduction of laser capture microdissection of motor neurons in 
the spinal cord has been a major focus, although mixed-cell samples are still used. 
There is correspondence between the functions implicated in motor cortical and spinal cord 
studies; these involve the cytoskeleton, protein turnover, apoptosis, and neurotransmission 180, 
182, 184, 185 186. Cytoskeleton defects have long been attributed to ALS pathology187 and have been 
hypothesised to interact with ALS gene mutations such as those in SOD1188 and VAPB189. Protein 
turnover is believed to be a central problem in ALS pathology, and this has been confirmed by 
the recent discovery of mutation in UBQLN2. This protein associates with ubiquilin and p62 
proteins183, 190; two problem proteins consistently found to differentially expression throughout 
post-mortem corticospinal tracts. Apoptosis also has a long history in ALS research, and has been 
studied in relation to oxidative stress caused by SOD1 mutations191. Neurotransmitter regulation 
has not been majorly implicated in the pathology of ALS before. 
In terms of disease progression, a Japanese group192 were the first to compare spinal motor cells 
(via LCM) and ventral horn tissue samples, finding a different gene expression profile for the latter. 
Examination of exon splicing between 12 cases and 10 controls in lumbar samples confirmed 
clinical and pathological evidence that the disease probabilistically progresses caudally193. They 
also compared motor neurons to adjacent anterior horn samples, examining lateral spread, and 
found differential gene expression and aberrant exon splicing is more evident in motor neurons, 
and that there is a greater presence of aberrant exon splicing in comparison to differential 
expression193. This supports the hypothesis that ALS is largely due to a malfunction in RNA 
processing functionality (see Section 1 of this review). 
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Problems exist in human C.N.S. gene expression studies due to the wide variation of cases, 
associated (and often unknown) genetic mutations, array platforms, sample sizes, tissue (and 
blood) samples, bioinformatic and statistical approaches, set differential expression and cluster 
thresholds, concomitant medication use status, and underlying clinical heterogeneity. 
Furthermore few studies have taken an internal control in their cases, controlling person-specific 
gene expression variation with gene expression caused by ALS.  
 
1.3.3.3 Human periphery samples 
Extra-C.N.S. periphery samples have been taken from lymphocytes194 and mononuclear cells195 
from venous blood, and myocytes from muscle biopsies196, 197. There is correspondence in 
differential expression and functional enrichment analyses between blood samples and the 
C.N.S. findings described above, in genes involved in protein processing, RNA post-
transcriptional modification, and inflammation194, 198. Furthermore, differential expression of 
TARDBP was identified in lymphocyte samples194,  consistent with known ALS genetic mutations 
in this gene. There is poorer correspondence between biopsy samples and C.N.S. samples199.  
 
1.3.4 eQTL analyses 
It has been hypothesised that SNPs associated to traits are likely to be expression Quantitative 
Trait Loci (eQTL)200, genomic variants that affect the expression of a gene either nearby (cis-
acting) or at a genomic distance (trans-acting). This is primarily because greater variation of a 
complex can be captured using eQTLs than just the underlying SNP. However, eQTL have been 
successfully implicated in other complex diseases. The first and only eQTL analysis in ALS used 
a genome-wide marker dataset with gene expression levels from peripheral blood201. Eight SNP-
transcript pairs were found and replicated to significantly modulate CYP27A1 expression. 
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CYP27A1 mutations cause cerebrotendinous xanthomatosis, a disease of upper motor neurons 
that can mimic primary lateral sclerosis202, 203, making it a likely pleiotropic candidate in ALS. 
 
1.3.5 Summary 
The question of how ALS is both caused by ubiquitous genetic mal-expression and demonstrates 
focal-to-diffuse spread can be greater informed by corroborating the above methods. For 
example, we can regard the oligogenic combinations of ALS mutations as either causing a motor 
cell susceptibility or producing toxic aggressors, that facilitate some stochastic or non-genetic 
event to ultimately spread through functional and structural networks, Evidence predicts that this 
spread will be more often moving rostral-caudally and that the extent of its diffusion, or multi-distal 
disease locations, affects the heterogeneity and severity of the disease. 
Few studies have examined disease spread in relation to differences in gene expression. 
However, one confirmed that there is a preference for ALS to spread in a caudal direction. 
Findings highlighted in gene expression research implicate common functions found throughout 
motor cortical, spinal and peripheral samples, perhaps suggestive that these functions are 
important in the wider spread of ALS in the body. Many however can be attributed as tissue-
specific or cell responses to a pervasive neurodegenerative disease. Interestingly, one study 
found a greater involvement of aberrant splicing compared to differential expression. eQTL 
studies in ALS have yet to begin as a primary method, but the pioneering study identified a very 
plausible candidate gene,  CYP27A1, known in a disease with similar dysfunction of the motor 
cortex. 
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Chapter 2 Genetic analyses using genotypes: ATXN2 and 
PLCD1 
2.1 Introduction 
The genetic work in this and the following chapter builds upon previous findings from collaborators 
or publications. The genes examined are Ataxin2 (ATXN2) and Phospholipase C, Delta 1 
(PLCD1) which are detailed in the literature review. 
The aim of this work was to establish a better genetic understanding of whether or how these 
genes are involved in ALS. To do this I employed mostly bioinformatic methods using existing 
data. I will describe briefly describe the lack of understanding concerning how these genes 
contribute to ALS and the methods I took to resolve this. 
 
2.1.1 ATXN2 
In exon 1 of the ATXN2 gene, CAG-trinucleotide expansion repeats greater than 33 were 
discovered to cause Spinocerebellar Ataxia 2 (SCA2). In 2010 it was also found that between 27 
and 33 associated with ALS 97. The actual repeat size, sequence, the mutations’ exclusivity to 
ALS, the extent of causation and risk204, and the intriguing idea that variable repeat lengths can 
cause fundamentally different diseases have been debated205-207.  
Notwithstanding this debate, the evidence that intermediate ATXN2 polyQ repeats cause ALS 
now has several sources; by association of intermediate repeats in several populations97, 204, 205, 
207-213, the ataxin-2 protein interaction with TDP-4397, and the SCA2 Ataxia-ALS 
symptomatological overlap.  
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Lahut and Omur et al. (2013) found a 15-SNP haplotype in Turkish cases associated with ALS, 
which spanned ATXN2 and its neighbouring gene SH2B3213. They were unable to find a single 
SNP showing significant association with ALS, but the haplotype’s odds ratio (OR) was calculated 
at 2.23.  
In collaboration with this research group I aimed to replicate this finding using imputation and 
association analyses of genotypes and haplotypes between ALS cases and non-ALS controls 
across four international populations. I believe that exploring the ALS-associated haplotypic 
background of ATXN2 would help clarify whether intermediate ATXN2 repeats cause ALS. My 
approach is under the hypothesis that specific haplotypes cause risk of pathological expansion, 
similiar to the proposed scenario found with the C9ORF72 gene and the HREM. 
 
2.1.2 PLCD1 
Statistically ALS-associated markers from a microsatellite Genome Wide Association Study 
(GWAS) implicated the PLCD1 gene in ALS214. In the same study, fine-mapping the alleles in the 
PLCD1 marker (D3S1298) were found to associate with UK and Belgium ALS populations, but 
not USA. In a recent study215 PLCδ1 (the protein of PLCD1) and PLCD1 gene expression was 
shown to be up-regulated in ALS SOD1G93A mice. It is also a good candidate gene for ALS as it 
is involved in excitotoxicity function, a putative pathological pathway in ALS. In collaboration with 
this study215 I imputed genotype markers around PLCD1, and ran association analyses to 
ascertain a functional or mutation-tagging variant, and an ALS-related haplotype. 
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2.2 Methods 
2.2.1 Sample population 
All samples used in this chapter were from people with apparently sporadic ALS. The UK DNA 
samples are derived from blood and were given by the UK National DNA Bank for Motor Neuron 
Disease Research (MNDA DNA bank). The MNDA DNA bank acts, among other things, as a 
depository for DNA taken from ALS patients from 20 UK hospitals. UK control samples were taken 
from the Depression Case Control (DeCC) study216, the Bipolar Affective Case Control Study 
(BACCS)217, data deposited by Panos Deloukas from the Wellcome Trust Sanger Institute 
(Cambridge, UK) and published online from the British 1958 birth cohort DNA collection. 
In addition to UK samples, sporadic ALS cases and control samples were used from Ireland, The 
Netherlands and USA populations. The details, including demographics, methods of collection, 
and quality control procedures can be found Cronin et al. (2008)114, Van Es et al. (2009)79 and 
Landers et al. (2009)218. The breakdown by population is shown in Table 2-1. 
Country (N) Cases Controls % Female Genotype 
Markers 
Ireland (432) 221 211 47% 561466 
Netherlands (2113) 1046 1067 41% 535468 
USA (1533) 745 808 38% 307790 
UK 663 4519 51% 584414 
 
Table 2-1. Characteristics of international cases and controls before quality control 
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All participants were of white European ancestry and were matched for geo-ethnic origin. All 
participants gave informed written consent, and the research ethic committees from each 
institution gave approval for this study. 
 
2.2.2 UK Sample Collection 
All UK DNA samples were previously extracted from blood samples by the various institutions 
involved. DNA was extracted within one week of bleeding and stored at the UK DNA Banking 
Network in Manchester. Samples were bar-coded in a tracking system to reduce risk of clerical 
error. 
Blood samples from consenting ALS participants of the MND DNA Bank were used only. For 
sample homogeneity, selection was based on no family history of ALS, being of white European 
ancestry, and disease onset beginning January 2002 or after. 
UK Control samples were obtained from the Depression Case Control (DeCC) study, the Bipolar 
Affective Case Control Study (BACCS), from Panos Deloukas of the Wellcome Trust Sanger 
Institute (Cambridge, UK) and the British 1958 birth cohort DNA collection. This project was 
ethically approved at all institutes involved; see Shatunov et al. (2010)80. For Ireland sample 
collections methods please see Cronin et al. (2008)114, for Netherlands please see Van Es et al. 
(2009)219, and for USA please see Landers et al. (2009)218 
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2.2.3 UK Genotyping 
Please see Cronin et al. (2008)114, Van Es et al. (2009)79 and Landers et al. (2009)218 for non-UK 
genotyping methods. Genotyping UK samples were processed using HumanHap550 BeadChips 
(Illumina, CA, USA) at UCL Genomics, London, UK. The raw data were analysed, quality checked 
and genotypes called using BeadStudio (Illumina). The output allows conversion into PLINK file 
formats for association analysis.  
 
2.2.4 Genotype Statistical Quality Control 
Raw genotype images files were converted to a Pedigree file (PED) using Illumina BeadStudio. 
Statistical quality control excluded individuals with sex status incongruent with genetic sex, those 
marked for exclusion by the genotyping institution, those with genotyping < 0.98 per individual, 
those with phenotype missingness < 0.98, those with low heterozygosity (p < 0.05), those 
exhibiting identity by descent sharing >5% of alleles with another participant, and those not of 
white European ancestry by analysis of ancestral markers.. 
Excluded SNP markers were those with a minor allele frequency less than 0.015, SNP 
missingness <0.98, significant departure from Hardy-Weinberg equilibrium (p < 0.001), those 
marked for exclusion by the genotyping institution, and those on chromosome X (see Script A1 in 
Appendices). 
 
2.2.5 Phasing and imputation 
Phasing and imputation was completed using 1000 Genomes v2.20101123 autosomal release 
(http://www.1000genomes.org/), performed using MaCH 1.0.18 
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(http://www.sph.umich.edu/csg/abecasis/MACH/index.html) and minimac 
(http://genome.sph.umich.edu/wiki/Minimac). I performed association analysis on imputed data 
using ProbABEL (http://www.genabel.org/packages/ProbABEL), mach2dat 
(http://genome.sph.umich.edu/wiki/Mach2dat:_Association_with_MACH_output), and PLINK 
v1.07220, after creating input files using the GenGen (http://www.openbioinformatics.org/gengen/) 
conversion tool. For GenGen, I set the r2 threshold as 0.3 and, based on genotype posterior 
probabilities derived in MaCH, a quality control threshold of 0.9 (see Script A2 in Appendices). 
 
2.2.6 Association and haplotype analyses 
I used logistic regression, modelling case-control comparisons with sex as a covariate, and with 
population stratification covariates derived from SmartPCA and EIGENSTRAT221 (see Script A3 
in Appendices), in PLINK220 (see Script A4 in Appendices). 
I set the Bonferroni-corrected threshold of statistical significance at 1.13 × 10−7, and the genome-
wide threshold as p = 5 × 10−8. I used the R statistical Bioconductor package ggplot2{Wickham, 
2009 #1470} to construct Manhattan and Q-Q Plots, LocusZoom 
(http://csg.sph.umich.edu/locuszoom/) for regional Manhattan plots, and Haploview for haplotype 
block maps (http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/haploview). To correct for genomic inflation, p values were 
adjusted by the median χ² statistic (genomic control factor). I ran all genetic tests using additive 
models. 
For haplotype analyses I used PLINK v1.07 sliding windows between 2 and 100 SNPs to explore 
significantly associated haplotypes using the phased imputed dataset (see Script A5 in 
Appendices). The prevalence of the most associated haplotypes were refined in Haploview and 
tested for their association with ALS using an omnibus haplotype association analysis. 
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2.3 Results 
2.3.1 ATXN2 
Using the 1000 genomes reference panel I imputed genotypes in and around ATXN2, including 
neighbouring genes to include SH2B3. Sliding windows analyses identified significant haplotypes 
associated with ALS in both UK and international datasets. The most significant associations were 
variations of a 47-SNP haplotype between rs10849944 and rs1544396, which incorporates 
SH2B3 and ATXN2 and the originally reported 15-SNP haplotype213 (see Appendix Table A1). 
The frequencies of these occur approximately 45-50% in cases and 50-55% in controls, and none 
of these were significant after correcting for Bonferroni multiple testing.  
This analysis also identified Lahut and Omur et al.’s (2013)213 haplotype as the second most 
significantly associated with ALS in the international and UK datasets, but was not significant after 
multiple-testing correction. 
It is likely that this correction is too stringent as there seemed to be distinct associations in multiple 
populations. I analysed the original 15-SNP haplotype as reported by Lahut and Omur et al. 
(2013)213, using a conditional haplotype-based association test with a generalised linear model 
(GLM). Two SNPs were missing from out dataset, which reduced it to a 13-SNP haplotype. 
Using a GLM meant we could account for population stratification using principal components. I 
found a significant association of the 13-SNP haplotype with ALS in the international population 
(OR: 0.48, p = 0.002). When I examined populations individually I found a significant association 
with the UK (OR: 0.49, p = 1.97x10-4) and near significant association with the Netherlands (OR: 
0.47, p = 0.06) (see Figure 2-1 for 13-SNP haplotype). For the USA and Ireland this was not 
significant.   
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Figure 2-1. ATXN2-SH2B3 haplotype associated with UK ALS cases. 
 
2.3.2 PLCD1 
Using the 1000 Genomes reference panels I imputed the region around PLCD1 in both UK (cases 
n = 599, controls n = 4142) (see Figure 2-2) and international datasets (cases n = 2611, controls 
n = 6228). Only one genotyped marker was found in PLCD1 and I found no association in PLCD1 
or in neighbouring SNPs before or after imputation (see appendix Figure A1 for international 
dataset Manhattan plot). I began with 28 genotype markers in and around PLCD1 and imputed 
1774, covering 11 genes in the neighbouring area from ITGA9 to OXSR1. 
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I found an association of a 47-SNP haplotype spanning ATXN2 and SH2B3, as well as replicating 
the original 15-SNP haplotype as reported by Lahut and Omur et al. (2013)213, in multiple datasets 
confirming a significant ATXN2 haplotype association with ALS in UK, Turkish and possibly 
Netherlands populations213.  
The original finding by Elden et al. (2010)97 has been replicated in a wide range of populations 
since 204, 205, 208-210, 212, 222-224, confirming ATXN2 association with ALS. The association of an 
ATXN2 haplotype in this thesis substantiates the original finding, as it confirms association in 
multiple ALS populations and with ATXN2 polyQ repeat carriers directly213. 
It is possible that a specific ATXN2 haplotype gives rise to polyQ expansions by causing regional 
instability. The fact that repeat lengths seem to be highly variable may be indicative of this. This 
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is a similar argument put forward to how the C9ORF72 hexanucleotide mutation haplotype gives 
rise to the hexanucleotide mutation itself225-227. Although establishing a definitive ATXN2 
haplotype has been difficult, even across similar populations (for example USA and UK). It may 
be the case that (a) there is multiple founder effects for ATXN2 repeat instability, (b) that there 
have been frequent recombination events that have caused divergence in ATXN2 haplotypes, (c) 
that there is common variation of an ATXN2 haplotype making to identify using GWAS methods, 
or (d) that the penetrance of ATXN2-caused ALS is too rare be identified using current GWAS 
methods and available ALS population sizes. 
Specificity of this haplotype to the UK may be a consequence of a great marker density in the 
genotyping platform than other countries compared here. However a highly iterative imputation 
of genotypes was conducted using a method found to correlate very highly with the original raw 
genotypes 228.  
An alternative explanation is that there is significant underrepresentation of the ATXN2 polyQ 
repeat carriers, and therefore the associated haplotype, in non-UK populations. This is unlikely 
as the carriers have been shown to be proportional between USA, UK and Netherlands 
populations. It is more probable therefore that if there is a haplotype linked to the ATXN2 repeat 
mutation then there is a clear founder effect specific to UK and Netherlands populations, but this 
scenario is unlikely due to genetic similarity between USA and UK Caucasian populations. 
 
2.4.2 PLCD1 
PLCD1 was found to have significantly associated with two populations (UK and Belgium) but not 
the USA214, 215. There is also statistically significant evidence of differential gene expression in 
SOD1 mice215. Unfortunately I was unable to replicate the association using the dataset above, 
nor did I identify significant differential expression of PLCD1 in Chapters 5 and 6. 
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As Staats et al. (2013)215 discusses, fine-mapping the microsatellite association in Belgium and 
UK populations show different associated alleles214. One possibility is that rare PLCD1 point 
mutations are heterogeneous between populations, similar to the population heterogeneity of 
point mutations in SOD1. If this is true then the method of imputation and association analysis of 
genotypes is unlikely to uncover these mutations. 
PLCD1 lies in a very gene dense neighbourhood. It is 22 kilobases (kb) long and has 15 coding 
exons, but unfortunately we had coverage of only one actual (non-imputed) genotype within 
PLCD1. Correlation comparing imputed and actual genotypes in this region was r2 = 0.87, 
suggesting a reasonable accuracy of imputed genotypes. However this is an average and imputed 
genotypes in and around PLCD1 may have been uninformative. 
A third possibility for the null finding is that common variants may not be suitable for elucidating 
PLCD1 pathology. For example, in ELP3 there is linkage disequilibrium between the microsatellite 
marker and allelic markers outside of the ELP3 gene. This may be capturing an ALS-linked ELP3 
haplotype but may also, for example, be elucidating an eQTL or repeat yet unexamined. As has 
been witnessed recently with C9ORF72, association with a genomic region in ALS does not 
immediately elucidate its genetic involvement in the disease. 
If the lack of genetic association of PLCD1 with ALS is true, then PLCD1 involvement is likely due 
to post-translational processes. As it stands, it is therefore unlikely that PLCD1 is a causative 
gene of ALS. 
 
2.4.3 Summary 
Linkage, GWAS and sequencing analyses allow genetics to be examined through different 
magnitudes, progressing from large genomic regions to the signal nucleotide. But also, each 
method also carries along with them assumptions about the disease. Under the assumption that 
ALS disease regions co-segregate with the disease, linkage analyses are useful for familial 
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inherited diseases, which putatively make up 5% of ALS patients. There has been success in 
identifying genetic mutations using ALS families, although the genetic inheritance of ALS in these 
families are examined using somewhat Mendelian principles. Unfortunately the oligogenic and 
complex genetic contribution in ALS weakens the justification that we can take these Mendelian 
inherited large-effect size mutations and draw conclusions about the much larger 95% sporadic 
ALS population. 
GWAS brings assumptions in line with the common variant common disease hypothesis, where 
an orchestra of common small effect-size genetic variants cause the disease. GWAS in ALS has 
been successful but less informative about genes outside of C9ORF72. This may be a power 
issue with ALS cases difficult to obtain and high heterogeneity within the disease. Many genes 
we know to be involved in ALS, for example SOD1, do not contain variants that are significant in 
ALS GWAS studies, despite having over 120 different point mutations, many of which are highly 
penetrance but rare. We should therefore not expect strong genotypic associations with ALS for 
genes that we believe have an involvement from other analyses.  
I have examined two genes, ATXN2 and PLCD1, using the same method of imputation and 
association testing of genotypes individually and as haplotypes. For ATXN2 I elucidated a 
previously identified haplotype that associates with ALS. But the same method was unsuccessful 
for PLCD1. I believe this highlights the difficulty in identifying various types of genetic mutations 
involved in ALS. ATXN2 harbours a repeat mutation and may support the involvement of a 
haplotype background, identifiable using genotype association methods. The data for PLCD1 
however currently suggests a more 3-dimensional modulatory alteration to genes functionality, 
unidentifiable using these methods. 
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Chapter 3 Residual association at C9ORF72  
3.1 Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that causes 
relentless paralysis, with death occurring within two to five years. The lifetime prevalence of ALS 
is 1 in 300 229 with peak onset about 60, and an increased incidence in men 230. Genetic studies 
of ALS have begun to yield insights, with ten moderate to high penetrance Mendelian risk genes 
now identified for adult onset ALS, with or without frontotemporal dementia (FTD): SOD1 231, 
TARDBP 44, 45, 232, FUS 59, 60, ANG 233, OPTN 73, VCP 76, C9ORF7282, 83, FIG4 234, UBQLN2 3 and 
PFN1 235. Other variations acting to increase risk may include intermediate expansion of the 
ATXN2 gene 97, ELP3 intron 10 variation , an UNC13A SNP 79, and indels in the NEFH tail domain 
90, 91.  
 
In about 5% of cases, a family history of ALS is recorded, with the remaining cases labelled 
sporadic 236, but this distinction is artificial, with an increased risk of other neurodegenerative 
diseases including Parkinson's disease, and frontotemporal dementia 72, 236 as well as an 
increased risk of ALS in relatives of those with apparently sporadic disease 237. Furthermore, 
variants in every  Mendelian ALS gene have also been reported in those with apparently sporadic 
ALS 4, 238, and the heritability of apparently sporadic ALS has been estimated at 61% 13. 
 
Genome-wide association studies in ALS and FTD recently identified a locus on chromosome 9 
within a known linkage peak for ALS-FTD 79-81. The disease-causing mutation has now been 
identified as a massive expansion mutation of a hexanucleotide repeat between non-coding 
exons 1A and 1B of C9ORF72 82, 83. Unaffected individuals have 2 to 23 repeats of the 
(GGGGCC)n hexanucleotide microsatellite, while the pathological repeat mutation may be several 
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hundred repeats. The mutation is interesting in manifesting with at least four phenotypes: ALS, 
ALS-FTD, FTD and normality. 
 
Although three different genome-wide association studies all identified rs3849942 as the most 
associated SNP at the C9ORF72 locus, and it is clear that this is in strong linkage disequilibrium 
with the repeat mutation 225, the UK sub-population showed stronger genome-wide significant 
association at a different SNP, rs903603. The most parsimonious explanation is that rs903603 
and rs3849942 are in strong linkage disequilibrium and both are tagging the pathological 
expansion. If that is the case, one would expect that removal of cases with the repeat mutation 
from the analysis would obliterate the association at both SNPs. We therefore tested this 
hypothesis in the UK population. 
 
3.2 Method 
3.2.1 Sample collection 
Whole blood samples from the MND DNA Bank were used. Selection was based on no family 
history of ALS, being of white European ancestry, and disease onset January 2002 or after. 
Control samples were obtained from the Depression Case Control (DeCC) study, the Bipolar 
Affective Case Control Study (BACCS), from Panos Deloukas of the Wellcome Trust Sanger 
Institute (Cambridge, UK) and the British 1958 birth cohort DNA collection. This project was 
ethically approved. 
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3.2.2 Sample preparation 
DNA was extracted from blood samples by standard methods within one week of bleeding and 
stored at the UK DNA Banking Network in Manchester. Samples were bar-coded in a tracking 
system to reduce risk of clerical error. 
 
3.2.3 Genotyping 
Genotyping and quality control was carried out as described previously 80, but in brief, genome-
wide association was performed by genotyping on various Illumina DNA microarrays followed by 
standard quality control and association testing using PLINK 220 . 
The mutation was identified using repeat-primed PCR as described 82. Non-mutation repeat 
length for alleles of the hexanucleotide repeat was quantified using Amplified Fragment Length 
Polymorphism (AFLP), using fluorescently-labelled primers as detailed previously. 82 Both 
analyses were performed using an automated 3130XL capillary electrophoresis-based Genetic 
Analyser and GeneMapper v4.0 software (Applied Biosystems). 
 
3.2.4 Statistical quality control 
Statistical quality control (see supplementary data) excluded individuals with incongruent sex, 
those marked for exclusion by the genotyping institution, those with low genotyping per individual 
<0.02, those with phenotype missingness <0.02, those with low heterozygosity (p<0.05), those 
exhibiting identity by descent sharing >5% of alleles with another participant, and those not of 
white European ancestry.  
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SNP markers were excluded with a minor allele frequency (MAF) below 0.015, SNP missingness 
<0.02, significant departure from Hardy-Weinberg equilibrium (p < 0.001), those marked for 
exclusion by the genotyping institution, and those on chromosome X. 
 
3.2.5 Phasing and imputation analyses 
Phasing and imputation was completed using 1000 Genomes v2.20101123 autosomal release 
(http://www.1000genomes.org/), performed using MaCH 1.0.18 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html) and minimac 
(http://genome.sph.umich.edu/wiki/Minimac). We performed association analysis on imputed 
data using ProbABEL (http://www.genabel.org/packages/ProbABEL) , mach2dat 
(http://genome.sph.umich.edu/wiki/Mach2dat:_Association_with_MACH_output), and PLINK 
v1.07(http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml), after creating input files using the 
GenGen (http://www.openbioinformatics.org/gengen/) conversion tool. For GenGen, we set the 
r2 threshold as 0.3 and, based on genotype posterior probabilities derived in Mach, a quality 
control threshold of 0.9. 
 
3.2.6 Association and haplotype analysis  
To test for residual association and identify SNPs not related to the mutation we used logistic 
regression, modelling case-control comparisons with sex as a covariate, stratified by the presence 
or absence of the repeat mutation.  
 
We set the Bonferroni-corrected threshold of statistical significance at 1.13 x 10-7, and the 
genome-wide threshold as 5 x 10-8. We utilised the R statistical package  to construct Manhattan 
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and Q-Q Plots, LocusZoom (http://csg.sph.umich.edu/locuszoom/) for regional Manhattan plots, 
and Haploview for haplotype block maps (http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/haploview). To correct 
for genomic inflation, p-values were adjusted by the median χ² statistic of the genomic inflation 
factor. 
 
For linear regression analysis of the non-mutated microsatellite repeat lengths as a quantitative 
variable we used PLINK v1.07 and IBM SPSS 20. For haplotype analyses we used PLINK v1.07 
sliding windows between 2 and 100 to explore significantly associated haplotypes using the 
phased imputed dataset. The prevalence of the most associated haplotypes were refined in 
Haploview and tested for their association with ALS using an omnibus haplotype association 
analysis.  
 
We ran all genetic tests under additive, dominant and recessive models, with little difference in 
results between dominant and additive models. We have reported the additive model for 
association of SNP alleles with the repeat mutation, and a dominant model (using the larger allele) 
for the analysis of repeat lengths. 
 
An epistasis analyses utilised a logistic regression interaction coefficient, examining cases-only 
through a synthetically created fakeSNP (representing the HREM) against all SNPs genome wide.  
The fakeSNP (rsFAKE10592147) was integrated into the dataset at chromosome 9 at base 
position 27,563,540, the estimated start point of the HREM, close to rs10592147 (HG18, Genome 
Reference Consortium Human Build 36 (GRCh37)). The SNP was coded homozygous for carriers 
and heterozygous for non-carriers. To confirm that this did not violate assumptions of an additive 
- 60 - 
model we implemented the HREM status into the model as a bivariate covariate and obtained 
identical results. 
 
3.2.7 Sequencing C9ORF72 
Four hundred and eighty DNA samples of patients with sporadic ALS were pooled in sets of eight. 
Each pool was tagged with one of 12 identifying DNA sequences and then combined into a further 
pool containing one representative of each identifying sequence. Thus each final sample for 
sequencing contained the DNA of 96 different individuals which could be resolved down to a 
group of eight. Samples were sequenced using Illumina GAIIx platform generating 38 base-pair 
paired-end, indexed reads.  Preliminary analysis and QC of reads was carried out using Illumina’s 
CASAVA v1.7 software and output files contained all filtered, but unaligned, sequences for each 
sample stored in a simple exportable FASTQ format. Alignment of short reads against reference 
mRNA sequence (uc003zqq.2, C9ORF72, length=3233) and variations calling was done using 
maq 0.7.1 mapping short DNA sequencing reads and calling variants using mapping quality 
scores with default parameters 239.  
 
3.2.8 Sequencing the repeat 
Forward (GGTTTAGGAGGTGTGTGTTTTTGT) and reverse primers 
(CCAGCTTCGGTCAGAGAAAT) were designed to create a 424bp amplicon (64% GC-rich) 
covering the repeat sequence. A touchdown PCR protocol (see protocol P1 in appendix) was 
used to amplify the region of interest followed by gel electrophoresis to inspect the amplicon 
length.  
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Samples were purified and analysed using an ABI 3130xl Genetic Analyser (Applied Biosystems) 
with the BigDye Terminator v1.1 Cycle Sequencing Kit. ABI’s Sequencing Analysis 5.3.1 software 
was used to analyse base calls and identify repeat patterns. 
 
3.3 Results 
3.3.1 C9ORF72 genotyping 
There were 632 cases and 4,519 controls. After quality control there were 599 cases and 4,136 
controls. There were 585,919 SNPs; after quality control 442,057.  39 cases tested positive for 
the mutation; the remaining samples had repeat lengths of less than 23 (Table A2 and data 
analysis D1 in appendix). 
 
3.3.2 Residual association 
Genomic inflation λGC was 1.00 – 1.03 for all analyses. Genome-wide association of all UK cases 
vs. controls confirmed the findings of the original study80, with no new associations (Figure A2 
and Table A3). The top three SNPs were rs10967976 (p-value = 6.164 x 10-8; OR: 1.41), rs903603 
(7.548 x 10-8; OR: 0.71), and rs10812611 (9.819 x 10-8; OR: 1.4), all at 9p21.2. rs903603 was the 
most associated SNP in the previous independent analysis 80. In that study rs10967976 and 
rs10812611 had been removed for compatibility with the other platforms used in the joint analysis. 
To confirm that the association signal seen was a result of the mutation and that there were no 
new associations, we performed association testing excluding the 39 mutation positive cases 
(Figures A3 and A4, and Table A4). There was a residual association at 9p21 with the same top 
three SNPs; rs903603 (1.87e-05, OR: 0.76), rs10967976 (3.63e-05; OR: 1.31) and rs10812611 
(5.02e-05; OR: 1.30), suggesting that despite being at the disease locus, they are not tagging the 
pathological repeat mutation.  This is reflected in the change in p-value ranks with the most 
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associated SNP from our original study, rs903603, remaining one of the ten most associated 
SNPs after removal of cases with the mutation, compared with the SNP tagging the repeat 
mutation, rs3849942, dropping from 7th to 1,225th place, as expected (Table 3-1). 
 With hexanucleotide 
repeat  mutation 
Without hexanucleotide repeat 
mutation 
SNP Rank P-Value Odds ratio 
(allele) 
Rank P-Value Odds ratio 
(allele) 
rs10967976  1st 6.16E-08 1.41 (G) 23rd 3.63E-05 1.31 (G) 
rs903603  2nd 7.55E-08 0.71 (A) 8th 1.87E-05 0.76 (A) 
rs10812611  3rd 9.82E-08 1.4 (G) 34th 5.02E-05 1.3 (G) 
rs3849942  7th 3.28E-06 1.39 (A) 1225th 2.57E-03 1.25 (A) 
rs2814707  9th 5.00E-06 1.38 (A) 1562nd 3.30E-03 1.24 (A) 
 
Table 3-1. Change in Rank by P-value for Residual and Mutation-Specific SNPs 
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We confirmed that the mutation tagging SNP rs3849942 is strongly associated with ALS when 
only samples positive for the mutation were tested against controls (p = 9.77 x 10-12, OR: 5.225, 
rank = 1), while rs903603 was not as strongly associated as rs3849942 (p = 7.73 x 10-7. OR 0.24, 
rank =22) (Figure A5). A QQ plot (Figure A6) did not show evidence of inflation of the test statistic. 
 
3.3.3 Epistasis analysis 
The genome-wide epistasis analyses revealed several candidate regions showing statistical 
interaction with the repeat mutation. Note that these are not corrected for multiple testing and that 
the bonferroni line is 1.12x10-7. None of the associated SNPs were the residual SNPs found in 
the previous section. The synthetic SNP in our dataset (rsFAKE10592147) represented HREM 
presence in 39 cases and the 560 non-HREM cases. Controls were excluded. Examining 
statistical interactions between rsFAKE10592147 against all SNPs genome wide resulted in three 
of these SNPs being the top hits (Table 3-2). We noted four none chromosome 9 SNPs from 
comparing HREM only with controls, and HREM-cases with non-HREM cases, that nearly made 
genome-wide significance in the previous analyses. These were found the top SNPs (highlighted 
in Table 3-2). Note that the residual association logistic regression parameter and the interaction 
parameter taken from this epistasis regression model are very similar. This result highlights 










SNP Statistic P-Value 
9 rsFAKE10592147 17 rs218679 24.41 7.81E-07 
9 rsFAKE10592147 10 rs2499081 20.05 7.54E-06 
9 rsFAKE10592147 22 rs12165820 19.93 8.03E-06 
9 rsFAKE10592147 9 rs3763662 19.19 1.18E-05 
9 rsFAKE10592147 17 rs9910747 18.72 1.51E-05 
9 rsFAKE10592147 8 rs2294011 18.63 1.59E-05 
9 rsFAKE10592147 16 rs886434 18 2.21E-05 
9 rsFAKE10592147 10 rs11198878 17.98 2.23E-05 
 
Table 3-2. Genome-wide epistasis analysis with rsFAKE10592147 representing the HREM 
 
3.3.4 Residual association and mutation-specific haplotypes 
To explore linkage disequilibrium in the region, we phased and imputed SNPs at C9ORF72 and 
the surrounding region (chr9:27303051-27750375) using the 1000 Genomes Project reference 
panel. Haplotype association analyses and refinement of haplotype blocks in Haploview identified 
a 79-SNP haplotype in 100% of the cases with the mutation (n =39), of which 72 SNPs were from 
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an 82-SNP haplotype published previously 225. Using the same method we also identified a 
distinct 11-SNP haplotype present in 76% of the samples without the mutation (Figure A7). 
 
3.3.5 Repeat length and risk allelic distribution 
We examined the relationship between the hexanucleotide repeat length of phased cases without 
the mutation (n=448) and the allelic frequency and distribution of ALS-associated SNPs to explore 
the linkage disequilibrium pattern of the locus. The mutation-tagging SNP rs3849942 risk allele 
was associated with increased hexanucleotide repeat numbers for the larger allele in linear 
regression (β = 5.711, p = 3.02x10-84) (Table A5). Allele frequency distributions of the repeat 
length stratified by rs3849942 alleles showed a marked difference between those with six or less 
against seven or more (Figure 3-1). Non-mutation samples with seven or more repeats (n=208) 
showed the strongest genome-wide association with ALS when compared to controls (n=4142) 
OR: 4.99; p = 1.35 x 10-43) (Table A6). 
 
Figure 3-1. Relationship between rs3849942 alleles and repeat length in non-mutation cases 
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The risk allele is strongly associated with longer repeat lengths, suggesting it may lie on a 
haplotype promoting repeat length instability. 
A similar relationship between risk alleles and hexanucleotide repeat length was observed for the 
SNPs showing residual association. Repeat numbers greater than two (the minimum length) for 
the larger allele were significantly associated with risk alleles at all of the three SNPs showing 
residual association (Figure 3-2). Modelling repeat length as a quantitative variable in a linear 
regression confirmed that these SNPs were significant predictors of having greater than two 
repeats (example SNP rs10812611, β = 5.835, p =1.50x10-52) (Table A5). Again, association 
testing of samples with repeat length greater than two (n=385) against all controls (n=4142) 
showed that SNPs showing residual association were most significantly associated with ALS; 
rs903603: OR: 0.39; p = 2.21 x 10-28, rs10812611: OR: 2.78; p = 6.96 x 10-33, and rs10967976: 
OR: 2.82; p = 1.19 x 10-33 (Table A7). 
The identified 11-SNP haplotype for the residual association SNPs was found in 100% of the 
samples with greater than two repeats for larger allele (71% in controls). Extension of the 
haplotype to include a further SNP, rs2492816, was very specific for longer repeat lengths.  This 
12-SNP haplotype was strongly associated with ALS in the sample set excluding cases with the 
mutation, or with two or less repeats (χ² = 114, p-value = 1.56 x 10-24, Figure 3-3). This haplotype 
was not significantly associated with ALS in cases with two hexanucleotide repeats and was not 
found at all in cases with the pathological repeat mutation.  
An omnibus association analysis comparing mutation-specific and residual association 
haplotypes in those with the mutation and those with greater than two repeats on their larger allele 
supported the hypothesis that the alleles showing residual association at C9ORF72 are 
significantly associated with ALS, but not by association with the pathological repeat mutation 
(Table 3-3).  
 
- 67 - 
 
Haplotype p-value for association with ALS 
Haplotype: Mutation-specific Residual 
Mutation Cases (n=39) 7.53 x 10-14 1.30 x 10-8 
Cases with hexanucleotide repeat 
length >2 (n=385) 
9.87 x 10-9 5.91 x 10-23 
 
Table 3-3. Association analyses of haplotypes with ALS in mutation cases and cases >2 repeat 
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Figure 3-2. The relationship between hexanucleotide allele repeat length and SNPs showing 
residual association at the C9ORF72 locus.   
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SNP rs903603 (top), rs10967976 (middle), and rs10812611 (bottom). Just as for the relationship 
for rs3849942 shown in Figure 3-1, the risk allele for SNPs on the alternative risk haplotype is 
overwhelmingly likely to be associated with repeat sizes greater than two. 
 
Figure 3-3. 12-SNP haplotype for cases with repeat length greater than size two  
 
3.3.6 Apparent homozygosity for larger hexanucleotide repeats associates with the risk 
allele of rs903603 
The association of risk alleles with greater than two hexanucleotide repeats suggests that residual 
association SNPs might predispose to instability, and therefore a repeat mutation, as has been 
postulated previously for the rs3849942 haplotypic background. Thus, one possible explanation 
of the residual association is an interrupted or alternative repeat sequence, also pathologically 
expanded, but not detected by repeat-primed PCR targeted at (GGGGCC)n (Figure 3-4). In that 
situation one would expect a similar problem to that reported by DeJesus-Hernandez: that cases 
appear homozygous because their larger repeat allele is too expanded to amplify. 93.8% (15/16) 
of cases with greater than two repeats and the rs903603 risk allele were apparently homozygous 
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for the hexanucleotide repeat allele, breaking Hardy-Weinberg equilibrium. In comparison, 66% 
(150/266) of cases with the same risk allele were heterozygous for the repeat and we found only 
4% (3/83) of cases with the risk allele homozygous for 2 repeats (Table 3-4). We did not observe 
this >2 repeat homozygosity bias for any other SNPs. For example, 37% of cases with the 
mutation-specific risk alleles had homozygosity for repeat alleles of length greater than 2, which 
satisfied Hardy-Weinberg equilibrium. 
 
 
Figure 3-4. Repeat-primed PCR results. 
Repeat-primed PCR of example cases showing a small expansion in the non-pathological size 
range (top), and a sample known to have a pathological (GGGGCC)n expansion mutation 
(bottom). 
 
Repeat Zygosity Non-risk Allele A (%) Risk Allele G (%) 
Heterozygous 76 (34%) 150 (66%)  
Homozygous 2 repeats 80 (96%) 3 (4%) 
Homozygous (repeats >2) 1 (5%) 18 (95%) 
- 71 - 
 
Table 3-4. Frequency of cases by residual rs10967976 alleles stratified by repeat length and 
zygosity 
 
3.3.7 Trimodal pattern of repeats 
We found a trimodal pattern of repeat allele sizes, where the occurrence of 2, 5 or 8 repeats was 
significantly more frequent than other repeat numbers (Figures A8 and A9). These findings 
suggest some repeat sizes are more stable than others. 
 
3.3.8 Sequencing Analysis of C9ORF72 
We identified two point mutations, a ketone G/T and an amine A/C substitution, across 31 (n= 
272) and 2 (n= 16) pools, respectively. No group analysed together or separately showed 
association with the residual or mutation-specific risk haplotypes. There was also no sample 
showing homozygosity for repeat sizes larger than 2. Thus it is unlikely that the residual 
association identified is a result of the point mutations seen. 
 
3.3.9 Sequencing Analysis of the C9ORF72 repeat 
We sequenced the repeat region in 56 samples: 18 cases homozygous for greater than two 
repeats with the risk haplotype showing residual association, nine homozygous for repeats of size 
two, 10 heterozygous for repeat length, and a mixture of non-ALS controls homozygous for repeat 
sizes greater than two (n = 6), homozygous for repeats of size two (n = 7), and heterozygous for 
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repeat length (n = 6). Our previous length and zygosity estimates based on AFLP (Figure A10) 
and repeat-primed PCR were correct for all these samples.  
 
3.4 Discussion 
We have shown that after removing cases with expansion mutation of the (GGGGCC)n repeat at 
C9ORF72 there remains residual association of SNPs at this locus with ALS. As expected, the 
SNPs associated with the mutation are no longer associated with ALS in this sample, but 
rs903603 and SNPs in strong linkage disequilibrium with it are associated, both before and after 
the removal of cases with the mutation. These SNPs showing residual association reside on a 
distinct haplotype, different from that of the mutation, and like the mutation-tagging SNPs, are 
also associated with non-pathological expansion of the hexanucleotide repeat, suggesting that 
they too promote instability of a repeat sequence. 
Because the SNPs showing residual association are not associated with the mutation but are 
associated with ALS, repeat instability, and apparent homozygosity for the repeat, one possible 
explanation is an alternative pathological expansion that is not detected by repeat-primed PCR 
targeting (GGGGCC)n. Such an alternative repeat sequence might be the result of an interrupted 
repeat. Interrupted repeat sequences are found in ALS resulting from intermediate expansion of 
a CAG trinucleotide repeat in the ATXN2 gene, with CAA interrupting the sequence and resulting 
in an alternative 240. Interrupted sequences are also found in Fragile X syndrome, a condition with 
a massive pathological repeat expansion 241.  
Others have reported evidence of pathological C9ORF72 hexanucleotide expansions by 
Southern blotting without corresponding detection of repeat-primed PCR in FTD cases, consistent 
with an alternative repeat sequence 242.  
Current evidence supports the idea that the sheer size of the disease-associated C9ORF72 
hexanucleotide repeat expansion causes pathology, with no evidence for repeat lengths below 
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23 being associated with ALS. One would expect that an alternative repeat that is also 
pathological should also be very large and not readily amplified by PCR. In that case, samples 
carrying the alternative repeat should appear homozygous for the non-expanded allele since the 
pathological allele would appear null by PCR. Consistent with this, we find cases with more than 
two repeats are overwhelmingly likely to appear homozygous. 
One factor increasing the likelihood of pathological expansion in transmission to the next 
generation is the current size of the repeat, and it is particularly interesting that the SNPs showing 
residual association also strongly associated with alleles showing larger numbers of non-
pathological repeats. The C9ORF72 region is very GC-rich, known to increase vulnerability 
towards repeat mutations. Additionally, a familial study examining inheritance of the repeat 
mutation suggests that larger repeat lengths are indeed more unstable and prone to expansion 
227. 
We found a trimodal pattern of repeat allele sizes with significant departure from a uniform 
distribution for repeat lengths 2, 5 and 8. This pattern is also apparent in previous publications 82, 
225, although not explicitly described. The tendency to increase the allele size by 18 nucleotides 
might be related to the underlying pathological mechanism of expansion, either because the 
mechanism results in preferential expansion in units of 18 base pairs, or because expansion in 
other unit sizes is unstable and leads to massive pathological expansion.  
An epistasis analyses helped confirmed the presence of several non-9p21 SNPs that statistically 
associated with the HREM cases compared to non-HREM cases and controls. The most 
significant was rs218679 which is found in intron 1 of solute carrier family 13, member 5 
(SLC13A5), involved in the sodium-dependent transport of citrate in cellular entry and functionally 
involved in circulating citrate for metabolic energy 243. The second epistatic SNP was rs2499081 
found in the intergenic region before c10orf112, which carries the Alzheimer’s risk marker 
D10S1423 that is likely to affect the gene through LD 244. The third epistatic SNP was rs12165820 
in intron 1 of FAM19A5, which (intron and gene) has been implicated in ALS previously in 
Schymick et al. 245 GWAS and in a GWAS study presented as an abstract at the Annual Meeting 
San Francisco 2008 (http://www.ashg.org/2008meeting/abstracts/fulltext/f22492.htm), both 
through the identification of rs130110, 129kb away from rs12165820. FAM19A5 is a member of 
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the TAFA family and its putative function is in brain specific neurokines that help regulate immune 
and nervous cells. Rs130110 was not significant in our analyses and LD between rs130110 and 
rs12165820 was r² = 0.006 and D’ = 0.110.  
A weakness of this study is that we relied on repeat-primed PCR to identify cases with the 
mutation. It is possible that some cases with the mutation were missed and this explains the 
residual association. Several factors make this unlikely. First, the mutation is tagged by 
rs3849942, and as expected, this SNP lost association with ALS after the removal of mutation-
positive cases, while rs903603 remained in the top ten associated SNPs. Second, the frequency 
of identified mutation cases in our sample is among the highest in the world 225, suggesting we 
are not missing a large proportion of these. Third, we performed a standard PCR of the 
hexanucleotide repeat and assayed the length polymorphism of the alleles (AFLP); in all cases, 
there were no heterozygous cases with the expansion, suggesting that the detection method 
worked. Fourth, in all cases where we had sequence data, the repeat size on sequencing matched 
our estimate of size based on AFLP and repeat-primed PCR. 
Another explanation for our findings is a substitution or similar mutation, rather than an alternative 
repeat mutation. This seems unlikely because for several years many groups, including ours, 
performed sequencing through the region finding no segregating point mutations or indels. 
Furthermore, the point mutations we identified on sequencing do not occur in individuals carrying 
the alternative risk haplotype. It does however remain possible that for a small subset of 
individuals with sporadic ALS, point mutations of C9ORF72 are pathogenic, but it is then difficult 
to explain the association between rs903603 risk alleles and hexanucleotide repeats greater than 
length two. Nevertheless, we cannot exclude this possibility. 
A third possibility is that SNPs showing residual association tag repeat alleles greater than size 
two because such repeats are themselves pathogenic. Cases and controls share the same 
frequency and distribution of repeat lengths 246 making this unlikely, but recent evidence suggests 
that moderate expansion in the number of repeats can actually be pathogenic 247. 
A fourth weakness is that I was unable to replicate the residual association in non-UK populations 
(Netherlands, Ireland, and USA). Statistical power was not an issue (except for Ireland) and we 
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do find the statistical association of rs3849942. It is possible that the residual association exists 
in the UK only, due to second founder event. Alternatively the haplotypes between countries may 
be different and was not captured combining the genotypes from their various platforms. 
We present evidence of residual association at the C9ORF72 locus in ALS, not accounted for by 
the known pathological GGGGCC hexanucleotide repeat expansion but consistent with the 
hypothesis of an interrupted GGGGCC or alternative sequence repeat. We present a new 
pathological haplotype associated with ALS at this locus that is associated with having greater 
than two repeats for the larger allele, suggesting this haplotype predisposes to repeat instability. 
Further investigation including Southern blot analysis of individuals carrying the risk haplotype 
and sequence analysis of the region will help to identify the cause of the residual association 
signal we have identified. 
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Chapter 4 Genetic analyses using RNA-sequencing: ELP3 and 
Chromosome 9p21 
4.1 Introduction 
The genetic work in this and the following chapter builds upon previous findings from collaborators 
or publications. The genetic regions examined cover the Elongator Protein 3 (ELP3) gene and 
the intergenic region between chromosome 9 open reading frame 72 (C9ORF72) and Mps One 
Binder kinase activator-like 2B (MOBKL2B); which are both detailed in the literature review. 
The analysis below uses pre-existing RNA sequence (RNA-seq) data for generating hypotheses 
on the pathological causes of the ALS, and therefore upcoming research. The RNA-seq data 
comprises of control and Alzheimer brain tissue. Mainly bioinformatic approaches were used to 
examine any unusual variation in these genes, mainly by examining alternative transcripts, which 
may give us clues to their contribution to ALS. I then followed these up using wet-lab methods. 
Unfortunately both projects ended before completion; ELP3 due to grant completion and 
C9ORF72 due to the hexanucleotide expansion mutation discovery82, 83. 
 
4.1.1 ELP3 
ELP3 was implicated in ALS through a UK GWAS using microsatellites214. From 1884 
microsatellite markers, four markers were selected based on their association statistical 
significance and candidacy. Using Monte Carlo based permutation for the multiple alleles of each 
marker, STS microsatellite marker D8S1820 significantly associated with ALS in UK and Belgium 
populations, but not USA. D8S1820 is found in intron 10 of ELP3. 10 alleles in this marker, when 
grouped, have an OR of 2.07 of causing risk of ALS. 
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The authors searched for a functional variant in 61 possible SNPs, showing linkage disequilibrium 
with D8S1820 in three international populations. No convincing variant was found, nor in 
association studies following the original study, with the exception of Kwee et al. (2012) in US 
Veterans248.  
The original paper214  also reported differential expression of the ELP3 protein between ALS 
cases and controls, as well as stunted motor axonal growth after ELP3 knock-down in Zebrafish. 
Overall these findings suggest a definitive role in motor neural growth and an involvement in ALS 
pathology. 
As there is a genetic association of ELP3 with ALS, but no analysis has provided convincing 
findings in terms of DNA mutation or abnormal gene expression, except for indirect evidence of 
lowered expression of the ELP3 protein in ALS patients and its knockdown has aberrant effects 
on motor axonal growth, I adopted an approach looking at transcription variation. My method was 
to use RNA-seq data from non-ALS samples to identify alternative isoforms which may act as 
possible candidates for ELP3 pathology. 
 
4.1.2 Chromosome 9p21 
Before the HREM was discovered in C9ORF7282, 83, we were aware only, through linkage analysis 
of “9p21-families” and large-scale international GWAS79-81, that  a locus at chromosome 9p21 
associated with a significant proportion of ALS cases.  Several research groups had sequenced 
the DNA and RNA of C9ORF72 with a high coverage depth (unpublished). C9ORF72 was the 
most likely candidate in this region, but at the time neighbouring gene MOBKL2B and Interferon, 
Kappa (IFNK) were also candidates as the linkage area extended to cover this region. These 
genes too were sequenced extensively. Differential expression analyses of these genes showed 
little difference between cases and controls, despite selecting cases using the proposed 9p21-
disease haplotype (which was somewhat similar to the final HREM haplotype) (unpublished).  
- 78 - 
I therefore proposed to look at intergenic regions using the RNA-seq data which may uncover 
single exon genes, aberrant non-coding RNA, cryptic exons, or a fusion site between C9ORF72 
and MOBKL2B (as the haplotype spanned across this region). Our main target was to examine 
rs3849942 and rs2814707, the top two and consistently associated SNPs with ALS from the 
international GWAS. These SNPs lie in the intergenic region between C9ORF72 AND MOBK2LB. 
My approach was to search for erroneous expression in the RNA-seq data that could be linked to 
these SNPs as eQTLs. This project was disbanded in November 2011 following the C9ORF72 
hexanucleotide mutation discovery. 
 
4.2 Method 
4.2.1 RNA-seq samples and sequencing 
Brain tissue from the MRC Brain Bank was used from four healthy individuals and five with 
Alzheimer’s disease (AD), from two different brain regions- Entorhinal cortex (EC) and Brodmann 
area 9 (BA9). EC is affected early on and severely in AD; BA9 in the course of AD. The tissue 
was homogenised and RNA extracted by commercially available kits (Qiagen) and converted to 
cDNA by standard methods. The yield was approximately 100 micrograms of RNA from 100mg 
of tissue. Next-generation sequencing of samples was performed using an Illumina Genome 
analyser by Benjamin Blencowe from the University of Toronto.  RNA-seq outputs were generated 
in the form pooled sequenced fragments  of 36 base pairs long. I used the nine non-Alzheimer 
controls, to identify non-referenced variations around ALS candidate genes with the nine 
Alzheimer cases which I used as a cross-reference. 
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4.2.2 Sequencing alignment and quality control 
The RNA-seq files were in Illumina fastq format, and were converted to Sanger fastq format using 
Perl script and FASTQC. This was primarily to convert headers for downstream tools, and to have 
quality score ranges into ASCII format.  
Quality control was performed using FASTQC, which provides analyses of per base sequence 
quality, per sequence QC scores, per base sequence content, per base GC content, per 
sequence GC content, per base N content, sequence length distribution, duplicate sequences, 
overrepresented sequences and overrepresented k-mers.  
To align reads I used TopHat249 and Bowtie250 to manipulate the reference genome HG18 (see 
Script A6 in Appendices). The output from TopHat is an "accepted_hits in a binary Sequence 
Alignment/Map" (BAM) format, which is a list of successful read alignments, and an exon-intron 
junction file and DNA insertion file, both in Browser Extensible Data (BED) format. 
SAMTools251 functions were used to manipulate these files; sorting and indexing were the two 
main functions used (see Script A6 in Appendices). IGV Tools were used to view the BAM files.  
The MarkDuplicates function in Picard Tools (http://picard.sourceforge.net/) was used to identify 
duplicate reads. 
At the time there was a compatibility issue between TopHat BAM files with GATK252 and Picard 
Tools, so I used Stream Editor (SED) to alter header BAM header details (see Script A6 in 
Appendices). 
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4.2.3 Sequencing Analysis Methods 
Two methods were used for variant calling; (a) using SAMtool mpileup -> BCFTools -> 
VCFTools253, and SAM varFilter to identify high quality SNPs, and (b) GATK SNP calling function 
(see Script A6 in Appendices). 
For transcript abundance estimates, regulation and differential expression analyses, using FPKM 
and RPKM, I used Cufflinks 254. This tool produces Gene Transfer Format (GTF) files, in which 
can be used in Cuffcompare to compare transcript abundance in the data between genes or 
against a reference GTF file (used here from the UCSC). Cuffdiff was not used here as I was not 
comparing case and controls (see Script A6 in Appendices). 
To identify novel splice junctions I used (a) SpliceMap255  (see Script A6 in Appendices)and (b) 
TopHat without a reference genome 
To identify and analyse expression of alternative transcripts not listed on the reference 
transcriptome I used MISO (see Script A6 in Appendices). 
 
4.2.4 Genotyping 
For genotyping of Sheffield University’s Institute for Translation Neuroscience (SITraN) cases I 
used Invitrogen’s TaqMan genotyping with an ABI 7900 HT Real-Time PCR system. I used 
TaqMan Genotyper to make allelic discriminations for cases and controls. Primers were designed 
and purchased using Eurofins MWG Operon primer design tool. 
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4.3 Results 
4.3.1 ELP3 
Initial results using Splicemap found previously unreported novel splice junctions; these can been 
seen in Figure 4-1 below. The Y-axis corresponds to the novel splice junctions found (in red), the 
X-axis is the ELP3 gene (in blue) and below this is, are known transcripts (in black). We found 
approximately 20 transcripts with various abundance (not shown). The Ensemble database 
calculates ELP3 to have 16 different transripts. There are (a) multiple known and possibly 
unknown ELP3 transcripts and (b) our data shows novel splice junctions leading to transcripts not 
previously reported in the human genome reference dataset NCBI36/HG18. These transcripts 
are unlike the other ELP3 transcripts, being shorter with one transcript ending not at a 
transcription codon stop sequence. This was found in seven out nine controls examined. MISO 
revealed that the abundance levels were low.  
 
Figure 4-1. ELP3 novel splice junctions detected using RNA-seq mapped to the UCSC Genome 
Browser 
 
- 82 - 
4.3.2 Chromosome 9p21 
I analysed reference and de novo transcripts derived from Tophat using the RNA-seq data. I came 
across small sections of RNA expression in the intergenic region between MOBK2B and 
C9ORF72. On closer inspection I found that the intergenic transcripts lay close to rs3849942, the 
most significantly associated SNP with ALS worldwide. I examined this in relation to the HG18 
reference genome using UCSC Genome Browser (see Figure 4-2), and found reported 
expression sequence tags (ESTs) in the same location. I gauged that this region might be a good 
candidate because either rs3849942 or rs2814707 could be acting as an expression trait locus 
(eQTL) in this region. 
 
 
Figure 4-2. ESTs near rs3849942 near the 3’ end of C9ORF72 
I genotyped 124 samples from SITraN using ABI’s TaqMan for SNPs rs3849942, rs2814707, and 
rs10122902. These three SNPs are known to form the 9p21 haplotype highly associated with 
ALS. Identifying ALS cases with this haplotype would isolate cases carrying the yet unknown 
mutation. During the course of this project the variant causing the association signal was identified 
as a hexanucleotide repeat expansion mutation in intron 1 of C9ORF7282, 83, thus making the 
hypothesis I was testing unlikely to be true. Further testing was therefore abandoned.  
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4.4 Discussion 
4.4.1 ELP3 
Replication of the ELP3 association with ALS has been supported by Kwee et al. (2012)248, who 
found a SNP (rs6985069) located near ELP3, showing a significant albeit small association with 
ALS. Kwee et al. highlight the difficulty of accounting for genetic disease variance using common 
variants. It is becoming increasingly likely that they will not greatly inform the future of ALS 
research. Many large-scale multi-population genome wide analyses examining common variants 
have so far yielded only one convincing finding, C9ORF72, despite many attempts. The majority 
of findings in ALS so far have been rarer point mutations or repeat mutations.  
Notwithstanding, ELP3 does seem to have a role in ALS. Differential ELP3 protein expression 
between ELP3 risk-carriers and protective-carriers is evident. I hypothesised that ELP3 pathology 
may be due to some transcriptional disruption without a definitive genetic mutation, for example 
an eQTL or aberrant transcription factor.  
I explored alternative isoforms in healthy subjects to select candidate transcripts. I identified three 
rare alternative transcript isoforms in the majority of the samples, which are uncharacteristically 
like the other isoforms in the reference transcriptome for ELP3.  
Interestingly there is one reoccurring isoform with moderate abundance incorporating many ELP3 
exons buts fails to transcribe to the final exon. This isoform stops short in the middle of the final 
intron and not at a termination codon sequence. The other two isoforms are short, but have their 
5’ and 3’ ends in exons containing promoter sequences.  
In comparison with other genes in our data and on the transcriptome, ELP3 transcription is 
complex and is possibly vulnerable to aberrant splice formations. Future research should seek to 
characterise and measure alternative isoforms between cases and controls using qPCR as well 
genotyping rs6985069 and SNPs in LD to assess their eQTL status. 
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4.4.2 Chromosome 9p21 
The haplotypic background of the C9ORF72 hexanucleotide mutation, now believed to explain 
the original 9p21 linkage and GWAS signals, has been greatly detailed225, 256. rs3849942, the SNP 
examined in this thesis, is now known to be direct marker of the mutation, with 100% of mutation 
cases having the risk allele (A). rs3849942 and its associated haplotype may even give rise to 
the hexanucleotide mutation itself225. Nevertheless, with this findng the project was determined 
obsolete. 
My findings suggested that the intergenic region between C9ORF72 and MOBKL2B showed 
definitive areas of DNA sequence that were being transcribed, and which lay close to rs3849942 
and the final exon of C9ORF72. More intriguingly was that the sequence showing transcription in 
our data was characterised by ESTs. ESTs are sequences of DNA believed to transcribe, usually, 
messenger RNA (mRNA). If rs3849942 was modulating intergenic mRNA in this region then this 
may interfering with the normal transcription of C9ORF72 or MOBKL2B. I genotyped cases and 
controls in SITraN for rs3849942 and rs2814707; the project ended before I could move on to 
using qPCR to measure the largest EST in the region. 
A benefit to analysing C9ORF72 expression using this method would be (a) to elucidate whether 
there is differential expression between cases and controls without the repeat hexanucleotide 
mutation and (b) to clarify whether one transcript variant is pathogenic or whether it is all. 
It is possible that epigenetic events may reduce C9ORF72 expression leading to a similar 
pathogenicity comparable to repeat-mutation carriers. Research examining this has so far been 
null {Belzil, 2013 #1456}. Furthermore, which transcript variants are affected by the mutation 
remains unclear. There are 3 variants, and there has been evidence that the mutation reduces 
transcript variants V1 and V2 but not V3, however C9ORF72 protein levels were normal 
{DeJesus-Hernandez, 2011 #867}{Gijselinck, 2012 #931}. Other studies show that the mutation 
affects all 3 variants {Fratta, 2013 #1457}. 
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4.4.3 Summary 
Sequence analysis is mainly driven by gene or region candidacy. In this chapter I have used RNA-
seq data to generate hypothesis where common variant and post-GWAS analyses had failed. 
Following up the hypotheses was not possible due to a discovery and a project grant ending that 
rendered both research aims obsolete.  
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Chapter 5 Gene expression by anatomy 
5.1 Introduction 
The spinal regions involved in the lower motor neuron symptoms of ALS are bulbar causing 
symptoms such as dysphagia, mastication difficulties, slurred speech, and dysarthria; the cervical 
regions affect upper limb and diaphragmatic function; the thoracic; and lumbar regions affect 
lower limb function. Each spinal segment has a functional role in ALS which is reflected in 
pathological changes. This chapter examines whether there are different gene expression profiles 
that associate with ALS in each region of the spinal cord and whether these inform us about 
differences in pathology across the spinal cord. 
No study of which I am aware has examined changes in gene expression in multiple segments 
throughout the spinal cord. I hypothesise that each spinal segment will have an inherent normal 
gene expression profile; specific to the functionality of that region, which is changed in ALS, and 




All patients kindly consented to donating their brain and spinal cord to the Medical Research 
Council’s London Brain Bank for Neurodegenerative Disease based at the Institute of Psychiatry, 
King’s College London, or Brains for Dementia Research at King’s College London. Please see 
Table 5-1 for demographic and disease information. 
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5.2.2 Tissue repository and RNA and DNA isolation 
Tissue was flash frozen post-mortem and stored at -80°C as formalin-fixed wax embedded blocks. 
Tissue blocks of 20mg were taken from available thoracic, cervical, lumbar and medullary regions.  
RNA isolation was performed by submersing the 20mg tissue block in 900µl QIAzol lysis reagent 
within a lysing matrix D provided by MP Biomedicals. The tissue in the lysing matrix was 
homogenised in a FastPrep 24 for 30 seconds at 4 metres per second Qiagen’s RNeasy Universal 
Kit was used to isolate the RNA. This entailed using gDNA eliminator solution and chloroform for 
separation of the homogenate into aqueous and organic phases. In several steps the (aqueous) 
homogenate is mixed with ethanol and washed using Qiagen buffers. This kit uses spin column 
technology that binds total RNA to a silica membrane, which allows the RNA to be washed using 
Qiagen buffers and centrifugation. RNA storage temperature was -80°C in RNase-free water. 
DNA isolation began by submersing the 25mg tissue block in 80µl PBS and homogenising the 
tissue using a rotor-stator homogeniser. DNA was isolated using Qiagen’s QIAamp DNA Mini and 
Blood Mini Kit. Proteinase K was added to the homogenate to deactivate protein activity. Similarly, 
the Qiagen QIAamp protocol uses spin-column technology that allows suspension of DNA in the 
QIAamp membrane, so the person can wash the DNA using various reagents. DNA was stored 
at -20°C in Buffer AE (10 mM Tris·Cl; 0.5 mM EDTA; pH 9.0). 
 
5.2.3 RNA and DNA quantification and quality control 
RNA quantification was completed using a Life Technologies Qubit 2.0 fluorometer and kit 
reagents. RNA quality was examined via 260/280 absorbance ratios using a Nanodrop and RNA 
integrity (RIN) using an Agilent 2100 Bioanalyzer.  The RIN algorithm applies electrophoresis and 
fluorescence to the RNA sample. RNA fragments are separated by molecule size and their 
fluorescence levels quantified. Degraded samples will show shorter RNA fragments. A RIN score 
of greater than 7 is the industry standard for successful downstream microarray applications. 
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However, by using cDNA-mediated Annealing, Selection, Extension, and Ligation (DASL) 
technology, one can effectively process RNA samples with a RIN number lower than 7. Twelve 
samples had a RIN score greater than 7, 12 samples had a RIN score between 6 and 7, and 8 
samples had a RIN score less than 6. Because certain RNA samples were partially degraded I 
used Illumina Whole-Genome DASL HT Assay kit for the array expression procedure. 
DNA quantification was done using 2µl of the sample solution in a Nanodrop spectrophotometer. 
DNA quality was inspected using an Agilent 2100 Bioanalyzer. 
 
5.2.4 Whole-Genome Gene Expression using Illumina DASL HT Assays 
We used Illumina Human Whole-Genome DASL HT Assay with UDG kit, containing protocol, 
reagents and BeadChips necessary for the expression analysis, on the Illumina BeadArray 
platform. 
After quantification, the RNA was reverse transcribed using a SUR enzyme, with biotinylated and 
random nonamer primers. The cDNA was then hybridised to the DASL Assay Pool (DAP) target 
probes and bound to streptavidin conjugated particles (SA-PMPs).  
The supernatant was removed and non-hybridised and mis-hybrised oligos were washed away 
using UB1. The oligos were then extended and ligated using polymerase to their corresponding 
downstream-specific oligo (DSO). This created template for PCR.  
The oligos then underwent PCR using fluorescently labelled primers, washed, eluted and 
resuspended into an intermediate plate. The labelled single-stranded PCR product was then 
isolated and hybridised to the whole-genome expression Illumina BeadChip in an Illumina 
Hybridisation oven. The BeadChip was then washed using E1BC solution and ethanol, and 
imaged using an Illumina BeadArray Reader. 
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5.2.5 Gene expression statistical quality control 
Illumina GenomeStudio 2011.1 was utilised to examine and control the quality of RNA expression 
data.  
Normalisation was established by averaging quintiles; standardising the distribution, median and 
mean probe intensity to the same values for each case. No background subtraction was 
performed as one platform was used. 
Outliers were examined by examining signal averages of control probes by case.  
To assess the gene expression data quality and number of genes for each case for each case 
the housekeeping gene average signal was compared to background noise. The 95th percentile 
was compared to background noise using as a signal-to-noise ratio to assess quality of 
expression, and to assess the strength of probe signals. An overall average signal was examined 
using a box-plot; an average signal > 64,000 was deleted as recommended by Illumina for this 
gene expression method. 
Cluster analyses and related dendrograms were utilised to help to confirm biological replicates 
and identify any significant outliers. This analysis used the metric 1 – r, r being a correlation 
coefficient of gene expression, for all cases and controls. A scatter plot was performed to examine 
signal intensities across two samples at a time, with exclusion criteria of r < 0.99. 
 
5.2.6 Gene expression statistical analyses 
Differential expression analyses were run using Illumina GenomeStudio 2011.1. Both Mann-
Whitney and Illumina custom differential tests were used, but the latter is reported here as there 
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was little incongruence between the two methods. Genes with a false discovery rate <0.01 were 
excluded. The false discovery rate is a statistic on the proportion of significant results (with p < 
0.05) that will be false positives. The threshold of 0.01 has been statistically predetermined, 
similarly to the alpha level of the probability value (p-value). Fold change was calculated by 
dividing the reference group (controls) average signal with the target group (ALS case) average 
signal. 
Functional annotation clustering and gene ontological analyses of significant differentially 
expressed gene were analysed using DAVID 6.7257, 258, and AmiGO. DAVID uses a modified 
Fisher Exact test to ascribe a metric (EASE score) and p-value to the probability that multiple 
differentially expressed genes are co-expressing significantly in a cluster. AmiGO was able to 
identify functional classification of these genes. DAVID also provides an enrichment score, which 
estimates whether there is over-representation (i.e. enrichment) of target gene cohort in 
comparison to a reference gene cohort. An enrichment score (for each functional classification) 
is given to rank the putative importance of the gene-function clusters. It is given p-value from 
calculating the geometric mean of the EASE values.  An annotation cluster enrichment score of 
1.3 is equivalent to p-value = 0.05 and therefore annotation clusters with more than > 1.3 are 
mostly reported, unless stated otherwise. Benjamini and Hochberg corrections are reported which 
corrects p-values to correct for multiple testing. I have not excluded cluster GO terms that were 
as it the statistic is conservative and enrichment scores are my main statistic of interest in 
identifying relevant genes that may be involved in ALS. 
5.2.7 Bioinformatics interaction analyses 
 
Genes found to show significant differences in expression and those highly enriched in the 
functional annotation cluster analysis were examined using the protein-protein network tool 
STRING 9.05259 and the gene-gene and gene-protein network tool GeneMANIA260.  Networks 
showing some relevance with previous ALS research are reported as I am interested in their 
candidacy. Follow-up analyses exploring the association and interactions between genes were 
performed using BioGraph261. 
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5.3 Results 
5.3.1 Patient Characteristics 
Please see Table 5-1 for demographic and disease information for cases and controls  







ALS_1 F 75 38 72.4 Limb onset  
ALS_2 F 80 37 65.4 Limb onset 
ALS_3 F 65 14 61.3 Limb onset  
ALS_4 F 63 25 58.6 Limb onset 
ALS_5 M 50 26 46.5 Limb onset 
ALS_6 F 51 33 Missing ALS-FTD 
CTRL_1 F 54 31 - - 
CTRL_2 M 89 41 - - 
CTRL_3 F 21 21 - - 
 
Table 5-1. Case and controls demographic information with disease information for cases 
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5.3.2 Differential analyses comparing cases with control using all spinal segments 
Comparing cases with controls, 167 genes were selected based on an expression difference p-
value of < 0.05, and with the exclusion of genes with a false-discovery detection-threshold ratio 
of < 0.01 (see Appendix Table A8). None of these genes had any reported involvement in ALS 
pathology using a literature search.  
The 167 genes were analysed using DAVID functional annotation clustering. Clusters with an 
enrichment score of 1.3 were selected and are displayed in Table 5-2 (function: Glycosylation 
& Transmembrane activity), 5-3 (function: Symporter activity), and 5-4 (function: Glycan metabolic 
process). Table 5-5 (function: Calcium Binding) is also included as its function is relevant to known 
ALS pathology and gene expression research. The list of genes, and corresponding fold-change, 
that belong to each functional classification can be found in the appendix table A9. 
Gene MSRA, implicated in glycan metabolic processes, showed an interesting network 
connection with KIF3A (Figure 5-1), as did PLCD3 with ITPR1 (Figure 5-2). These genes were 
selected as KIF3A is a part of the kinese II complex with ALS gene KIFAP3, and ITPR1 is an ALS 
gene whose protein product interacts with TDP-43. 
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Figure 5-1. Gene Protein network map of MSRA using GeneMANIA 
 
 
Figure 5-2. Protein-Protein network map of PLCD3 using STRING 






























Enrichment Score: 1.68    
Term Gene 
count 








glycosylation site: N-linked 
(GlcNAc...) 
48 30.77 >0.01 1.49 0.70 
Glycoprotein 48 30.77 0.01 1.44 0.73 
GO:0031224~intrinsic to 
membrane 
56 35.90 0.02 1.25 0.97 
Transmembrane region 50 32.05 0.03 1.31 0.88 
Transmembrane 50 32.05 0.03 1.30 0.97 
topological domain: Cytoplasmic 36 23.08 0.04 1.37 0.90 
GO:0016021~integral to 
membrane 
53 33.97 0.04 1.23 0.97 
topological domain: Extracellular 30 19.23 0.04 1.42 0.88 
Membrane 59 37.82 0.05 1.22 0.91 
 
Table 5-2. Most enriched functional cluster: involved in glycosylation and transmembrane activity 
  
















Enrichment Score: 1.41    
Term Gene 
count 










3 1.92 0.01 15.90 0.91 
GO:0015294~solute:cation symporter 
activity 
4 2.56 0.03 5.58 0.97 
Symport 
 
4 2.56 0.05 4.65 0.89 
GO:0015293~symporter activity 
 
4 2.56 0.08 3.87 0.99 
 
Table 5-3. Second most enriched functional cluster: involved in symporter activity 
  























Enrichment Score: 1.37    
Term Gene 
count 








GO:0006790~sulfur metabolic process 
 
6 3.85 >0.01 6.66 0.85 
GO:0006029~proteoglycan metabolic 
process 
3 1.92 0.04 8.90 1.00 
GO:0005976~polysaccharide metabolic 
process 
4 2.56 0.06 4.60 1.00 
GO:0030203~glycosaminoglycan metabolic 
process 
3 1.92 0.07 6.96 1.00 
GO:0006022~aminoglycan metabolic 
process 
3 1.92 0.09 5.89 1.00 
GO:0009100~glycoprotein metabolic 
process 
4 2.56 0.21 2.53 1.00 
 
Table 5-4. Third most enriched functional cluster: involved in metabolic processes 
  












Enrichment Score: 1.13    
Term Gene 
count 




Fold Enrichment Benjamini Correction 
calcium-binding region:1; low affinity 3 1.92 0.01 21.38 0.87 
calcium-binding region:2; high affinity 3 1.92 0.01 18.33 0.84 
domain:EF-hand 2 5 3.21 0.05 3.52 0.91 
domain:EF-hand 1 5 3.21 0.05 3.52 0.91 
EF hand 3 1.92 0.08 6.45 0.91 
IPR018247:EF-HAND 1 5 3.21 0.08 3.02 1.00 
IPR011992:EF-Hand type 5 3.21 0.10 2.78 1.00 
GO:0005509~calcium ion binding 11 7.05 0.15 1.59 1.00 
Calcium 10 6.41 0.17 1.61 0.97 
calcium binding 3 1.92 0.19 3.76 0.97 
IPR018249:EF-HAND 2 3 1.92 0.49 1.83 1.00 
 
Table 5-5. Fourth most enriched functional cluster: involved in calcium binding. 
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5.3.3 Differential analyses comparing cases with controls by spinal segments 
5.3.3.1 Medulla 
Comparing cases with controls using just medulla samples identified 115 differentially expressed 
genes, which were analysed with DAVID functional annotation clustering. The main functional 
cluster identified was regulation of insulin, peptides and hormone secretion, with an enrichment 
score of 1.22 (Table 5-6). Other clusters had poor enrichment scores, with functions involved in 
cell junctions (enrichment score: 1.06) and embryonic organ development (enrichment score: 




Comparing cases with controls identified only 12 differentially expressed genes in the cervical 
samples, which were analysed with DAVID functional annotation clustering. The main functional 
cluster identified was regulation of muscle contraction, response to external stimulus & apoptosis, 
with an enrichment score of 1.20 (Table 5-7 and appendix table A11). The gene ADA, which 
differentially expressed in this category, was predicted to interact with ALS2 and known to interact 
with DPP4 (Figure 5-3). No other cluster had a reasonably high enrichment score or showed 
relevance in terms of function with known ALS pathology. 
- 100 - 
 
Figure 5-3. Gene Protein network map of ADA using GeneMANIA.  
Purple line indicates a co-expression, pink line physical interactions, orange line predicted interaction, light 
blue line shared pathway, dark blue line co-localisation, and a beige line shared protein domains. 
 
5.3.3.3 Thoracic  
Comparing cases with controls using thoracic cord samples identified 20 differentially expressed 
genes, which were analysed with DAVID functional annotation clustering. The main functional 
cluster identified was involved in conjugation pathways & catabolic processes, with an enrichment 
score of 0.95 (Table 5-8 and appendix table A12). The gene UFD1L, which differentially 
expressed in this category, binds with VCP to form a protein complex. No other cluster had a 
reasonably high enrichment score or showed relevance in terms of function with known ALS 
pathology. 
 
- 101 - 
 
Figure 5-4. Protein-Protein network map of UFD1L using STRING 
 
5.3.3.4 Lumbar 
Comparing cases with controls using lumbar samples identified 29 differentially expressed genes, 
which were analysed with DAVID functional annotation clustering. The main functional cluster 
identified was involved in flavoproteins and oxidoreductase function, having the highest 
enrichment score of 1.68 across all spinal segments (Table 5-9 and appendix table A13). The 
gene CYB5R1, which showed differential expression in this cluster, binds with UBQLN4 which, 
similarly to VCP and UBQLN2, regulates proteosomal protein catabolic processes (Figure 5-5). A 
second significant functional cluster implicated pleckstrin homology domains with an enrichment 
score of 1.63 (see Table 5-10).  No other cluster had a reasonable enrichment score or showed 
relevance in terms of function with known ALS pathology. 
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Figure 5-5. Protein-Protein network map of CYB5R1 using STRING 

















































Enrichment Score: 1.22    
Term Gene 
count 








GO:0032024~positive regulation of insulin secretion 3 2.70 >0.01 27.84 0.90 
GO:0002793~positive regulation of peptide secretion 3 2.70 0.01 21.78 0.84 
GO:0046887~positive regulation of hormone secretion 3 2.70 0.02 13.92 0.95 
GO:0050796~regulation of insulin secretion 3 2.70 0.02 12.53 0.93 
GO:0002791~regulation of peptide secretion 3 2.70 0.03 10.89 0.94 
GO:0046883~regulation of hormone secretion 3 2.70 0.06 7.59 0.93 
GO:0051046~regulation of secretion 4 3.60 0.12 3.31 0.98 
GO:0051047~positive regulation of secretion 3 2.70 0.14 4.60 0.99 
GO:0051050~positive regulation of transport 3 2.70 0.38 2.25 1.00 
GO:0010033~response to organic substance 6 5.41 0.42 1.39 1.00 
GO:0060341~regulation of cellular localization 3 2.70 0.43 2.02 1.00 




































































GO:0006937~regulation of muscle contraction 3 27.27 >0.01 62.63 0.28 
GO:0010035~response to inorganic substance 3 27.27 0.01 22.00 0.73 
GO:0010648~negative regulation of cell communication 3 27.27 0.01 18.18 0.72 
GO:0044057~regulation of system process 3 27.27 0.01 14.59 0.77 
GO:0042127~regulation of cell proliferation 3 27.27 0.07 5.73 1.00 
GO:0042981~regulation of apoptosis 3 27.27 0.08 5.61 1.00 
GO:0043067~regulation of programmed cell death 3 27.27 0.08 5.55 0.99 
GO:0010941~regulation of cell death 3 27.27 0.08 5.53 0.99 
GO:0046872~metal ion binding 5 45.45 0.15 1.96 1.00 
GO:0043169~cation binding 5 45.45 0.16 1.94 1.00 
GO:0043167~ion binding 5 45.45 0.16 1.91 0.98 
GO:0046914~transition metal ion binding 3 27.27 0.46 1.75 1.00 
Polymorphism 7 63.64 0.63 1.06 1.00 
sequence variant 7 63.64 0.70 1.01 1.00 
Table 5-7. Most enriched cervical functional cluster involved in regulation of muscle contraction, response to external stimulus & apoptosis 















































ubl conjugation pathway 3 15 0.07 6.30 0.78 
GO:0019941~modification-dependent protein catabolic process 3 15 0.09 5.44 1.00 
GO:0043632~modification-dependent macromolecule catabolic process 3 15 0.09 5.44 1.00 
GO:0051603~proteolysis involved in cellular protein catabolic process 3 15 0.10 5.20 1.00 
GO:0044257~cellular protein catabolic process 3 15 0.10 5.18 1.00 
GO:0030163~protein catabolic process 3 15 0.10 5.02 1.00 
GO:0044265~cellular macromolecule catabolic process 3 15 0.13 4.31 1.00 
GO:0009057~macromolecule catabolic process 3 15 0.15 4.00 1.00 
GO:0006508~proteolysis 3 15 0.24 2.96 1.00 
 
Table 5-8. Most enriched thoracic functional cluster involved in conjugation pathways & catabolic processes 
  































% of Total 
Genes 
EASE P-value Fold Enrichment 
Benjamini 
Correction 
Flavoprotein 3 1.57 0.01 19.97 0.50 
FAD 3 1.57 0.01 18.75 0.32 
Oxidoreductase 4 2.09 0.04 5.07 0.63 
GO:0055114~oxidation reduction 4 2.09 0.05 4.46 1.00 
 
Table 5-9. Most enriched lumbar functional cluster involved in flavoproteins and oxidoreductase 
  

















Enrichment Score: 1.63    
Term Gene count 
% of Total 
Genes EASE P-value Fold Enrichment 
Benjamini 
Correction 
IPR011993:Pleckstrin homology-type 4 2.09 0.01 8.80 0.50 
SM00233:PH 3 1.57 0.02 10.93 0.24 
IPR001849:Pleckstrin homology 3 1.57 0.06 7.22 0.90 
 
Table 5-10. Second most enriched lumbar functional cluster involved in pleckstrin homology domains 
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5.4 Discussion 
Differential expression analyses identified significant changes in gene expression in spinal 
regions collectively and in each anatomical spinal region separately, when comparing ALS cases 
and non-ALS controls.  
 
5.4.1 Functional categories of differentially expressing genes combining all anatomical 
regions 
5.4.1.1 Glycosylation and transmembrane activity 
The most enriched annotated function identified when comparing all anatomical regions across 
cases and controls was for Nitrogen(N)-linked glycosylation and transmembrane activity. 
Glycosylation refers to the formation of glycoproteins. These are multifunctional ubiquitous 
proteins. One major function of such proteins is to act as receptors on cell membranes, which 
plays an important role with transmembrane activity. Aberrant, possibly reduced, glycosylation of 
an excitatory amino-acid transporter was implicated in ALS as a possible mechanism of disease, 
as a consequence of a point mutation in EAAT2262. Increased levels of sialylated glycans and 
lowered levels of fucosylated glycans, examined in N-glycans, were found comparing ALS cases 
against controls263. Recently a glycoprotein GPNMB was found to be increased in mutant-SOD1 
(SOD1MT) mice and ALS patients’ spinal cords, consistent with the findings here (see Appendix 
Table A8)264.  
For alternative glycans, Oxygen(O)-linked glycosylation in the tail domain of neurofilament protein 
M has been tentatively implicated in ALS265. O-linked glycosylation with β-N-acetylglucosamine 
residues have been found to be reduced in spinal cord motor neurons in SOD1MT mice266. 
Transmembrane activity refers to proteins which pass through the cell membrane in either 
direction, and to functions in guiding proteins in or out of the cell. Prensenilin-1 (PSEN1) is a 
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transmembrane protein and also implicated in apoptosis, another process associated strongly 
with ALS pathology191. PSEN-1 was associated with ALS in 2000, but it has been difficult to 
replicate this finding in ALS excluding FTD. Since this discovery, several genes have been 
implicated in dysfunctional membrane trafficking, including VAPB in a family linkage study267, 
DPP6 identified in an Irish Genome Wide Association Study (GWAS)114, FIG4 via a 
nonsynonymous mutation234, SEMA6A in a GWAS218, the transmembrane domain of SIGMAR1 
in a familial homozygosity mapping study268, and CRIM1 from a resequencing analysis.  
GPNMB was also found to be differentially expressed in this category echoing previous findings 
using SOD1(G93A) mice, suggesting that it may be a neuroprotective factor264. 
 
5.4.1.2 Symporter activity 
Symporter activity describes the action of symports, which are membrane proteins that transport 
two or more different molecules through the membrane simultaneously. This action has not been 
implicated in ALS pathology so far. Vesicle-associated membrane protein-associated protein C 
(VAMP) and the FIG4 gene, both found to cause ALS pathology when mutated, function as 
membrane regulators.  
 
5.4.1.3 Glycan metabolic processes 
The glycan metabolic processes cluster is related to glycan and glycoprotein related activity, the 
most enriched functional category in this section (please refer to 5.1.1).  A literature search into 
sulphur, proteoglycan, polysaccharide, glycosaminoglycan, aminoglycan and glycoprotein 
metabolic processes in ALS revealed little reported association between glycan related metabolic 
processes and ALS. 
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One gene identified in this category was peptide methionine sulfoxide reductase MSRA. It 
functions as a repair protein in response to oxidative damage, and showed several interesting 
network associations. There is a strong predicted functional relationship between MSRA and 
KIF3A. KIFAP3, a gene previously found to affect survival in ALS218, 269, acts as an important 
mediator in KIF3A function. Furthermore KIF3A proteins have been found to be under-expressed 
in ALS motor cortex270. Figure 5-6 displays multiple routes in which MSRA could affect or be 
affected by KIFAP3. 
 
Figure 5-6. Functional relationships between MSRA and KIFAP3. Solid lines represent well-
supported associations; dotted lines represent less-supported associations. 
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5.4.1.4 Calcium binding 
Calcium-binding has long been implicated in ALS pathology271. Intracellular calcium levels are 
raised in ALS mice and patients272, especially linked to those with SOD1 mutations273. Intracellular 
calcium activity has also been linked to SOD1 based putative pathological mechanisms; 
glutamatergic excitotoxicity274 and free radical propagation275, exacerbating and being 
exacerbated by both. 
In the current analysis, PLCD3 was found to differentially express between cases and controls 
when using all spinal samples. PLCD3 is closely related to PLCD1, both belonging to 
phospholipase C delta protein family. PLCD1 has been implicated in ALS through a genome-wide 
microsatellite association analysis214, and there is evidence of significant over-expression of 
PLCD1 RNA and protein215. PLCD3 also interacts with ITPR1, which when knocked down assists 
autophagosomal clearance of TDP-43276, a hallmark  of pathology in ALS. ITPR1 is likely to be 
important for nucleoplasmic shuttling and proteostasis of TDP-43. 
 
5.4.2 Functional categories of differentially expressing genes for each specific 
anatomical section 
5.4.2.1 Medulla - Regulation of insulin, peptide and hormone secretion 
Abnormal secretion of pancreatic insulin in ALS was reported in 1972277. Insulin secretion was 
later believed by some to be a secondary effect and modify survival278, and it led to trials in ALS 
using insulin growth factors (IGF)279. Later, IGF-1 was found to be reduced in the ventral horn of 
ALS280 and was linked to SOD1 pathology281. Recently insulin was found to reduce the 
aggregation of TDP-43 in human cells282 
Thyrotropin-releasing hormone was seen as a hopeful candidate for clinical trials as it had been 
previously seen to be decreased in the anterior horn of ALS cases283. Unfortunately unexpected 
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negative pulmonary consequences upon the patient impeded this research until it was found 
through several trials not to alter survival284-286. 
5.4.2.2 Cervical - Regulation of muscle contraction, response to external stimulus & 
apoptosis 
The gene ADA showed differential expression in cervical spinal cord. It aids immunodevelopment 
as well as maintenance, and its deficiency causes severe combined immunodeficiency disease. 
GeneMANIA reported a predicted relationship with ALS2, a gene involved in endosomal 
trafficking and known to cause juvenile-onset ALS.287, 288 The network also revealed a known 
interaction between ADA and DPP4. DPP4 shares significant sequence homology with DPP6 and 
belongs to the same dipeptidyl aminopeptidase-like protein family. DPP6 was first implicated in 
ALS through a genome-wide association study. The functional relationship of how ADA and DPP6 
may interact through DPP4 is visualised in Figure 5-7. 
 
Figure 5-7. Functional relationships between ADA and DPP6, intermediated by DPP4.  
Solid lines represent well-supported associations; dotted lines represent less-supported 
associations. 
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5.4.2.3 Thoracic - Conjugation pathway & catabolic processes 
One of the three genes in this functional group was UFD1L. The UFD1L protein is known to 
degrade ubiquitinated proteins through forming a complex with NPL4 and VCP. VCP is involved 
in vesicle transport, membrane fusion and protein degradation. The VCP gene is reported to 
harbour point mutations that cause ALS289.   
Pathological remnants of a faulty ubiquitinated recycle process(es) are considerably present in 
ALS post-mortem tissue. We know point mutations in a gene UBQLN2 cause ALS290, resulting in 
the interruption of protein degradation regulation, using conjugated markers to identify targeted 
proteins. UBQLN2 encodes for ubiquitin-like protein ubiquilin, which is a very salient biomarker in 
ALS tissue. It is an important finding for ALS as it is the first genetic mutation that is directly linked 
to this biomarker, and this biomarker is present regardless of what genetic mutations the patient 
has. Furthermore, it implicates a dysfunction of ubiquilin-based recycling processes as a direct 
cause, instead of consequence, of ALS. In this analysis it is supported by the possible dysfunction 
caused by VCP and UFD1L under-expression. 
 
5.4.2.4 Lumbar - Flavoproteins and oxidoreductase 
The most ALS relevant gene from this group, CYB5R1, is involved in desaturation and elongation 
of fatty acids, cholesterol biosynthesis, drug metabolism, and in erythrocyte reduction. It binds 
with UBQLN4, which also aids regulation of protein degradation, which in turn interacts with 
UBQLN2290, sharing considerable sequence homology (Figure 5-8). Furthermore UBQLN4 
interacts with ATXN1, which causes spinocerebellar ataxia; a disease with known overlap with 
ALS97. 
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Figure 5-8. Functional relationships between CYB5R1 and UBQLN2, intermediated by DPP4.  
Solid lines represent well-supported associations; dotted lines represent less-supported 
associations. 
 
5.4.2.5 Lumbar - Pleckstrin homology 
Pleckstrin homology domains occur in a wide range of proteins, modulating intracellular signalling 
and membrane protein interaction. ALS2 has a pleckstrin homology domain alongside an N-
terminal RCC1-like domain, Dbl homology, and a C-terminal VPS9 domain. Pleckstrin homology 
domain-containing protein, family h, member 2 (PLEKHH2) was found in this functional group to 
differentially express between cases and controls. PLEKHH2 and PON1 are believed to be 
implicated in microvascular complications in diabetes 5, although this is not yet replicated. For 
ALS, PON1 is believed to protect against toxins that may augment lipid oxidation pathology. There 
- 115 - 
are point mutations in this gene associated with ALS and an ALS-associated haplotype thought 
to decrease gene expression291-294. 
 
5.4.3 Methodology criticism 
Like all gene expression analyses, it is difficult to establish how much gene activity is a 
consequence of responses to the disease itself, how much is directly involved in ALS pathology. 
For this chapter there is an additional dimension, of how much of the genes identified are a 
consequence of the chosen spinal segment and the extent of which it is affected. It follows that, 
for example,  a majority of upper-limb onset patients will have cervical segments heavily affected 
whereas lumbar and medulla may be less so. Furthermore we are comparing across pathological 
severity because we have a mixed number of patients with different onset locations, which will 
cause a different pattern of disease spread. Therefore knowing the spread and pathology of the 
disease is an important dimension, which is what is examined in the following paragraph. Through 
direct comparison with findings from the following paragraph, we are able to identify those genes 
showing differential expression as consequence of spread and pathology, and those genes which 
are important for ALS at a specific spinal anatomical region. 
Screening the patients used in this chapter for genetic mutation would have been insightful as we 
may have seen, or rather been able to ascertain, whether the gene expression profiles identified 
were related to a particular mutation. It may be that genetic mutations create differences in gene 
expression profiles between patients. 
The method utilised GenomeStudio as its main statistical program. There has been criticism 
against using proprietary software in gene expression studies. As a comparison with 
GenomeStudio, the R package Lumi {Du, 2008 #1458} integrates additional quality control steps 
and allows the user more freedom in selecting alternative normalisation, variance stabilisation, 
and background correction methods. Additional quality control plots, differential expression, and 
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gene annotation methods can be achieved using non-proprietary software, which may have led 
to clearer and alternative results. 
 
5.4.4 Summary 
The functional categories statistically attributed to groups of differentially expressing genes 
replicated some well-established pathological pathways and identified new gene candidates. 
Transmembrane dysfunction is a disease mechanism with much pathological and genetic 
evidence in ALS; however I also find here that symporter activity may play a major functional role. 
Symporter activity has been implicated before in ALS, especially with regards to the gene 
SLC1A2. The involvement of calcium-binding proteins has had strong support from ALS research 
since the early 1990s, and this is also suggested by the results presented here. I also found 
glycans and glycosylation activity in the gene expression profiles, both of which have increasing 
evidence for involvement in ALS through pathology research. 
The insulin pathway has been somewhat implicated through insulin-like growth factor 1 (IGF-1), 
as have flavoproteins, both of which have moderate support in the results presented here. Muscle 
contraction, apoptosis and oxidoreductase have a significant role in ALS, and this was also 
replicated in this chapter. We found conjugation pathways, catabolic process, and pleckstrin 
homology to be of importance in ALS pathogenesis based on differential expression of RNA but 
these have had very little evidence for involvement in ALS previously. This may be a consequence 
as little research has been performed on thoracic segments of the spinal cord.  
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Chapter 6 Gene expression by spread and pathology 
6.1 Introduction 
There is evidence to support the idea that ALS spreads sequentially through each anatomical 
segment of the nervous system from an initial onset point. Yet ALS has a definitive genetic 
component, and it is unclear how this component interacts with the spread of disease. My 
objective is to examine how ALS genetics plays a role in each segment of the spinal cord as it 
becomes sequentially drawn in to the disease, and to examine ALS genetics at different levels of 
pathological severity. 
By using differential expression analyses I assess whether gene activity at different disease 
stages and pathological severity categories alter as a consequence of having ALS. Although one 
cannot draw inferences about causation or response, it may be possible to hypothesise whether 
a change is primary or secondary based on the pattern of expression changes. 
Clinical observation is largely consistent with the idea that ALS, in most cases, spreads 
contiguously through the spinal cord and brain stem156. Motor neural density of a spinal cord 
region is decreased by the extent of time ALS has been present in that region.  It follows that this 
density decreases as one moves away from the epicentre of the disease150, 295. Similarly, the 
presence of ALS inclusions, such as the hallmark ubiquitin-positive aggregates, is again relative 
to the extent of time ALS has been present in an anatomical region. Proteins with conformational 
abnormalities have been shown to be toxic for motor neurons, and it has been hypothesised that 
spread of ALS disease is via inter-neural prion-like propagation. An alternative hypothesis is that 
protein abnormalities and motor neuron death are due to the spread of a toxin with an external 
origin. 
In this chapter I estimate contiguous disease spread through anatomy using clinical 
symptomatological data alongside estimations of motor neural density that used haematoxylin 
and eosin (H&E) stains. I then examine changes in gene expression in these spinal regions 
parallel with the inferred spread of disease, to assess changes in gene expression present at 
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each location. I also examine whether any differential expression genes show a dose-dependent 
response to the clinical description of disease burden at each segment. 
In the second analysis I ignore the spread of disease and examine directly the severity of 
pathology. This, I have taken as an indicator of the time that ALS pathology has been present in 
that spinal region. With four categories of rating pathological severity, I assess whether each 
implicates different genes and has a different gene expression profile. This will help elucidate if 
there is involvement of different genes in ALS as a consequence of severity and the time ALS 




All patients kindly consented to donating their brain and spinal cord to the Medical Research 
Council’s London Brain Bank for Neurodegenerative Disease based at the Institute of Psychiatry, 
King’s College London, or Brains for Dementia Research at King’s College London. Please see 
Table 6-1 for demographic and disease information. 
 
6.2.2 Tissue repository and RNA and DNA isolation 
Tissue was flash frozen post-mortem and stored at -80°C as formalin-fixed wax embedded blocks. 
Tissue blocks of 20mg were taken from available thoracic, cervical, lumbar and medullary regions.  
RNA isolation was performed by submersing the 20mg tissue block in 900µl QIAzol lysis reagent 
within a lysing matrix D provided by MP Biomedicals. The tissue in the lysing matrix was 
homogenised in a FastPrep 24 for 30 seconds at 4 metres per second Qiagen’s RNeasy Universal 
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Kit was used to isolate the RNA. This entailed using gDNA eliminator solution and chloroform for 
separation of the homogenate into aqueous and organic phases. In several steps the (aqueous) 
homogenate is mixed with ethanol and washed using Qiagen buffers. This kit uses spin column 
technology that binds total RNA to a silica membrane, which allows the RNA to be washed using 
Qiagen buffers and centrifugation. RNA storage temperature was -80°C in RNase-free water. 
DNA isolation began by submersing the 25mg tissue block in 80µl PBS and homogenising the 
tissue using a rotor-stator homogeniser. DNA was isolated using Qiagen’s QIAamp DNA Mini and 
Blood Mini Kit. Proteinase K was added to the homogenate to deactivate protein activity. Similarly, 
the Qiagen QIAamp protocol uses spin-column technology that allows suspension of DNA in the 
QIAamp membrane, so the person can wash the DNA using various reagents. DNA was stored 
at -20°C in Buffer AE (10 mM Tris·Cl; 0.5 mM EDTA; pH 9.0) 
 
6.2.3 RNA and DNA quantification and quality control 
RNA quantification was completed using a Life Technologies Qubit 2.0 fluorometer and kit 
reagents. RNA quality was examined via 260/280 absorbance ratios using a Nanodrop and RNA 
integrity (RIN) using an Agilent 2100 Bioanalyzer.  The RIN algorithm applies electrophoresis and 
fluorescence to the RNA sample. RNA fragments are separated by molecule size and their 
fluorescence levels quantified. Degraded samples will show shorter RNA fragments. A RIN score 
of greater than 7 is the industry standard for successful downstream microarray applications. 
However, by using cDNA-mediated Annealing, Selection, Extension, and Ligation (DASL) 
technology, one can effectively process RNA samples with a RIN number lower than 7. Twelve 
samples had a RIN score greater than 7, 12 samples had a RIN score between 6 and 7, and 8 
samples had a RIN score less than 6. Because certain RNA samples were partially degraded I 
used Illumina Whole-Genome DASL HT Assay kit for the array expression procedure. 
DNA quantification was done using 2µl of the sample solution in a Nanodrop spectrophotometer. 
DNA quality was inspected using an Agilent 2100 Bioanalyzer. 
- 120 - 
 
6.2.4 Whole-Genome Gene Expression using Illumina’s DASL HT Assays 
We used Illumina Human Whole-Genome DASL HT Assay with UDG kit, containing protocol, 
reagents and BeadChips necessary for the expression analysis, on the Illumina BeadArray 
platform. 
After quantification, the RNA was reverse transcribed using a SUR enzyme, with biotinylated and 
random nonamer primers. The cDNA was then hybridised to the DASL Assay Pool (DAP) target 
probes and bound to streptavidin conjugated particles (SA-PMPs).  
The supernatant was removed and non-hybridised and mis-hybrised oligos were washed away 
using UB1. The oligos were then extended and ligated using polymerase to their corresponding 
downstream-specific oligo (DSO). This created template for PCR.  
The oligos then underwent PCR using fluorescently labelled primers, washed, eluted and 
resuspended into an intermediate plate. The labelled single-stranded PCR product was then 
isolated and hybridised to the whole-genome expression Illumina BeadChip in an Illumina 
Hybridisation oven. The BeadChip was then washed using E1BC solution and ethanol, and 
imaged using an Illumina BeadArray Reader. 
 
6.2.5 Gene expression statistical quality control 
Illumina GenomeStudio 2011.1 was utilised to examine and control the quality of RNA expression 
data.  
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Normalisation was established by averaging quintiles; standardising the distribution, median and 
mean probe intensity to the same values for each case. No background subtraction was 
performed as one platform was used. 
Outliers were examined by examining signal averages of control probes by case.  
To assess the gene expression data quality and number of genes for each case for each case 
the housekeeping gene average signal was compared to background noise. The 95th percentile 
was compared to background noise using as a signal-to-noise ratio to assess quality of 
expression, and to assess the strength of probe signals. An overall average signal was examined 
using a box-plot; an average signal > 64,000 was deleted as recommended by Illumina for this 
gene expression method. 
Cluster analyses and related dendrograms were utilised to help to confirm biological replicates 
and identify any significant outliers. This analysis used the metric 1 – r, r being a correlation 
coefficient of gene expression, for all cases and controls.. A scatter plot was performed to 
examine signal intensities across two samples at a time, with exclusion criteria of r < 0.99. 
 
6.2.6 Gene expression statistical analyses 
Differential expression analyses were run using Illumina GenomeStudio 2011.1. Both Mann-
Whitney and Illumina custom differential tests were used, but the latter is reported here as there 
was little incongruence between the two methods. Genes with a false discovery rate <0.01 were 
excluded. The false discovery rate is a statistic on the proportion of significant results (with p < 
0.05) that will be false positives. The threshold of 0.01 has been statistically predetermined, 
similarly to the alpha level of the probability value (p-value).  
Functional annotation clustering and gene ontological analyses of significant differentially 
expressed gene were analysed using DAVID 6.7257, 258 and AmiGO. DAVID uses a modified 
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Fisher Exact test to ascribe a metric (EASE score) and p-value to the probability that multiple 
differentially expressed genes are co-expressing significantly in a cluster. AmiGO was able to 
clarify functional classification of these genes. An enrichment score (for each functional 
classification) is estimated to test for over-representation (i.e. enrichment) of target gene cohort 
in comparison to a reference gene cohort. It is given p-value from calculating the geometric mean 
of the EASE values.  An annotation cluster enrichment score of 1.3 is equivalent to p-value = 0.05 
and therefore annotation clusters with more than > 1.3 are mostly reported, unless stated 
otherwise. Benjamini and Hochberg corrections are reported which corrects p-values to correct 
for multiple testing. I have not excluded cluster GO terms that were as it the statistic is 
conservative and enrichment scores are my main statistic of interest in identifying relevant genes 
that may be involved in ALS.  
Chapter 6 includes gene-expression cluster-analyses using Illumina’s GenomeStudio. Clusters 
are based on similar gene-expression signals which are integrated with the cluster analysis 
dendrogram with a heat-map of fold-change stratified by pathological severity. This is to identify 
dose-dependent changes as a consequence of pathological severity. The upper limit fold-change 
(2 or greater) is coloured green with the lower limit fold-change (0) coloured red. The blue arrows 
denote interesting clusters that show extreme changes in fold-change as we move through each 
severity category. Genes that show extreme alteration in fold-change are shown in the tables 
adjacent to the heat-map. 
Gene-expression cluster analyses and dose-dependent examination of expression stratified by 
anatomy (Chapter 5) and stratified by spread (Chapter 6) are not reported as they were unable 
highlight convincing changes in expressions of ALS spread due to a lack of significant differentially 
expressing genes. 
6.2.7 Gene expression across severity 
Bioconductor R Package Lumi{Du, 2008 #1458} was utilised for additional quality control steps, 
which included variance stabilising transformation which makes the expression data more 
symmetric, and quantile normalisation. Density, cumulative distribution function, and sample 
hierarchal clustering plots were drawn to highlight possible abnormalities in expression data. 
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An additional quality control step was performed, where probe differential expression between 
tissue types was found to be statistically significant and therefore subsequently removed from the 
analysis. This was performed using Limma{Smyth, 2005 #1467}. 
To test whether gene expression change was dose-dependent across different levels of severity 
I used a genome-wide one way ANOVA with expression level as the dependent variable and four 
levels of one factor (severity), which were four severity levels ascribed in the histological analyses 
section. Using genes with small statistical p-values from the ANOVA anlayis, I used Bioconductor 
package Heatmap.2 and hclust which we were able to cluster and display genes in terms of their 
expression profile throughout progressing severity. MFuzz, a time-based soft-clustering algorithm 
for gene expression, was also used to identify clusters of gene who share similar changes in gene 
expression as a consequence of tissue severity. 
 
6.2.8 Bioinformatic interaction analyses  
Genes found to show significant differences in the expression analysis and those highly enriched 
in the functional annotation cluster analysis were examined using the protein-protein network tool 
STRING 9.05259 and the gene-gene and gene-protein network tool GeneMANIA260.  Networks 
showing some relevance with previous ALS research are reported as I am interested in their 
candidacy. Follow-up analyses exploring the association and interactions between genes were 
performed using BioGraph261. 
 
6.2.9 Histological analyses 
Consultant neuropathologist Dr Andrew King of the MRC London Neurodegenerative Diseases 
Brain Bank based at the Institute of Psychiatry, King's College London, kindly performed 
histological analyses at each spinal segment and the medulla for all cases and controls. 
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Haematoxylin and eosin (H&E) staining was used to examine the extent of loss of motor neurons 
in each sample. The extent of loss was categorised as follows (left column) and I collapsed these 
into four categories (right column) to increase statistical power and to distribute the sample size 
of each category equally (Figure 6-1). 
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No loss (0)  
  
Mild-Moderate (mild-mod) 
Very Mild (1) 
Mild (2) 
Mild-Moderate (3) 
Moderate (4)  Moderate (mod) 
Mod-Severe (5)  Mod-Severe (mod-sev) 
Severe (6)  Severe (sev) 
 
Figure 6-1. Left-hand column showing original classification of motor neuron loss severity with 
right-hand column showing collapsed categories used in analyses. 
The number of spinal cord segments available for gene expression analysis by each category 
was as follows: 
Mild-Moderate  = 5 
Moderate = 5 
Mod-Severe  = 7 
Severe  = 4 
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6.2.10 Clinical progression 
Each case sample used in this chapter was a patient who had attended King’s College Hospital. 
With ethical approval I examined ALS symptom progression over time to ascertain where disease 
spread may have occurred neuroanatomically. This entailed examining clinic notes and patient-
reported details. I compared this with the histological analyses in 6.2.8. 
 
6.2.11 Differential expression analyses 
6.2.11.1 Analysis by spread 
The first analysis examined differential expression and disease spread in four upper limb onset 
cases and three controls. I assessed genes which differentially express between cases and 
controls at each stage of the disease as it progresses from onset, 2nd region, 3rd region and final 
region (see Figure 6-2). I also aimed to identify dose-dependent effects of disease progression 
on gene expression for any gene identified through gene-expression cluster analysis.  
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Figure 6-2. Anatomical diagram of analyses of disease spread 
 
6.2.11.2 Analysis by pathological severity 
For the second analysis I assessed genes that differentially express as a consequence of 
pathological severity (Figure 6-3). Pre-analysis I identified genes that naturally express 
differentially between spinal segments using all controls, so they could be excluded. Then I took 
each spinal segment and medulla for all cases, and grouped them by the four categories of 
pathological severity. Then I compared gene expression in cases with expression in all controls 
regardless of anatomical location and based only on pathological grade, excluding the genes that 
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Figure 6-3. Anatomical diagram of analyses of pathological severity 
 
6.3 Results 
6.3.1 Spinal cord disease spread and severity analysis 
I used clinical data and H&E staining to track disease spread in all six cases. All cases had limb 
onset, four with upper limb and two with lower limb. Based on previously published observations 
of disease spread, I predicted that for upper limb cases the disease would begin in the cervical 
region and spread caudally faster than rostrally155. Symptoms corresponded to the predicted 
spread pattern. Table 6-1 displays combined data for each case. 
Patients with upper limb involvement (cases 2, and 4-6) followed the predicted cervical to rostral 
regions faster than cervical to caudal regions. For lower limb onset patients, the disease 
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cord followed exactly what we had predicted using previous research. Although several cases 
showed severe pathology that was widespread across their spinal cord and it was therefore 
difficult to ascertain their sequence of disease spread. This is likely to be a consequence of long 
disease duration at multiple spinal segments. 
 
To demonstrate this pathological severity was rescored according to the original coding, from 0-
6 for each spinal segment for the upper limb onset patients; 0 = No loss, 1 = Very Mild, 2 = Mild, 
3 = Mild-Moderate, 4 = Moderate, 5 = Moderate-Severe, 6 = Severe. I excluded case ALS_2 from 
this analysis as they lacked both pathological and clinical data for the lumbar region which skewed 
the data and had unusual disease duration of 14.5 years (Figure 6-4, see appendix Figure X for 
equivalent figure with ALS_2 included).  
 
Figure 6-4. The progression of upper-limb onset ALS (n = 3) through the spinal cord using average 
severity scores, represented by blue bars.  
The predicted pathological spread of upper-limb onset ALS is defined by the red trend-line and 
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 Medulla Cervical Thoracic Lumbar 




4th Mod-sev 3rd region 3rd  Mod-sev 
2nd 
region 




4th   Mild-mod Onset 1st  Moderate 
2nd 
region 
2nd  N/A 3rd region 3rd  
ALS_3 Very Mild N/A 4th  Mild N/A 3rd Mild N/A 2nd N/A Onset 1st 




4th   Severe Onset 1st  Mod-sev N/A 2nd  Mod-sev N/A 3rd  
ALS_6 Moderate N/A 4th   Mod-sev Onset 1st  Moderate 
2nd 
region 
2nd  Moderate 3rd region 3rd  
 
Table 6-1. Pathological and clinical information for each case by spinal segment.  
The pathology column for each spinal segment displays extent of pathology and the clinical column displays disease onset and spread sequence. Using both these 
columns the grey column infers which region the disease began and consequently spread to in sequence of 1st to 4th. 
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6.3.2 Differential expression analysis of disease spread 
As I could estimate the disease progression for the four upper-limb onset ALS patients, these 
patients were used in the proceeding analyses. The disease was estimated to move from cervical 
to thoracic, to lumbar and finally to the medulla. I performed differential expression analysis 
comparing cases (n = 4) with controls (n = 3) for each of the spinal anatomical segments in the 
estimate sequence of spread (see appendix table A14).  
 
6.3.2.1 Onset region – Cervical 
The most significant gene to differentially express between the cervical region of cases and 
controls was solute carrier family 1 (glutamate transporter), member 7 (SLC1A7), with p = 6.15E-
04 after multiple testing adjustment using the Benjamini and Hochberg (BH) False Discovery 
Rate. The fold-change was 0.20 compared to controls. In Chapter 5, this gene was the most 
significant comparing cases and controls expression for the thoracic region, and was in the top 
five most significant for cervical and lumbar segments.  
The protein encoded by SLC1A7 is a glutamate and excitatory amino acid transporter, excitatory 
amino acid transporter 5 (EAAT5), which is vital for reducing toxic levels of extracellular 
glutamate. EAAT5 highly expresses in the spinal cord, temporal and prefrontal cortices, and 
thalamus, more-so than any other major brain or spinal cord region (UCSC Genome 
Bioinformatics – Genome Browser), and the retina where EAAT5 was first functionally described.  
Analysis through STRING did not show any candidate or major genes already identified as 
important in ALS.  GeneMANIA found a co-expression relationship between SLC1A7 and the ALS 
candidate Sodium Channel, Beta-3 Subunit (SCN3B) gene (Figure 6-5). It is a regulatory subunit 
of voltage-gated sodium channels296 and has been found to differentially express in ALS 
previously196. 
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Figure 6-5. Gene-gene network of SLC1A7 using geneMANIA. Purple line indicates a co-
expression, blue line co-localisation, and a beige line shared protein domains. 
 
Examination of SLC1A7 dose-dependent expression as a function of disease progression did not 
reveal a linear step-wise reduction in fold change as the disease moved through the spinal cord 
(Figure 6-6). On the contrary, SLC1A7 showed statistically significant differential expression in all 
spinal regions but not the medulla, although even in the medulla, the direction of change was 
consistent with that of the other regions. 
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Figure 6-6. Fold-change of SLC1A7 in each spinal cord segment.  
The pink bars represent that SLC1A7 showed significant differential expression at these 
segments, blue bars represents non-significance. 
 
The second and last most significant gene was Pote Ankyrin Domain Family, Member B (POTEB), 
which has no well-characterised function.  POTEB showed no network associations with any ALS 
gene and has not been implicated in ALS previously. 
 
6.3.2.2 Second region – Thoracic 
The most significant gene to differentially express was, as described for the cervical region, 
SLC1A7 (p = 1.90E-06), with a fold-change of 0.22 (Figure 6-6). The second and last significant 
gene was Interleukin 7 Receptor (IL7R), which has no known association with ALS and revealed 
no interesting network connection. IL7R synthesises a glycoprotein that helps regulate 
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6.3.2.3 Third region – Lumbar 
The most significant gene to differentially express between cases and controls was again SLC1A7 
(p = 2.89E-10), with a fold-change of 0.15 (Figure 6-6). Table 6-2 displays the genes of the lumbar 
segment that showed statistically significant differential expression when compared with controls. 
None of these genes have previously been implicated in ALS or show a functional network 
association with an ALS gene. 
Gene name Symbol Fold 
Change 
Adj. P-Value Function 
Solute Carrier Family 1 
(glutamate transporter), 
Member 7 
SLC1A7 0.151 2.89E-10 Glutamate transporter 
Interleukin 7 Receptor IL7R 3.165 3.11E-07 Regulation of lymphopoiesis 
Quinolinate 
Phosphoribosyltransferase 
QPRT 1.945 4.68E-06 Catabolises quinolinic acid  
Acyl-CoA Synthetase 
Family Member 5 
ACSM5 2.557 4.28E-05 Involvement in energy 
storage and metabolism 
5', 3'-Nucleotidase, 
Cytosolic 
NT5C 1.917 1.50E-04 Catalyses dephosphorylated 
C4H4N2 monophosphates 
Alkaline Ceramidase 2 ACER2 0.445 1.14E-02 Generates sphingosine for 
ITGB1 and cell adhesion 
Dihydrofolate Reductase-
like 1 
DHFRL1 1.685 1.40E-02 Enyme for folate metabolism 
Dynein, Axonemal, 
Assembly Factor 2 
DNAAF2 1.752 4.53E-02 Helps motility in cilia and 
flagella 
Recoverin RCVRN 0.471 4.69E-02 Helps generate neuronal 
calcium sensors 
Table 6-2. Genes that significantly differentially expressed between cases and controls at the 
third onset region 
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6.3.2.4 Last region – Medulla 
The gene expression profile of the Medulla is somewhat different from other spinal cord 
anatomical profiles (as shown in Chapter 5). Table 6-3 displays the genes found to differentially 
express between upper-limb onset cases and controls. None of the genes have been previously 
implicated in ALS or showed functional network connection with known ALS genes.   
Gene Name Symbol 
Fold 
Change 
Adj. P-Value Function 
Family with 
Sequence Similarity 
43, Member A 
















SOX17 0.60 9.60E-03 




1B, Member 1 
SULT1B1 0.46 1.34E-02 
Catalyse sulphate conjugation 
of  hormones, drugs 
Centromere Protein 
V 
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6.3.3 Differential expression analysis of pathological severity 
The analysis in the previous section showed relatively uniform gene expression with little 
difference between each region as the disease progressed. For the analysis in this section I 
categorised each spinal region, including Medulla, by pathological severity. Creating four 
categories of severity, I compared each category with the all regions from all the controls. I also 
compared gene expression between each region, using all cases and controls, to obtain and 
control for genes that naturally differentially expression between the regions I was examining. I 
then excluded these genes from the below analyses (see appendix table A15). 
 
6.3.3.1 Mild-moderate pathology 
Differential expression analysis of regions with Mild-Moderate pathology between cases (n = 5) 
and controls (n = 12) revealed 333 genes that differentially expressed. Table 6-4 shows the top 
five of these genes (for all genes see Appendix Table A16).
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Gene Name Symbol Fold Change Adj. P-Value Function 
FBXL19 Antisense RNA 1 (head to head) FBXL19-AS1 0.19 2.16E-33 Possible non-coding RNA 
Family with sequence similarity 21, Member 
A 
FAM21A 0.08 9.50E-19 Endosomal activity 
Major Histocompatibility Complex, class II, 
DR beta 4 
HLA-DRB4 0.09 2.56E-15 Membrane-based antigen presenter 
MCM3AP antisense RNA 1 MCM3AP-AS1 3.54 8.81E-11 Unknown 
SRY (sex determining region Y)-box 18 SOX18 0.41 4.16E-10 
Transcription regulation of 
embryogenesis 
 
Table 6-4. Top five genes out 333 at Mild-Moderate spinal segments showing significant differential expression 
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Cluster-analysis of gene expression was performed for all 333 genes from this category. The 
dendrogram and heat-map (Figure 6-7) shows these clusters with corresponding fold-change as 
we move from Mild-Moderate pathology to Severe pathology. The genes in this diagram are the 
333 which significantly differentially expressed in the Mild-Moderate pathology category. None of 
these genes have previously been implicated in ALS and none showed relevant gene-gene or 
gene-protein network relationships with previously established in genes.  
Using DAVID functional annotation clustering for all 333 genes derived 14 clusters with an 
enrichment score greater than 1.3, where 12 contained terms that were significant after multiple 
testing corrections. See Table 6-5 for the cluster headings, and appendix A13 for the entire list of 
cluster significant genes. 
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Blood vessel development 3.42 14 
Glycoprotein signalling 2.86 95 
Glycoproteins & transmembrane activity 2.84 114 
Fibronectin 2.69 11 
Leukocyte migration & cell motility 2.65 15 
Leukocyte migration & response to external stimuli 2.31 8 
Defence response 2.27 20 
Surface antigen & binding 2.06 14 
Extracellular region 2 46 
Plasma membrane 1.71 47 
Leukocyte migration & response to bacterial molecule 1.67 7 
Phosphate activity 1.66 7 
Leukocyte migration & chemotaxis 1.51 12 
EGF-like domain 1.41 12 
 
Table 6-5. Functional annotation clustering with enrichment score > 1.3 of 333 genes found to 
differentially express at regions with Mild-Moderate pathology. 





OTOS Neurosensory epithelium of the inner ear 
ST14 Degrades extracellular matrix 
EFCAB3 Calcium-binding 
HLA-DRB1 Contributes to antigen presenting molecules 
LOC401233 Pseudo gene 
IRF5 Transcription factor for interferons IFNA and 
INFB 
Gene Function 
ZKSCAN1 Transcription regulation 
DEGS2 Sphingolipid enzyme 
DKFZP451A211 Uncharacterised 
BMP8B Functions in cartilage and bone formation 
REM1 Endothelial cell sprouting & cytoskeletal 
reorganization 
Gene Function 
TBC1D2B GTPase-activating protein 
C4ORF31 Promotes neuron migration, growth & survival  
PAX6 Master control gene for sensory organs 
CHPF Transferase activity 
ZBTB7B Transcription regulation of immature T-cell 
precursors 
DCLK2 Possible down-regulation of CRE-dependent 
activation 
FAHD2B Possible role in hydrolase activity 
Gene Function 
TMEM132E Transmembrane protein, function undetermined  
IL6 Important for fever and of the acute phase 
response. 
CYP2S1 Possible extrahepatic xenobiotic metabolism 
CCL2 Recruitment of white blood & T-Cells for 
inflammation  
HAMP Signalling molecule for iron homeostasis 
Gene Function 
STXBP5L Likely vesicle trafficking and exocytosis 
IL17RB Proinflammatory cytokine receptor for 
IL17 






















Figure 6-7. Gene-expression cluster analysis and heat-
map.  
Examining fold-change across pathological severity 
categories for genes that differentially expressed in the 
Mild-Moderate category. X-axis (top) is pathological 
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One of the genes found to differentially express, Sushi domain containing 1 (SUSD1), has been 
previously implicated in ALS in a genome-wide association study in 2007245.  The finding has not 
yet been replicated. The sequence and putative function of SUSD1 is similar to other proteins 
containing EGF-like domains, involved in calcium-binding and immune response and apoptosis. 
In this thesis the SUSD1 gene belonged to the EGF-like domain cluster.  
Using GeneMANIA and STRING there were no significant interactions between any of the 333 
genes here and known major ALS genes. Non-replicated ALS genes CRIM1, KDR, and RAMP3 
showed network relationships with genes involved in blood vessel development and glycoprotein 
function, mostly weak interactions through co-expression, co-localisation, and shared protein 
domains. Most of the interactions were indirect. It is reasonable to expect some low-level 
interaction between ALS genes (n = 110) and the genes found here (n = 333), as 333 genes is 
nearly 2% of all human genes. 
 
6.3.3.2 Moderate pathology 
Analysis of pathologically Moderate spinal regions (n = 5) revealed 34 genes that differentially 
expressed. All significant genes are display in the gene expression cluster-analysis heat-map 
(Figure 6-9) and the top five are displayed in Table 6-6 (for all genes see Appendix Table A17). 
GEMIN5 physically interacts with putative ALS gene Survival Motor Neuron 1 (SMN1) to create 
protein complexes which are important for the synthesis of cytoplasmic small ribonucleoproteins 
(snRNPs) and the splicing of nucleic pre-mRNA (Figure 6-8).  
The gene-expression cluster-analysis revealed four genes that showed Moderate dose-
dependent alteration in fold-change between pathological categories. All four genes are involved 
in immune responses. No gene had been implicated or had a network interaction with a previous 
ALS gene.  
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In the functional annotation analysis the top cluster had an enrichment value of 1.2 and was again 
involved in glycosylation (see Appendix Table A17), although no term was significant after 
correcting for multiple testing. I found no other notable interaction with genes differentially 




Figure 6-8. Gene-gene network of GEMIN5 using geneMANIA.  
Purple line indicates a co-expression, pink line physical interactions, orange line predicted 
interaction, light blue line shared pathway, dark blue line co-localisation, and a beige line shared 
protein domains. 
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Gene Name Symbol Fold Change Adj. P-Value Function 
Solute Carrier Family 1 (glutamate 
transporter), Member 7 
SLC1A7 0.26 2.96E-05 Glutamate transporter 
Leucine-Rich repeat LGI Family, 
Member 4 
LGI4 0.58 1.04E-04 Encodes for leucine-rich protein in brain 
Major Histocompatibility Complex, Class 
I, A 
HLA-A29.1 0.17 3.36E-04 Antigen presenter 
Gem (nuclear organelle) Associated 
Protein 5 
GEMIN5 0.62 2.05E-03 Forms cytoplasmic complexes with SMN proteins 
Carboxypeptidase A4 CPA4 0.45 2.53E-03 Helps release carboxy-terminal amino acids 
Table 6-6. Top five genes out 34 at Moderate spinal segments showing significant differential expression 






















Figure 6-9. Cluster analysis and heat-map of significant differentially expressing genes. 
Examining fold-change in the cases with Moderate pathology. X-axis is pathological severity 
category and y-axis is gene. 
 
6.3.3.3 Moderate-severe pathology 
Analysis of pathologically Moderate-Severe spinal regions (n = 7) revealed 138 genes that 
differentially expressed. All significant genes are displayed in the gene expression cluster-
analysis heat-map (Figure 6-10) and the top five are displayed in Table 6-7 (for all genes see 
Appendix Table AX). 
Gene Function 
HLA-C Antigen presentation 
Gene Function 
HLA-A29.1 Antigen presentation 
Gene Function 
BTN3A2 T-cell response 
Gene Function 
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Gene Name Symbol Fold Change Adj. P-Value Function 
Solute Carrier Family 1 (glutamate 
transporter), Member 7 
SLC1A7 0.15 2.16E-33 Glutamate transporter 
Olfactory Receptor, Family 7, Subfamily E, 
Member 125 pseudogene 
PJCG6 0.44 2.85E-06 Pseudogene mRNA 
Mdm2, Transformed 3T3 cell double minute 
2, p53 Binding Protein, 104kDa 
MTBP 1.92 7.74E-06 Cell cycle regulation and tumour suppression 
Hyaluronan and Proteoglycan Link Protein 
3 
HAPLN3 0.46 6.73E-05 Hyaluronic acid binding 
Adenosine Deaminase ADA 0.50 7.24E-04 Hydrolyses of adenosine to inosine 
 
Table 6-7. Top five genes out 34 at Moderate-Severe spinal segments showing significant differential expression
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The gene-expression cluster-analysis revealed very few genes that showed dose-dependent 
changes in gene expression (see Figure 6-10). The only gene which showed some decrease in 
expression as pathology worsened was Rhox Homeobox Family, Member 1 (RHOXF1). This 
gene is not implicated in ALS and shows no network association with ALS genes. 
The functional annotation analysis top cluster was involved in metabolic and biosynthetic 
processes, with the latter having an enrichment value of 1.39 (see Appendix Table A18). No 
cluster was significant after correcting for multiple testing. MSRA, which was grouped in the 
metabolic processes category, showed an indirect association with ALS which has been 
discussed in Chapter 5. 
  





RHOXF1 Transcription factor in reproduction 
Figure 6-10. Cluster analysis and heat-
map of significant differentially expressing 
genes.  
Examining fold-change in the cases with 
Moderate-Severe pathology. X-axis is 
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6.3.3.4 Severe pathology 
Analysis of pathologically Severe spinal regions (n = 4) revealed 205 genes that differentially 
expressed. All significant genes are displayed in the gene expression cluster-analysis heat-map 
(Figure 6-12) and the top five are displayed in Table 6-8 (for all genes see Appendix Table A19). 
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Gene Name Symbol Fold 
Change 
Adj. P-Value Function 
Angiopoietin 2 ANGPT2 0.36 1.55E-13 Disrupts vascular remodelling & induces apoptosis 
epididymal sperm binding protein 1 ELSPBP1 3.44 2.43E-08 Sperm-coating protein 
Inositol Polyphosphate-4-Phosphatase, Type II, 105kDa INPP4B 1.68 2.50E-07 Phosphatidylinositol signalling pathway 
Olfactory Receptor, Family 7, Subfamily E, Member 125 
Pseudogene 
OR7E125P 0.43 4.87E-07 Pseudogene mRNA 
Transketolase-like 1 TKTL1 2.03 1.53E-06 Links pentose phosphate & glycolytic pathways 
Table 6-8. Top five genes out 34 at Severe spinal segments showing significant differential expression 
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The Angiopoietin 2 (ANGPT2) protein closely interacts with the protein of ALS gene VEGFA. The 
relationship is believed to be context dependent with two relatively opposing functions; (a) through 
direct binding, and/or in the absence of VEGFA, it is believed to inhibit expression of VEGFA 
inducing endothelial cell apoptosis. On the other hand (b) the relationship facilitates endothelial 
cell proliferation through VEGFA activation of ANGPT2 (Figure 6-11). 
 
Figure 6-11. Protein network of ANGPT2 using STRING.  
Green arrows represent activation, blue lines binding, yellow co-expression, red line-end 
inhibition, and grey lines putative interaction through searching experiments, databases, text-
mining, and homology. 
 
The gene-expression cluster analysis revealed 18 genes with altered activity corresponding to 
categories of pathological severity. These genes are highlighted in the tables within Figure 6-13. 
No gene listed has previously been found to contribute to the disease, but do implicate ALS genes 
through network associations. The network analyses of DNAH2 revealed gene-gene interaction 
in sharing a pathway with Dynactin 1 (DCTN1) (Figure 6-12). DCTN1 produces the multifunctional 
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protein Dynactin, which when dysfunctional in ALS is believed to impair axonal transport 
supporting the axonopathy hypothesis of pathogenesis297 (Figure 6-12).  
 
Figure 6-12. Gene-gene network of DNAH2 using geneMANIA.  
Purple line indicates a co-expression, pink line physical interactions, light blue line shared 
pathway, and a beige line shared protein domains. 
 
No functional annotation cluster had an enrichment score greater than 1.3. The highest two 
clusters had a score of 1.17 and the third 1.12. Cluster terms were striated muscle cell 
development, microsomes and vesicular fraction, and fatty acid metabolic processes (see 
appendix table A19). There were no other meaningful interactions with the genes differentially 
expressing at regions showing Severe pathology and known ALS genes. 
  






QDPR Recycling enzyme for BH4 
NDUFB1 Subunit of NADH dehydrogenase  
Gene Function 
DNAH2 Respiratory cilia protein involved in sperm 
motility 
CCDC33 Testis-expressed possible peroxisomal protein. 
Gene Function 
STON2 Possible vesicle recycling 
ZNF135 Cell morphology & cytoskeletal regulation 
GSTM5 Conjugation of glutathione to hydrophobic 
electrophiles 
Gene Function 
CYP4F3 Contributes to a leukocyte 
chemoattractant 
LOC442245 Pseudogene 
SFTPD An innate immune system collectin 
Gene Function 
ZSCAN12L1 Pseudogene 
GALNT6 Oncofetal fibronectin synthesis 
TUBAL3 Major component of microtubules 
Gene Function 
SGTB Regulates HSC70 & HSP70 ATPase 
activity 
Gene Function 
ACSF2 Catalyst in fatty acid metabolism 
FBXL16 Ubiquitination of cell-cycle 
proteins 
Figure 6-13. Cluster analysis and heat-map 
of significant differentially expressing genes.  
Examining fold-change in the cases with 
Moderate-Severe pathology. X-axis is 
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6.3.4 Changes in gene expression as a consequence of severity 
 
Using a genome-wide ANOVA of gene expression by severity, there four genes significant after 
BH multiple testing correction. These were ST5, PARD3B, CNTFR, and RNF216L. None of these 
have been previously implicated in ALS. 
63 genes with a non-adjusted p-value < 0.001 (see Appendix Table A20) were selected, and I 
performed cluster analysis represented by a heatmap (Figure 6-14).  This included two genes that 
have been previously implicated in ALS, DIAPH3{Daoud, 2011 #1378} via resequencing and 











Figure 6-14. Cluster analysis and heat-map of genes that show dose-dependent gene expression 
with severity level. 
 
Genes in clusters circled 1 and 2 were analysed using DAVID’s functional annotation analyses. 
Cluster 1 showed a gradual increase in intracellular protein transport and localisation, with an 
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change in leukocyte response, with an involvement of 12 genes and a resulting enrichment score 
of 1.22. 
 
I also performed soft-clustering analyses on patterns of gene expression change through each 
severity (Figure 6-15). 
 
 
Figure 6-15. Cluster analysis of changes in expression through severity. Time can be 
supplemented by severity level (where 1 = mild-moderate and 4 = severe). The Y-axis represent 
expression changes. Colour of line represent distance from cluster centre. 
 
Each cluster was examined using DAVID’s functional annotation analyses. Cluster 1 was involved 
in regulation of GTPase activity (enrichment score = 1.64), Cluster 2 in Regulation of leukocytes 
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proliferation (enrichment score = 1.52) and regulation of transcription activity (enrichment score 
= 1.39), Cluster 3 in nucleic methylation (1.6), Cluster 4 in calcium related cell-adhesion (1.67) 









- 156 - 
6.4 Discussion 
Through the analysis of gene expression and disease spread, inferred via clinical and pathological 
information, I have identified significant differences in expression between cases and controls.  
Analyses of gene expression by spread found only two genes to differentially express for cervical 
(onset region) and thoracic (second region) regions, four genes for the lumbar (third) region, and 
five genes for the medulla (final) region. 
Analyses of gene expression by pathological severity also identified significant differences 
between cases and controls. The number of differentially expressing genes ranged between 34 
and 333 according to pathology category, and each category revealed an expression profile 
analysed by functional annotation enrichment to vary from all others. The functional categories of 
pathologically Mild-to-Moderate samples were multifarious with 14 gene clusters highly enriched, 
covering functions such as blood vessel development, glycoprotein signalling and leukocyte 
activities. As the severity increased there were fewer annotated cluster. These clusters showed 
a reduced enrichment score but were associated with glycosylation for Moderately pathological 
samples, metabolic processes for Moderately-Severe samples, and striated muscle development, 
microsome involvement, and vesicular fractions in the Severely pathological samples.  
One gene showed expression changes in all three spinal regions excluding medulla, and all four 
categories of severity: SLC1A7. Evidence shows that this gene is less expressed in the Medulla 
in comparison to the other spinal regions examined in this thesis. SLC1A7 is discussed in the 
next section. 
 
6.4.1 The spread of ALS 
Spread of ALS in upper-limb onset cases was estimated to have onset in the cervical regions and 
moved caudally faster than it did rostrally.  However, this was not reflected in the gene expression 
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analyses. The gene expression was relatively uniform throughout the spinal cord, with the 
exception of SLC1A7, which was under-expressed very significantly in cervical, thoracic and 
lumbar regions. 
 
SLC1A7 has been implicated in ALS previously in a comparative genomic hybridisation study 
examining genome-wide copy number variation in 71 sporadic ALS cases and 700 non-ALS 
controls298. The most promising gene was SLC1A7, which showed a copy number gain found 
exclusively in one patient298. In a recent study SLC1A7 was up-regulated with the authors 
reasserting its candidacy due its likely functional involvement in ALS pathology299. 
SLC1A7 protects motor neurons from excitotoxicity by transporting extracellular glutamate300 
through synthesising the protein EAAT5. EAAT5 shares 36% sequence identify with glia protein 
EAAT2, which is encoded by SLC1A2 of the same gene family and has almost the exact same 
function as EAAT5. EAAT5 is considered to be a retinal specific glutamate transporter301 but it 
also highly expresses in the spinal cord, temporal and prefrontal cortices, and thalamus, more-so 
than any other major brain or spinal cord region (UCSC Genome Bioinformatics – Genome 
Browser). 
EAAT2 expression levels have been found to be significantly reduced in brain and spinal cord in 
approximately 60% of ALS patients302. The cause of EAAT2 reduction may be alternative aberrant 
splicing303 but this has not yet been confirmed. An alternative hypothesis is that it is indirectly 
involved in ALS. Knockdown of TDP-43 in drosophila, which causes an ALS cytological 
phenotype, significantly affects glia EAAT1 and EAAT2 expression304. It is plausible that EAAT2 
expression either delays or exacerbates ALS onset, but does not cause ALS, as has been seen 
in mice305.  
EAAT2 dysfunction, or perhaps inefficiency, most likely contributes to ALS via glia. It is also 
possible that EAAT5 is expressing from glia in our data as there was no dose-dependent change 
across different stages of onset. We would expect almost non-existent expression in regions 
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where onset had occurred early, because by the time there is severe involvement, motor neurons 
would be very few in number, whereas glia counts would be almost unchanged. In the work 
presented here, the cervical and thoracic regions were where ALS manifested for the longest 
period of time. Therefore, in these regions, we would expect near non-existent expression of 
known ALS genes in these regions in which we did not, nor did we find any other gene showing 
differential expression. 
The expression profile of the Medulla was different from the other spinal regions. The number of 
genes found to differentially expression was small compared to previous research with ALS spinal 
regions. This may be a power issue but a more likely explanation is that that the disease duration 
for the cases used in this analysis was above average. This meant that the disease had 
manifested for a long period of time in the second, third and fourth regions, which could make the 
pathology of this region indistinguishable from the first onset region. The H&E pathological 
evidence does show some decrease in pathological severity, but this is only slight. An alternative 
explanation is that there is no changing gene expression as the disease progresses, but this 
would not be concordant with previous gene expression work in ALS and other neurodegenerative 
diseases. 
The medulla presented a different gene expression profile from the spinal cord in relation to ALS. 
It could be that the disease manifests itself differently here and the background expression profile 
is naturally different between the medulla and the spinal regions examined. When comparing 
gene expression between spinal regions in controls, the Medulla shows many significantly 
differentially expressing genes when compared with non-Medulla regions. It is anatomically very 
different than the spinal regions examined in this thesis and it may be very different functionally 
for ALS pathology. Its involvement in ALS is likely due to its proximity of ALS initial onset and 
rostral spread. 
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6.4.2 Pathological severity and ALS 
The changes in gene-expression profiles as the disease travels from its early beginnings to later 
stages should be informative about its pathogenesis. I would expect that at more mildly affected 
regions gene expression profiles reflect motor neural responses to the disease, whereas more 
severe pathologically effected regions reflect glia-based responses. 
 
6.4.2.1 Mild-moderate pathology 
The least severe group, with mild to moderate pathology defined by loss of motor neurons, had 
the most genes showing differential expression. It showed high enrichment for 14 annotation 
clusters (see Table 6-5). These cover a vast range of functions but present us with a picture of 
gene activity just after the spinal cord begins to show pathology. 
Blood vessel development was the most enriched cluster. This cluster also contained 
angiogenesis as an important function, with nine of the 14 genes loading onto this category. The 
association of two functions with ALS is not new. There is strong evidence implicating the 
Angiogenin gene (ANG) as important in ALS, with mutations causing sub-type ALS941. However, 
blood vessel development and angiogenesis were first implicated through the identification of the 
vascular endothelial growth factor A (VEGFA) gene 106 as associated with ALS. This gene codes 
for a growth factor and signalling protein for ANG. In the most Severe group there was also an 
relationship between VEGFA expression and the most significantly expressed gene from the 
cluster, ANGPT2, suggesting that blood vessel development and angiogenesis was a major factor 
for these cases throughout the course of their disease. Figure 6-14 shows the predicted 
relationship between ANGPT2 and ANG through angiogenesis. I will return to this relationship 
later. There was no relationship of genes in this category with ANG other than through shared 
functional annotation. 
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Figure 6-16. Interactions and pathways between genes ANGPT2 and ANG 
- 161 - 
Angiogenesis and blood vessel development work towards the growth and maturation of healthy 
blood vessels. Angiogenesis itself implicates cell migration, proliferation and tubular structural 
formation as possible means of pathological dysfunction306. Furthermore the ANG gene 
contribution to angiogenesis can come through four (currently known) pathways; through 
ribonucleolytic activity, through membrane binding and basement degradation, through signalling 
transduction, and through enhancement of nucleic rRNA transcription.  
ANG may be important to ALS, not only because several genomic findings and several genes 
found to significantly differentially express support angiogenesis as a pathogenic pathway, but  
the functions in which ANG is related to , have all been independently implicated in ALS. These 
include RNA regulation57, 89, 307, 308, both membrane trafficking and binding309, signal 
transduction310, 311, and dysfunctional nucleic localisation56. Furthermore, angiogenin normally 
operates in endothelial which are neuroprotective for spinal motor neurons306.  
There are several significant functional annotation categories in the analysis of pathologically 
Mild-Moderate regions that lend support to the idea of angiogenesis and ANG-like dysfunction. 
Membrane activity, phosphatase activity (indicating problems with signal transduction) and EGF-
like domains (opening up possible issues with cell growth and proliferation), were all highly 
enriched significant annotation clusters identified by DAVID. Examining the gene-expression 
cluster analysis for dose-dependent effects, we see genes TMEM132E (possible transmembrane 
protein) and HAMP (a signalling molecule for iron homeostasis) reduce in gene expression as the 
disease worsens, whereas gene expression for ZKSAN1 (transcription regulation) and REM1 
(endothelial cell sprouting and cytoskeletal reorganization) gradually becomes increased when 
the disease is in its final stages, the last stage being death.   
With four out of 14 functionally annotated clusters implicating gene expression abnormalities in 
angiogenin-like malfunction, with several functionally related genes showing graded change as 
the disease progresses, these results suggest the that angiogenin expression is pivotal in ALS 
pathogenesis. 
The Mild-Moderate category was also extensively characterised by several functional annotated 
clusters involving glycoproteins, specifically membrane activity possibly linked to signalling and 
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Fibronectin. Although glycoproteins are ubiquitous and multifunctional, given the findings of the 
Mild-Moderate category, it is of interest that such proteins are most concentrated in blood. This 
may point to problem with membrane based signalling which leads to aberrant blood vessel 
development.  
Glycoprotein functional annotated clusters in this analysis were the second and third most 
enriched. Fibronectin was the fourth most enriched, which is also a glycoprotein.  Fibronectin is 
multifarious, involved in cell growth, adhesion, differentiation and migration. It was also first 
suspected to contribute to ALS pathology in 1980312. Increased levels of multi-domain 
glycoproteins in ALS tissue were found in 1992313, and their presence have been replicated in 
various post-mortem material including cerebral spinal fluid314 and plasma315. Glycoproteins have 
also showed differential expression in ALS mice316, especially in motor neurons and astrocytes264. 
In this analysis and somewhat in ALS research there seems an unclear connection between 
angiogenin based activity and glycoprotein function. I found four genes (SUSD1, CRIM1, KDR, 
and RAMP3) previously implicated in ALS that showed a significant relationship with genes that 
differentially expressed in this analysis linking blood vessel development and glycoproteins 
through a wide variety of aberrant genetic functions. 
So far I have covered eight of the 14 functional annotation clusters for the Mild-Moderate category. 
The remaining six annotated clusters point to abnormal expression concerning leukocyte 
migration in relation to cell motility, regulation of responses to an external stimulus, responses to 
a bacterial molecule, and chemotaxis. These alterations suggest a response to an environmental 
agent. The remaining two clusters relating to leukocyte activity were defence response, and 
surface antigen and binding, also suggesting an external agent.  
Very few findings in ALS relate leukocyte activity as a whole to disease pathogenesis, however 
there is evidence of neuroinflammation and lymphocytes seem to play an important role. Before 
genetic advances in ALS began to accelerate around the mid 1990’s, autoimmunity was a 
dominant hypothesis to why ALS occurred317.  
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In patients there is a strong immunological response to the disease mostly in blood and the 
CNS318. IN ALS lymphocytes infiltrate perivascular cells (smooth muscle cells)319 and invade the 
spinal cord in high concentrations. A study found 79% of ALS cases to have lymphocytic 
infiltration320, in which the majority will likely be T-cell321. Lymphocytes show abnormal 
concentrations in patients early on in their disease, which suggests possible recruitment of T-cells 
to the rescue of dying motor neurons322. Neuroinflammation is mediated by T-cells as well as 
macrophages and mast cells323, and this process has been shown to be neuroprotective towards 
motor neurons in mutation SOD1 (SOD1MT) mice324 and humans through regulatory 
lymphocytes325. 
However, CNS T-cell responses can also be detrimental; for example this process slows 
Alzheimer’s disease while it seems pathological in Parkinson’s disease326. An ALS SOD1MT 
mouse model manipulating the presence of lymphocytes showed them to be deleterious in the 
early stages of the disease, hastening onset through inhibition of M2 microglia327. The 
discrepancy between these consequences is likely to be due to the sub-classification of cell types 
and extent of ALS pathology. It is known that T lymphocytes can induce either cytotoxicity (M1 
microglia) or neuroprotection (M2 microglia) in ALS, depending on disease stage328. 
What is also relevant here and important in this pathological pathway is that leukocytes interact 
with the Blood-Brain Barrier (BBB). In ALS, lymphocytes show small concentrations in the CNS 
until inflammation occurs which alter endothelium. This leads to expression of cellular adhesion 
molecules, which bind to leukocytes allowing leukocytes to cross the BBB into the CNS329-332.  
The evidence from the work presented in this chapter strongly points to leukocyte migration, cell 
motility, chemotaxis and surface antigen binding. All these functions are necessary for the 
leukocyte-BBB migration to occur. Furthermore blood vessel development and glycoprotein 
membrane signalling may also play a crucial role in allowing this to happen. For example, I found 
gene IL7R differentially expressing in both the second onset group in section 6.3.2.2 and the 
Severe pathology category in section 6.3.4.4. IL7R synthesises a glycoprotein that helps regulate 
lymphopoiesis. Taken together these findings closely link all three glycoprotein, angiogenin 
function, and leukocytes categories together. 
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In support of changes in immune-based gene expression, the cluster analysis and corresponding 
heat map of fold-change showed at least six immunogenes (HLA-DRB1, IRF5, IL17RB, ZBTB7B, 
IL6, and CCL2) that highly express in ALS cases to begin with and become unexpressed by the 
time the spinal region has reached Severe pathology. There are no immunogenes that increase 
expression over this period.  
 
This analysis supports the involvement of immune function in ALS spinal cord pathology. The 
gene expression analysis of Mild-Moderate pathology can be divided into three major 
components, (a) angiogenesis and blood vessel development function, (b) glycoprotein-based 
membrane activity, and (c) leukocyte response. Membrane signalling and leukocyte responses 
are important for angiogenin efficacy, and all three are known ALS pathological pathways 
independently. Here I also suggest the idea that they are related, with leukocyte-led cytotoxicity 
occurring as the primary defect in one or all three of the above major components. 
It is possible that a defect somewhere in the angiogenin or glycoprotein pathways cause the 
infiltrated CNS immune response which ultimately fails and becomes toxic. The fact that ALS 
research has found mutations in genes relevant to angiogenin and glycoproteins supports this 
hypothesis, whereas evidence for genetic involvement in immune based activity is non-existent. 
Furthermore it seems that the immunoresponse in the CNS, at least in terms of lymphocytes and 
neuroinflammation, can be beneficial if activated at the right stage of disease. 
An alternative is that the pathology may arise in immunity itself which allows or leads to alterations 
in angiogenin and glycoprotein function. Under this reasoning we may conclude that genetic 
mutations found in genes like VEGFA and ANG are more like susceptibility factors rather than 
causers of ALS. In this scenario it is likely that immune responses are not caused by genetics as 
there is little evidence for this. The data here suggests that the immune response is towards an 
external stimulus or even pathogenic bacteria. But despite much research in ALS no convincing 
pathogen or environmental toxin has yet been identified. 
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A third hypothesis is that gene expression analyses here are all reacting to an unidentified 
pathology, of genetic or environmental origin. This is possible but unlikely as the findings replicate 
genetic and proteomic research that has previously shown direct causation between the functions 
described in this chapter and ALS. Furthermore, their implication in ALS pathology is supported 
by the bioinformatic post-hoc analyses showing interactions of differentially genes found here with 
known ALS mutated genes.  
 
6.4.2.2 Moderate pathology 
Moving on to the next category, Moderate pathology, we find the story changes little. No functional 
annotation cluster passed the 1.3 enrichment benchmark, but the most significant cluster was 
glycosylation and glycoproteins with an enrichment score of 1.21. What is hidden from this 
analysis is that several genes differentially expressing in this category are immunoresponse 
genes and show dose-dependent changes as the disease progresses; HLA-C expression 
increased initially with increasing severity and fell as the disease took hold, BTN3A2 decreased 
with worsening pathology, whereas PADI4 and HLA-A29.1 increased expression.  
The most significant differentially expressing gene, shown to greatly under-express and which 
has been implicated in every gene expression analysis of this thesis, was the glutamate transport 
gene SLC1A7. Please see section 6.3.1 for a detailed exploration of this gene in ALS. 
The fourth most significant gene in this category, GEMIN5, physically interacts with SMN1 to form 
macromolecular complexes involved in cytoplasmic assembly of snRNPs. It is also involved in 
nucleic pre-mRNA splicing. SMN1 was first implicated in ALS through the examination of SMN2, 
in which abnormal copy numbers of SMN1 was found to increase ALS susceptibility101, 333, 334. 
Now both SMN genes have been found to contribute to ALS pathology, which share a gene-gene 
relation where SMN2 counteracts the phenotypic expression of aberrant SMN1335. SMN1 is 
thought to have a protective effect against SOD1 toxicity336. Abnormal copy number of SMN1 was 
initially found to be associated with ALS in a French ALS population101 and interference with SMN 
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protein production shortens survival in mice337. It is also possible that SMN1 shares a similar 
function to the ALS gene Fused in Sarcoma (FUS), with both genes perturbing cytoplasmic 
formation of snRNPs. How GEMIN5 and SMN1 relate to the current analysis is unclear other than 
possible link between transcription regulation and angiogenin function. 
 
6.4.2.3 Moderate-Severe pathology 
The most enriched and only significant functional annotation cluster for this category was 
metabolic and biosynthetic processes. This cluster contained ontological terms such as sulphur, 
coenzyme, and cofactor metabolic and biosynthetic processes. Increased concentrations of the 
sulphuric amino acid Taurine has been recorded in ALS338, 339 and has some unclear relation to 
excitotoxicity340. Recently Taurine Transporter (TauT) has been shown to over express in SOD1MT 
mice.  It is likely that sulphur amino acids bind with glutamate receptors due to high-affinity341, 
reducing receptor efficacy. Alternatively, the increase of sulphur amino acids in ALS may be a 
consequence of pathologically-related caspase enzyme activity. 
The second most enriched functional annotation cluster was haemopoiesis and lymphoid organ 
development, and had an enrichment score of 1.18. These functions have not been directly linked 
to ALS but haemopoiesis is a synthesising process for components of blood cells and continues 
the theme found with early stages of the pathological severity.  
 
6.4.2.4 Severe pathology 
The final Severe pathology category somewhat describes a region of the spinal that has become 
damaged and fragmented through self-destruction.  The most significant gene differentially 
expressing is ANGPT2, which has as one of its major functions endothelial cell apoptosis and 
vascular regression in the absence of VEGFA. Reduced VEGFA expression in SOD1MT mice 
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leads to a more severe ALS phenotype109 and reduces Age Of Onset (AOO) in human patients342. 
Increasing VEGFA expression led to greater protection of motor neurons from ischaemic death109. 
It has been proposed that VEGFA activates the PI3-K/Akt signal transduction pathway which 
reduces glutamate excitotoxicity343. I did not find any genes related to this pathway in this analysis. 
My findings suggest that the role of VEGFA in increasing motor degeneration severity is through 
ANGPT2, which will cause apoptotic death in endothelial cells when not modulated. 
The Severe pathology category also found the gene DNAH2 to be differentially expressed 
between cases and controls. DNAH2 is a respiratory cilia protein associated with microtubules. It 
may be involved in ALS pathogenesis through Dynein and the DCTN1 gene. DCTN1 protein 
product Dynactin, when mutated, is believed to lead to problems of microtubule binding which 
impedes axonal transport. There is no immediate reason why this gene is present at the most 
Severe category of the disease where there should be no surviving motor neurons.  
 
The top functional annotation clusters found for the Severe pathology category were striated 
muscle cell development, microsomes and vesicular fraction, and fatty acid metabolic processes 
(see Appendix Table A16). Paralysis of striated muscles is a consequence of denervation of motor 
neurons, which facilitates atrophy. It is possible that the expression activity found in the cluster 
represents an attempt to repopulate muscle cells in atrophied muscle. Fatty acid metabolites are 
too an indicator of cell death and neuroinflammation. Microglia synthesise fatty acid metabolites 
when producing inflammation and neurotoxic factors. It is most likely that the expression found in 
these two categories is from glia cells as they manage a post-apoptotic region. 
Microsomes are usually cytoplasmic artefacts constituted from broken up endoplasmic reticulum 
(ER) organelle or plasma membrane and are vesicle-sized. Similarly, vesicular fraction refers to 
obsolete broken vesicular particles. These can occur via experimental procedures of RNA 
extraction and centrifugation, or they can occur naturally due to pathology. As (A) I do not see 
these functional annotation clusters anywhere else in the dataset, (B) the samples’ RNA 
extraction was completely randomised and (C) extraction methods, laboratory, and scientist was 
the same, I will consider the microsomes to be naturally occurring.  Furthermore it is what one 
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may expect to identify at the worse extremity of ALS pathology. Microsomes and vesicular 
fractions, in addition to apoptotic glia cell activity, are likely to be conclusion of the disease when 
it has depleted a spinal region of its motor neurons. 
 
The gene-expression cluster-analysis and related heat-map concerning fold-change across each 
pathological category picked out several interesting changes in gene expression. Gene 
expression for ACSF2 (catalyst of fatty acid metabolism) and QDPR (recycling enzyme) 
decreased as ALS worsened. FBXL16 also decreased across categories. This is involved in the 
ubiquination of cell-cycle proteins and may also cause ubiquitin-like functions of protein 
degradation. Genes STON2 (possible vesicle recycling), CYP4F3 (contributes to a leukocyte 
chemoattractant), and SFTPD (an immune system collectin), revealed increased expression over 
the course of the disease.  
These selected genes and the evidence presented above support a picture of a late, possibly 
toxic, immune response most likely from glia, as well as possible fragmented remnants of dead 
motor neurons. 
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6.4.3 Expression by severity category 
Analyses of gene expression by different levels of tissue severity was performed to identify dose-
dependent changes, as a proxy to changes in expression as the disease progresses through the 
spinal cord. Two methods were employed, the first being a genome-wide one-way ANOVA of all 
gene expression by severity (this was represented using a cluster analysis and heatmap), and 
the second method using the MFuzz soft-clustering algorithm which clusters genes based their 
on changes in expression as a consequence of severity.  
The first method identified 63 genes with their expression significantly changing as a 
consequence of severity, with a non-adjusted p-value < 0.001. Two of these genes have 
previously been identified in ALS, DIAPH3{Daoud, 2011 #1378} and VEGFA{Oosthuyse, 2001 
#382}{Lambrechts, 2003 #590}. Dauod et al. (2011) identified DIAPH3 through a candidate gene 
resequencing approach where they identified two missense mutations and one nonsense 
mutation. One of the missense mutation was predicted to affect protein function, with the 
nonsense mutation causing a premature stop codon. 
VEGFA has previously been described in sections 6.4.2.1. Mild-moderate pathology and 6.4.2.4 
Severe pathology. It was identified to interact with the highly significantly down-regulated gene 
ANGPT2. The one-way ANOVA directly implicates VEGFA as it clearly changed from up-
regulation to down-regulation, when compared with its overall expression level, while moving from 
mild-moderately affected areas to severe areas. It seems that when ANGPT2 becomes down-
regulated as does VEGFA at the same stage of the disease. A pathological mechanism may be 
that lack VEGFA excitatory activation of ANGPT2 leads to lack an endothelial cell proliferation. 
Or, looking at the relationship in converse, improper ANGPT2 activity leads to poor inhibition of 
VEGFA and therefore improper activation of apoptosis function. 
 
The two clusters identified from the 63 genes identified by the ANOVA analysis were not 
significantly enriched. These were (1) intracellular protein transport and localisation, and (2) 
leukocyte response. The first cluster has relevancy in ALS pathology due to protein cytoplasmic 
mislocalisation of putative ALS-proteins as well as protein transport believed to be disrupted. Of 
interest in this analysis is how expression affected leukocyte response changes. It moves from 
down-regulation to up-regulation as the tissue is more severe. This concurs with the ALS 
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hypothesis regarding possible over-infiltration of C.N.S leukocyte that eventually become toxi to 
motor neurons. 
 
The second method employed was to cluster genes based on their expression changes alongside 
varying tissue severity. The analysis identified five clusters, all enriched over 1.3 by DAVID’s 
functional annotation analysis. Again we see an up-down change in leukocyte response but also 
coupled with regulatory transcription activity, suggesting that these two functions may be related. 
Interesting, but possibly ALS-relevant categories also included regulation of GTPase-activity, 
nucleic methylation, calcium-related cell adhesion, and nucleic lumen function.  
 
6.4.4 Summary 
This chapter approached the study of disease spread in ALS using gene expression analyses, 
histological analyses to estimate extent of pathology, and clinical history to establish where and 
when the disease began and spread, and how this changed in terms of gene expression. 
My first approach was to use upper-limb cases only, where I used pathology and clinical data to 
establish where the disease began, showing that in these cases it began in the cervical region 
and moved rostro-caudally before finally involving the medulla. I then performed differential 
expression analysis between spinal segments of the same region, classifying each in sequence 
of occurrence in disease progression. Relatively few genes were found to differentially express 
and there were not enough genes to run gene-expression cluster analyses and functional 
annotation clustering. One gene SLC1A7, which synthesises a glutamate transporter called 
EAAT5, was found consistently to under-express throughout the spinal cord. This is a potential 
candidate for ALS pathogenesis as we know that EAAT2 has been shown to be pathogenic in 
ALS. 
My second approach of analysing spread was to divide pathological severity into four categories. 
I compared each category of ALS severity with controls. These analyses revealed a large number 
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of significantly differentially expressed genes which I was able to functionally cluster by 
annotation, and through gene-expression cluster-analysis identify genes that showed dose-
dependent changes according to pathological severity. The overall picture revealed three main 
clusters of functions showing differential expression: (a) angiogenesis and blood vessel 
development function, (b) glycoprotein-based membrane activity, and (c) leukocyte response. As 
the analyses progressed through increasing levels of severity categories, clusters (a) and (b) 
became less prominent whereas immunity responses remained important. In light of other 
research there could be an inherent fault within any one of these systems, which eventually allows 
leukocytes to infiltrate the CNS possibly leading to toxicity or at least failure in protecting motor 
neurons. 
 
My final approach was to identify which gene’s expression changed in relation to the severity 
category of the tissue. My aim was to capture the change in gene function as ALS progresses. I 
identified two genes previously implicated in ALS, with one gene (VEGFA) showing a possible 
disrupted interaction with ANGPT2, which could be fatal to a cell. In addition, the cluster analysis 
of the ANOVA results statistically classified genes showing an up-down change in leukocyte 
response as the disease became more severe. This concurred with the results from my second 
approach where leukocyte response remained statistically present throughout each stage of the 
disease, even when the angiogenesis and glycoproteins functional categories started to waver as 
we move to more severely affected tissue. This third approach also identified clusters that are 
relevant to ALS, such as transcript variation and calcium-led cell adhesion. 
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Chapter 7 Temporal related disease phenotypes and gene 
discovery 
7.1 Introduction 
Disease genes in ALS have been categorised into susceptibility and disease-modifying. This 
chapter explores disease genes that modify ALS disease phenotypes. The major ALS 
phenotypes, which have been purported to have a genetic basis, some having heritability 
estimates to support this claim132, are age of onset (AOO), duration from onset to death (survival), 
and disease onset site (bulbar, limb, or respiratory onset).  
For an in-depth review of disease-modifying genes in ALS please see the literature review of this 
thesis. It is evident that disease-modifying genes are less frequently discovered than susceptibility 
genes, and have a poor history of replication. It may be that phenotypic data derived from 
multifarious clinics is not collected in a uniform manner, or that this area is under researched in 
ALS, or that there are simply fewer disease-modifying genes. A fourth possibility exists that the 
distinction between susceptibility and modification is fallacious and that all genes are both. 
This chapter uses two analyses that aim to (a) calculate the variance explained by a UK genome-
wide genotype dataset for AOO and survival, (b) identify genes using genome-wide linear 
regression that affect AOO and survival when modelled as quantitative traits. I also use logistic 




Sample collection, sample preparation, genotyping, statistical quality control, and imputation have 
been described previously (please see chapters 1 and 2). Only the UK samples used in Shatunov 
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et al. were used for this chapter’s analyses because I did not have phenotype data for the other 
countries. 
 
7.2.1 Advanced Complex Trait Analysis 
Advanced Complex Trait Analysis (ACTA) is a modified version of the Genome-wide Complex 
Trait Analysis (GCTA) software344, 345. Both aim to calculate the amount phenotypic variance in a 
quantitative trait explained in a genome-wide SNP dataset, while also estimating "missing 
heritability" (variance in heritability of the trait not accounted for by the SNP dataset). 
ACTA uses a mixed linear model (MLM); modelling the phenotypic variance as the dependent 
variable, fixed effects modelled with disease-modifying factors (in ALS, such as age, sex and 
population components), and SNPs modelled as random-effects. Modelling SNPs as random-
effects allows their overall variance to be estimated and used to calculate how much the genetic 
variance accounts for the phenotypic variance. Modelling SNPs as random-effects is also useful 
because they are often not useful when estimating of the effect of an individual SNP on a 
phenotype, because genotypes vary from person to person. Instead, we can neatly calculate the 
non-specific effects of all SNPs on a phenotype. 
By matching individuals, the estimation of genetic and phenotypic variance forms the basis of the 
genetic relationship matrices (GRM). ACTA then uses a restricted maximum likelihood (REML) 
analysis to calculate parameters for the GRM estimates, and test their likelihood given the 
dataset.  
We used only autosomal SNPs in our dataset with a Minor Allele Frequency (MAF) of 0.01 to 
estimate the GRM. Our data consisted mainly of common genotype markers which is unlikely to 
tag rarer variants with a MAF of 0.01. Lower than this may result in an overestimation of the 
model. 
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 We then pruned the matrices by (a) removing individuals with estimated relatedness greater than 
0.025 (the recommended default value) and (b) assuming possible causal loci as having the same 
allele frequency distribution as genotyped SNPs. We then performed principal component 
analyses (PCA), estimating the first twenty eigenvalues. The eigenvalues represent latent groups 
(or variables) within the dataset, which we can use to account for extraneous variance that may 
interfere with estimations of genetic-phenotypic variance. These groups were included in the 
REML model.  
The REML output consisted of variance estimates and standard errors for each model parameter; 
genetic variance, residual, and phenotype variance. It estimated genetic to phenotype variance 
ratio, and also performed a likelihood ratio test from the MLE in which the p-value is derived. 
This was performed for both AOO and survival. Please note for both analyses all patients are 
deceased. 
 
7.2.2 Genome-wide linear regression of quantitative traits 
Genome-wide linear regression has been described in chapter 2. In brief, here we considered 
AOO and survival as quantitative traits for 578 UK cases. We quality filtered our dataset excluding 
SNPs with MAF <0.02, HWE <0.0001, and genotype genome-wide coverage of <95%. We also 
accounted for stratification effects caused by sex and adjusted for multiple testing. 
830 SNPs were removed bringing the amount of SNPs analysed and corrected for 444,710, with 
a genomic inflation factor of 1.009. The inflation factor tests for unwanted population stratification 
by comparing the median observed distribution with the median expected distribution, using 
markers not relevant to the trait in question. The comparison is performed using chi-square.  
I examined normality for both quantitative traits using Kolmogorov-Smirnoff in Stata 12.0. Both 
significantly deviated and AOO was transformed using the square of each data point, and for 
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survival the log. Re-testing normality showed the data distributions were no longer significantly 
different from normal. 
I did not use genome-wide cox regression for survival data as patients were all deceased and so 
censor status is monomorphic, which is not supported by the R package GenABEL346. Cox 
regression survival analysis were run for individual SNPs highlighted as near significant in the 
survival genome-wide linear regression analysis. SNP alleles were used as covariates with 
survival in decimalised years and status, which all patients were deceased. 
 
7.2.3 Genome-wide logistic regression of onset-site 
Genome-wide logistic regression has been described in chapter 2. We quality filtered our dataset 
excluding SNPs with MAF <0.02, HWE <0.0001, and genotype genome-wide coverage of <95%. 
We also accounted for sex effects and adjusted for multiple testing for the 444,765 SNPs 
analysed. 
There were 364 limb-onset, 163 bulbar-onset and 10 respiratory cases, and 4142 controls. All 




We analysed AOO using ACTA (n = 572). The ratio of phenotype variance explained by our 
genotype data was 0.000001. A likelihood ratio test, examining whether this amount of variance 
explained was significant compared to a null model with no genetic variance component, was 
unsurprisingly not significant.  
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For AOO in the international dataset (n = 1366) this analysis was nearly significant with the 
genotype to phenotype variance ratio being 0.42 and a likelihood ratio test is 1.862 (p = 0.086). 
This analysis was conducting correcting for 20 eigenvectors. 
Analysing our survival data (n = 572), the genotype to phenotype ratio variance was almost 1. 
The likelihood ratio test (2.96) was significant, with a p-value of 0.04. This suggests that a 
significant proportion of survival variance is explained by the genotype data. 
 
7.3.2 Genome-wide linear regression 
After quality control procedures there were 444,710 SNPs and the Bonferroni-corrected 
significance threshold was 1.12x10-7. 
We treated AOO as a quantitative trait and analysed this phenotype using a genome-wide linear 
regression (n = 599). There was a significant association at locus 18q22.3 in the UK set, involving 
11 intergenic SNPs (see Figure 7-1 and Table 7-1).  
We sought to replicate this finding in several international datasets, independently and combined. 
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Figure 7-1. Manhattan plot of genome-wide linear regression of AOO 
Because the 18q22.3 SNPs show a definitive association with ALS and because SNP rs10514080 
is approximately 250kb from the nearest gene LOC100505817, I ran an epistasis analysis 
examining all significant chromosome 18 SNPs to try identify trans-acting interactions (Table 7-
2).  
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Chr SNP Base Pos. Allele Beta S.E. P-value 
Bonferroni 
Adjusted P 
18 rs10514080 69426930 G 431 79.39 8.35E-08 0.03715 
18 rs876964 69435617 A 396.3 76.66 3.23E-07 0.1435 
18 rs1107827 69435868 A 394.8 76.79 3.74E-07 0.1662 
2 rs4256004 48891658 G -506.6 111.3 6.42E-06 1 
17 rs4792941 39848546 A -340.7 77.24 1.23E-05 1 
15 rs7164838 32754866 A 359.5 81.96 1.37E-05 1 
18 rs2850481 69445149 G 356 81.26 1.40E-05 1 
2 rs2080727 24204411 G 337 77 1.43E-05 1 
15 rs1978809 32745481 A 428.1 98.14 1.52E-05 1 
18 rs1943902 69455480 A 353.1 81.11 1.59E-05 1 
20 rs7272567 40219855 A -647.6 150.1 1.87E-05 1 
18 rs6566754 69479113 A 343.6 79.81 1.96E-05 1 
18 rs11151895 69512617 A 338.1 78.79 2.08E-05 1 
18 rs9950388 69415070 G 319.1 74.39 2.10E-05 1 
13 rs2282022 40272186 G 330.8 77.24 2.16E-05 1 
13 rs1536805 40267658 A 338.1 79.08 2.23E-05 1 
13 rs3783163 40278453 G 338.1 79.08 2.23E-05 1 
18 rs1484217 68610550 A 332.6 78.05 2.37E-05 1 
18 rs8099013 69412772 A 317.5 74.63 2.45E-05 1 
2 rs4149372 24159016 C 332.7 78.43 2.58E-05 1 
 
Table 7-1. Genome wide linear regression of AOO showing top 20 most significant SNPs 
 
  






significant Best χ² Best Chr Best SNP 
18 rs6566754 444785 0.009688 31.01 7 rs6947780 
18 rs1943902 444785 0.009717 27.39 7 rs6947780 
18 rs2850481 444785 0.00971 26.52 7 rs6947780 
18 rs10514080 444785 0.009139 24.56 7 rs6947780 
18 rs1484217 444785 0.01025 22.29 10 rs10761563 
18 rs876964 444783 0.009234 21.66 10 rs10999801 
18 rs11151895 444785 0.009382 21.42 21 rs2827206 
18 rs1107827 444783 0.009097 21.26 10 rs10999801 
18 rs9950388 444785 0.01028 20.31 3 rs11720065 
18 rs8099013 444785 0.01048 19.86 19 rs9304656 
 
Table 7-2. Genome wide epistasis analysis using significant chromosome 18 SNP 
Four out of 10 SNPs interact with rs6947780, which is an intergenic SNP approximately 
equidistant from RNA gene LINC00265 and CDK13 by 100kb. Neither gene has been previously 
implicated in ALS. 
rs10761563 on chromosome 10q21.2 is in intron 3 of the RHOBTB1 gene, and  its function is 
GTPase signal transduction and actin filaments regulation. rs10999801 is an intergenic SNP 
10q22.1 and does not share linkage disequilibrium (LD) with rs10761563. rs2827206, rs11720065 
and rs9304656 are all also intergenic. 
We also treated survival as a quantitative trait in a genome-wide linear regression (n = 599), which 
identified no significantly associated SNPs after Bonferroni correction. There were two SNPs 
showing suggestive association that were in high LD with each at r2 = 0.98 and D’ = 0.99. These 
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were rs3781399 (unadjusted p = 9.62x10-06) and rs11818446 (unadjusted p = 1.32 x 10-5), in gene 
CTBP2 on chromosome 10. CTBP2 has not previously been implicated in ALS. 
Cox regression of SNP rs3781399 with alleles as covariates confirmed that it had a significant 
impact on ALS survival (p = 0.001, Exp (B) = 0.601). 48 patients had alleles AG and 529 had 
alleles GG (21 cases had no survival data and 1 case was exclude for being under-represented 
with alleles AA). The G allele is risk and significantly decreased survival in ALS  (see Figure 7-
2).  
 
Figure 7-2. Survival plot of cox regression of rs3781399 alleles effect on ALS survival 
 
Cox regression of SNP rs11818446 with alleles as covariates confirmed that it had a significant 
impact on ALS survival (p = 0.001, Exp (B) = 0.601). 49 patients had alleles GA and 528 had 
alleles AA (21 cases had no survival data and 1 case was exclude for being under-represented 
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with alleles GG). The A allele is risk and significantly decreased survival in ALS  (see Figure 7-
3). 
 
Figure 7-3. Survival plot of cox regression of rs11818446 alleles effect on ALS survival 
 
7.3.3 Genome-wide logistic regression 
7.3.3.1 Limb-onset 
After quality control procedures there were 444,765 SNPs, and the Bonferroni-corrected 
significance threshold was 1.12x10-7. 
A genome-wide logistic regression association analysis was performed comparing limb-onset 
patients (n = 364) with controls (n = 4142). No SNPs were significantly associated after Bonferroni 
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correction. However four pairs of SNPs, sharing the same genomic loci, had p-values that were 
suggestive of a disease association. To elucidate possible disease relevant haplotypes for each 
SNP-pair, linkage disequilibrium was calculated across all cases and controls (Table 7-3). 
Chr SNP1 SNP2 Linkage 
Disequilibrium r2  
Linkage 
Disequilibrium D’ 
10 rs11192617 rs951030 1 1 
10 rs8624 rs7904918 0.87 0.96 
22 rs9615919 rs9615341 0.91 0.96 
8 rs1494913 rs1389976 0.91 0.96 
 
Table 7-3. Linkage disequilibrium for SNP-pairs showing association with limb-onset ALS 
 
Chromosome 10 SNP rs8624 (unadjusted p = 1.09x10-5) is exonic and rs7904918 (unadjusted p 
= 1.46x10-5) is intronic in the gene ACSL5. Furthermore chromosome 22 SNP rs9615919 
(unadjusted p = 2.16x10-5) is exonic in LOC284933 and intronic in FAM19A5, and rs9615341 
(unadjusted p = 3.22x10-5) is intronic in both LOC284933 and FAM19A5. The remaining SNPs 
are intergenic and are not placed near a gene. FAM195A has been previously identified in ALS128, 
245. 
When examining cases and controls under a logistic regression not stratified by onset-region, 
rs8624 decreases in association by an order of magnitude (to p = 3.99x10-4) as does rs7904918 
(to p= 5.67x10-4), rs9615919 (to p= 7.72x10-4) and rs9615341 (to p= 3.85x10-4). It is therefore 
- 183 - 
possible that these SNPs associate with limb-onset ALS more frequently than ALS absent of 
onset location specification. 
 
7.3.4 Bulbar-onset 
After quality control procedures there were 444,765 SNPs and Bonferroni-correction significance 
threshold was 1.12x10-7. 
A genome-wide logistic regression association analysis was performed comparing bulbar-onset 
patients (n = 163) with controls (n = 4142). No SNPs were significantly associated after Bonferroni 
correction. However four pairs of SNPs, sharing the same genomic loci, showed a trend to 
association. To elucidate possible disease relevant haplotypes for each SNP-pair, linkage 
disequilibrium was calculated across all cases and controls as (Table 7-4). 
Chr SNP1 SNP2 Linkage 
Disequilibrium r2  
Linkage 
Disequilibrium D’ 
7 rs2049819 rs7805607 0.88 0.99 
1 rs11162065 rs12081931 1 1 
1 rs7411511 rs1441831 1 1 
7 rs10259252 rs17160623 0.76 0.99 
 
Table 7-4. Linkage disequilibrium for SNP-pairs showing association with bulbar-onset ALS 
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Chromosome 7 SNPs rs10259252 (unadjusted p = 1.09x10-5) and rs17160623 (unadjusted p = 
1.09x10-5) are both intronic of the gene KIAA1549, which has not been implicated in ALS.  
When examining cases and controls under a logistic regression not stratifying by onset-region, 
rs10259252 decreased in its association with ALS by three orders of magnitude (from p = 1.17x10-
2) and rs17160623 by two orders of magnitude (from p = 7.36x10-3). This presents the possibility 
that for this bulbar-onset cohort, these SNPs are important. 
 
7.4 Discussion 
Calculating the proportion of UK AOO phenotype variance explained by our genotype data, using 
ACTA, estimated that there is little genetic contribution to AOO in ALS. Somewhat contradictory 
is that AOO variance in the international dataset showed a near-significant proportion explained 
by its genotype data. The proportion of UK survival phenotype variance was significantly 
explained by our genotype data. We did not have international phenotype data. 
There was an intergenic SNP on chromosome 18q22.3, rs10514080, which significantly predicted 
AOO when modelled as a quantitative trait linear regression. Furthermore, 9 of the top 20 SNPs 
significantly predicting ALS AOO in this region showed LD with one another suggesting several 
disease related haplotypes. A genome-wide epistasis analysis of the 18q22.3 SNPS shows in 
four instances a significant interaction coefficient with rs6947780.  
The epistasis analysis did not elucidate any non-intergenic SNPs and it is not immediately clear 
what the biological basis may be for the 18q22.3 locus, and rs6947780, influencing AOO in ALS. 
One SNP was found to be intronic in the gene RHOBTB1, a gene involved in GTPase signal 
transduction and actin filaments regulation. The gene has not been previously implicated in ALS, 
however signal transduction347, 348 and actin349 have had been implicated in the ALS proteomic or 
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pathology research previously. Actin is central to PFN1 functionality, a gene recently implicated 
in ALS235, as is KIFAP3 implicated in survival, and NEFH showing association with ALS and 
coding for an essential component of the neuronal cytoskeleton. 
Linear regression of the survival phenotype revealed two SNPs in LD, with suggestive p-values 
but not beyond the Bonferroni adjusted correction, in gene CTBP2 on chromosome 10q26.2. A 
gene not previously implicated in ALS before, it codes for a protein involved in synapse 
specialisation and as a transcription repressor. We did not have an international dataset 
containing survival to replicate this finding. 
I also performed logistic regression, dividing the UK case population into limb and bulbar-onset. 
No SNP was significant beyond Bonferroni correction, but pairs of top-SNPs within the top 10 
most significant associations were highlighted as interesting. All pairs had LD greater than r2 = 
0.8. The genes ACSL5, FAM19A5 with sub-gene LOC284933, were implicated as associated 
with limb-inset using this method. ACSL5 is involved cell growth in fatty acids, a function that I 
was not able to identify in previous ALS research. Interestingly FAM19A5 and LOC284933 were 
identified in Chapter 2 as having an epistasis interaction with the hexanucleotide repeat mutation. 
It is unknown why these SNPs increase in significance for limb-onset and have an epistatic 
interaction with the hexanucleotide repeat mutation, as C9ORF72 carriers are known to have both 
bulbar and limb onset350.  
For bulbar-onset KIAA1549 was a candidate. Unfortunately not much is known about the function 
of this gene. It has been implicated in gliomas and known to transcriptionally fuse with BRAF, an 
oncogene351. 
Weaknesses of the above analyses are that ACTA most likely required a larger dataset than 572 
cases. It is probable that is why AOO phenotype variance explained genotypic variance was near 
significant in the international dataset. It would be contradictory to existing research which has 
identified genes that directly and indirectly influence AOO in ALS137, 352. Furthermore we were 
able to identify a significant SNP predictor of AOO in ALS; although the two methods are 
fundamentally different and ACTA does not identify specific SNPs.  
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Power to detect SNPs that significantly predict phenotype variance in the UK dataset was an 
issue, but there many SNPs in the top 10 shared LD with another top 10 SNP.  Although these 
LD relationships do not discount the possibility of false positives they do make them less likely. 
In relation to previous findings, the linear regression analysis did not replicate SNPs within genes 
known to affect AOO in ALS, including SNPs from the recently associated 1p34.1 loci 
{Consortium, 2013 #1116}, beyond bonferroni correction. One SNP rs17202060 (p = 0.009) 
showed prediction without multiple-testing corrections. This SNP lies in intron 13 of the previously 
implicated gene TXNRD1. Because of the large variance of AOO between patients, likely to 
multiple genetic and non-genetic factors, it is likely their identification requires much statistical 
power. AOO variance caused by genotype variance became only nearly significant when 
including the four countries used in this analysis. These results indicate that the genetic influence 
on AOO is far less than the genetic influence of survival. 
Similarly, I did not replicate genes found to modulate survival in ALS after multiple testing 
adjustment. A SNP lying in intron 8 of KIFAP3 showed prediction of ALS survival with p = 
0.038.KIFAP3 has been previously implicated in predicting ALS survival time. In contrast to AOO, 
the genotype:survival variance ratio was very significant, even within the UK only. Survival seems 
to be influenced by multiple small effect-size mutations, unidentifiable using genotype association 
methods. 
In summary, I found several genes that may be interesting to ALS pathology, when stratifying 
GWAS analyses by phenotype. 
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Chapter 8 Health utility and ALS clinical stage 
8.1 Introduction 
ALS is relentlessly progressive with over 50% of patients dying in the first 30 months, and only 
20% surviving more than 5 years after symptom onset353. As a result, it is a greatly feared 
diagnosis and the commonest reason to seek assisted suicide354. Although the poor prognosis 
means that ALS appears rare, the lifetime risk is one in 300 by age 85 years355, which represents 
a significant economic burden.  A study of the cost of ALS care in the Netherlands estimated the 
average cost per patient at €1336 per month, with cost increasing significantly towards the end 
of life356. A US study found that inpatient mechanical ventilation and nursing contributed 
considerably to the $300,000/annum cost of patients in the terminal phase of their disease357.  
  
Advances in the understanding of ALS, and its pathogenesis, management and treatment have 
largely occurred in the past decade358. Clinical trials have increased in frequency as national and 
international ALS consortia have formed, and novel therapeutic targets discovered. Many clinical 
trials use functional rating scales, and generic or disease-specific health-related quality of life 
(HRQoL) questionnaires to measure primary and secondary outcomes. A commonly used HRQoL 
measurement, recommended by the National Institute for Health and Care Excellence (NICE) for 
cost-effectiveness analysis359 is the EQ-5D, developed and validated for the UK population by the 
EuroQol Group360. 
 
We recently proposed a clinical staging system for ALS, defined by milestones in disease 
progression occurring at predictable proportions of time elapsed between onset and death163. 
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A major use of clinical staging systems is in clinical trials, either as a trial endpoint, or to allow an 
economic analysis by assessing time spent in each health state, with health states mapped to 
utility. Few disease-specific quality-of-life instruments have been used consistently to quantify 
health utility in ALS361, and there is little knowledge of whether any ALS clinical staging system 
can also predict patient quality of life or other secondary outcomes, such as scores on the Hospital 
Anxiety and Depression Scale, HADS. We therefore explored whether the King's ALS staging 
system could predict EuroQol EQ-5D health utility and HADS scores using data from a large 
multicentre clinical trial of lithium carbonate in ALS (UKMND-LiCALS Study Group362,363) in which 




8.2.1 Setting and patients 
EQ-5D and HADS questionnaires were collected from participants in the Lithium Carbonate in 
ALS (LiCALS) 18 month, multi-centre, double blind, randomized parallel group trial362,363. 
Questionnaires were completed at the pre-randomization visit and prior to the start of study 
medication, and subsequently measured at:  Months 3, 6, 9, 12, 15, and 18.  
We also collected basic demographic and clinical information such as age, sex, site of disease 
onset, age at onset, and ALS phenotype.  
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8.2.2 Estimation of clinical stage 
Clinical stage was not collected prospectively as part of this trial. We therefore used an algorithm 
based on responses to the ALS Functional Rating Scale-Revised (ALSFRS-R) to estimate clinical 
stage. This is possible because the domains in this system partly overlap the domains used to 
calculate stage.  
 
8.2.3 Modifications to King’s ALS Staging System 
Stage 1 patients are pre-diagnosis, and so were not eligible to enter the LiCALS trial. As a result 
there are no EQ-5D or HADS questionnaires labelled Stage 1 in the analysis, but those at Stage 
2A are the same as Stage 1 clinically, only differing in diagnostic status (Figure 8-1). Stages 4a 
and 4b can present in a varying order partly contingent on whether the patient had bulbar or limb 
onset of symptoms. While those with bulbar-onset usually require gastrostomy before non-
invasive ventilation, those with limb-onset usually require non-invasive ventilation before 
gastrostomy. As they occur at the same proportion of time through the disease course, these two 
stages were combined and labelled as Stage 4 for this analysis (Figure 8-1). 
 
Figure 8-1. King’s ALS Clinical Stages. Those at Stage 2a are the same as Stage 1 clinically, only 
differing in diagnostic status 
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8.2.4 Instruments 
The EQ-5D is a generic health-related quality-of-life questionnaire that is primarily designed for 
self-completion by respondents. The questionnaire is split into two parts: the descriptive section 
and the visual analogue scale (VAS).  The descriptive section classifies health status by 
measuring perception of functioning in five dimensions: Mobility (Mob), Self-care (SC), Usual 
activities (UA), Pain/discomfort (PD), and Anxiety/depression (AD). Each dimension is given a 
score out of three: no problems (1), some problems (2), and extreme problems (3). This results 
in 243 possible combinations. Through the use of a ‘value set’ (a set of weights), the five 
descriptive scores are then converted into a single aggregate ‘health utility’ score anchored at 1 
(perfect health) and 0 (death). The EQ-5D value set used in LiCALS is the most widely used in 
the United Kingdom, and is known as the “Measurement and Valuation of Health A1 Value set”. 
It is derived using time-trade off methods, and has been recommended by the Washington Panel 
on Cost Effectiveness in Health & Medicine and validated by EuroQol for use in cost-effectiveness 
analysis364, 365.  
 
The visual analogue scale component of the EQ-5D is a rating scale from 1 (worst imaginable 
health) to 100 (best imaginable health)366. The EQ-5D dimensions were also analysed 
individually, and were treated as continuous variables for better clinical interpretability. Each 
dimension resembled a normal distribution and statistical analysis corresponded to equivalent 
non-parametric multinomial regression analyses (not reported).   
 
For the remainder of this article ‘EQ-5D health utility’ will refer to the aggregate EQ-5D utility 
score, and ‘EQ-5D vas’ will refer to the score given by a patient on the VAS. 
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The HADS self- assessment form screens for anxiety and depression via an aggregated sum 
from seven questions. It is designed specifically for medical practice and physical health settings 
and can be used to assess how symptom severity and prognosis influence anxiety and depression 
in patients. We used an ALS-specific revised HADS scale, in which  a question is omitted from 
both depression and anxiety sub-scales, and the scoring structure of two items for depression is 
altered367. 
 
8.2.5 Statistical analysis 
Statistical analysis packages Stata v12.0 and IBM SPSS v21.0 were used. To assess distribution 
normality we used a Shapiro-Wilks test and data were transformed to normality where necessary. 
To assess heteroscedasticity, the Cameron’s and Trivedi’s decomposition of IM-test was used.  
We assessed four outcome measures individually (Health Utility, EQ-5D VAS, EQ-5D 
Dimensions, and HADS), each taken at seven different observations throughout the trial. We 
tested which ALS disease predictors significantly affected these outcome measures. Predictors 
examined were sex, Age of Onset (AOO), disease onset site, and treatment group 
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To test the statistical efficacy of the ALS clinical stages we created four models: 
 
Model 1. Null Model: yij = µ + fi + eij 
Model 2. Stage-only Model: yij = µ + β1xij + fi + eij 
Model 3. Non-stage covariates Model:  yij = µ + β2...5xij + fi + eij 
Model 4. With-stage covariates Model: yij = µ + β1xij + β2...5xij + fi + eij 
 
Where y = Outcome measure, µ = Grand Mean, f = between subject variation, e = Random error, 
β1x = Clinical Stage predictor, β2...5x = Other ALS predictors, i = observation, and j = case 
 
We tested the above models using random-effects regression with maximum likelihood estimation 
(MLE). This estimates the parameters of these models and informs us (except for Model 1) how 
well the predictors (for example AOO) predict the outcome measures (for example health utility). 
Random error caused by repeated measures across time for each case was accounted for by 
applying Person ID as the grouping variable, so we can test across case. 
To compare models we used a log likelihood ratio test. We compared the Stage-only Model (2) 
versus the Null Model (1) to assess clinical stage as an individual predictor, and compared the 
With-stage Covariates Model (4) versus the Without-stage Covariates Model (3) to assess clinical 
stage as a predictor alongside typical ALS predictors. We calculated how much additional 
variance was accounted for by inclusion of clinical stage into a model. 
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To assess efficacy in identifying statistical differences in outcome measures between ALS clinical 
stages we coded each stage versus stage comparison using dummy variables within the MLE 
regression. We report coefficient and mean differences, z-test and related probability statistics. 
To obtain Cohen’s D we collapsed the eight observations, corresponding to trial visits, into the 
four clinical stages, and used the mean differences, standard deviations, and Pearson’s 
correlation between stages. Where there were repeated measures at a particular stage we simply 
used the first observation. As a general rule, Cohen’s D effect sizes are regarded as small at 0.2, 
medium at 0.5, and large at 0.8. 
 
8.3 Results 
8.3.1 Patient demographics 
Table 8-1 shows the characteristics of the 214 individuals included in 10 centres participating in 
the LiCALS trial (for missing values see Appendix Table A20). The majority of patients were 
Caucasian (98%) and male (68%). The mean age of onset was 58 (s.d. ± 11 years) with 22% 
having bulbar-onset, and 78% of all cases were apparently sporadic. Ninety-seven patients had 
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Table 8-1. Patient Characteristics 
 
Characteristic Summary statistics Total n=214 
Gender Females: n (%) 66 (31%) 
 Males: n (%) 148 (69%) 
Ethnicity White: n (%) 210 (98%) 
Age at Onset mean (sd) 58·1 (10·8) 
Site of onset Bulbar: n (%) 47 (22%) 
Type of onset Sporadic: n (%) 167 (78%) 
El Escorial diagnostic category 
Clinically definite ALS: n (%) 82 (38%) 
Clinically probable ALS: n (%) 80 (37%) 
Clinically probable - laboratory 
supported ALS: n (%) 
38 (17%) 
Clinically possible ALS: n (%) 14 (5%) 
Number of Individuals progressing 
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8.3.2 Health utility 
The distribution of health utility scores was close to normality and so was not transformed. We 
assessed Model 1, comprising just the grand mean and random error, which gave a log likelihood 
score of -126.02. When we included clinical stage (Model 2) the log likelihood was -53.48. 
Comparing the two models using a likelihood ratio chi-square test we found that the with-stage 
model was significantly a better predictor of health utility scores (χ² = 145.08, p = 3.14x10-32).  
Using likelihood-ratio analyses, we found Model 3, which included sex, AOO, disease onset site, 
and treatment Group, was no better at predicting health utility than Model 1 (null model) (χ² = 
2.24, p = 0.32). Model 4 (which included clinical stages and all predictor covariates from Model 
3) compared with Model 3 was a significantly better predictor of health utility (χ² = 146.45, p = 
1.57x10-32), confirming that clinical stage predicts health utility.  
Clinical stages were coded as dummy variables to compare differences in health utility between 
stages using an MLE regression model. Differences in health utility were significant for 
comparisons of all clinical stages (Table 8-2), on average reducing by -0.12 points linearly through 
each consecutive stage, with significant differences between stage 2a and 2b (Z(1) = -4.30, p = 
1.7x10-5), 2b and 3  (Z(1) = -0.56, p = 6.8x10-8), and stage 3 and 4 (Z(1) = -5.56, p = 2.8x10-8) 
(Figure 8-2). 
  







Figure 8-2. Mean health utility scores across each clinical stage, showing p-values as asterisks. 
** p < 0.01 
*  p < 0.05 
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ALS stage 
Utility 
Change in utility when moving to ALS stage 
Stage 2b Stage 3 Stage 4 
Mean Mean 95% CI Mean Mean 95% CI Mean 95% CI 
2a 0·65 0·59 0·71 -0·12** -0·17 -0·06 -0·24** -0·18 -0·30 -0·38** -0·44 -0·32 
2b 0·53 0·49 0·58    -0·12** -0·17 -0·08 -0·26** -0·32 -0·21 
3 0·41 0·36 0·46       -0·14** -0·19 -0·09 
4 0·27 0·24 0·30          
 
Table 8-2. MLE regression comparing mean health utility scores between clinical stages. 
** p < 0.01 
*   p < 0.05 
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8.3.3 Visual Analogue Scores 
The distribution of VAS scores was close to normality and we did not transform the data. The Null 
Model 1 gave a log likelihood score of -3951.09, and Model 2 gave a log likelihood of -3920.30. 
Using a likelihood-ratio test comparing the two models we found Model 2 (which includes clinical 
stage) to be a statistically better predictor of VAS scores (χ² = 61.575, p = 4.21x10-14). 
We compared Model 3 with the null Model 1 using a likelihood-ratio test, and found no difference 
(χ² = 0.87, p = 0.65). However, Model 4 was a significantly better predictor of VAS than Model 3, 
due to the inclusion of clinical stage (χ² = 62.37, p = 2.86x10-14).  
Coding clinical stages as dummy variables, we found differences between all clinical stages for 
mean VAS scores, except between stages 3 and 4 (Z(1) = -1.75, p = 0.081, Cohen’s D = 0.50) 
(Table 8-3). The fact that the difference between stages 3 and 4 are near significant and has a 
medium effect size when stages are collapsed (n = 40), suggests that the non-significant p-value 
may be due to power issues and missing data points. Mean VAS scores fell -14.90 points between 
stage 2a and stage 4.  Closer inspection of the VAS analysis between stage 2a and 2b showed 
that Z(1) = -2.5, p = 0.013 and between stage 2b and 3 that Z(1) = -4.74, p = p = 2.2x10-6 (Figure 
8-3). 
  







Figure 8-3. Mean VAS scores across each clinical stage, showing p-values as asterisks. 
** p < 0.01 
*  p < 0.05 
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ALS stage 
VAS 
Change in VAS score when moving to ALS stage 
Stage 2b Stage 3 Stage 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 71·65 68·05 75·24 -4·59** -8·18 -0·99 -11·89** -15·64 -8·14 -14·90** -19·11 -10·69 
2b 67·07 64·09 70·04    -7·31** -10·33 -4·28 -10·32** -13·95 -6·68 
3 59·76 56·97 62·55       -3·01** -6·39 -0·37 
4 56·75 53·23 60·27          
 
Table 8-3. MLE regression comparing Mean VAS scores between clinical stages. 
** p < 0.01 
*   p < 0.05 
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8.3.4 EQ-5D dimensions 
Clinical stage was a significant predictor for each EQ-5D dimension comparing Model 2 against 
Model 1: Mob (χ² = 105.02, p = 1.66x10-23), SC (χ² = 123.69, p = 1.39x10-27), UA (χ² = 85.77, p = 
2.39x10-19), PD (χ² = 18.08, p = 1.19x10-4), and AD (χ² = 15.33, p = 4.70x10-4). This was even 
more so comparing Model 4 with Model 3: Mob (χ² = 105.35., p = 1.33x10-23), SC (χ² = 124.38, p 
= 9.78x10-28), UA (χ² =87.21, p = 1.16x10-19), PD (χ² = 17.84, p = 1.34x10-4), and AD (χ² = 14.98, 
p = 5.58x10-4). 
Treating EQ-5D dimension scores as continuous variables we tested differences between all 
stages and the subsequent stage (see Appendix Table A21; Figure 8-4). We identified significant 
differences between all clinical stages for Mobility, Self-Care, and Usual Activity. For 
Pain/Discomfort significant differences were not found between stages 2b and 3 (Z(1) = 1.26, p = 
0.21), 2b and 4 (Z(1) = 0.39, p = 0.70), and 3 and 4 (Z(1) = -0.71, p = 0.48). For Anxiety/Depression 
a significant difference was not found between stages 2b and 3 (Z(1) = -0.39, p = 0.69). These 
results are consistent with what is known about ALS progression. 
 
Figure 8-4. Mean EQ-5D dimension scores by dimension stratified by clinical stage, showing p-
values as asterisks. 
** p < 0.01 
*  p < 0.05 
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8.3.5 Hospital Anxiety and Depression Scale – Depression 
The distribution of both HADS depression and anxiety scores were slightly skewed to lower scores 
but no transformation significantly improved the distribution. The log likelihood score for Null 
Model 1 was -1879.92 and for Model 2 was -1858.11. Model 2 was a significantly better predictor 
of HADS depression scores with clinical stage (χ² = 37.62, p = 6.78x10-9).  
We compared Model 3 with Model 1 in predicting depression scores and found no difference (χ² 
= 1.89, p = 0.39). Model 4 was a significantly better predictor of depression scores than Model 3 
(χ² = 37.42, p = 7.45x10-9). 
Examining clinical stages as dummy variables we found statistical differences between all stages 
for depression scores (see Table 8-4 and Figure 8-5). The depression scores rose by 1.34 points 
from stage 2a to stage 4. 
Figure 8-5. Mean HADS depression scores by clinical stage, showing p-values as asterisks. 
** p < 0.01 
*  p < 0.05 
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ALS stage 
Depression Scores 
Change in Depression scores when moving to ALS stage 
Stage 2b Stage 3 Stage 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·92 1·52 2·32 0·45** 0·07 0·83 0·81** 0·41 1·20 1·34** 0·90 1·77 
2b 2·37 2·03 2·71    0·36** 0·04 0·67 0·88** 0·51 1·27 
3 2·73 2·40 3·05       0·53** 0·18 0·88 
4 3·26 2·87 3·65          
 
Table 8-4. Comparing differences in HADS depression scores across ALS clinical stage using MLE regression 
** p < 0.01 
*   p < 0.05 
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8.3.6 Hospital Anxiety and Depression Scale – Anxiety 
For anxiety scores, the log likelihood for Null Model 1 was -2126.53 and for Model 2 was -2123.71. 
Model 2 was not a better predictor of HADS anxiety scores (χ² = 0.14, p = 0.06), although the 
significance test was very close to the alpha level. We compared Model 3 against Model 1 in 
predicting HADS anxiety scores and found no difference (χ² = 4.20, p = 0.12), and also found no 
difference between Model 4 and Model 3 (χ² = 0.15, p = 0.93) (see Table 8-5).  
Examining clinical stages as dummy variables we found statistical differences between stage 2b 
and 4, and 3 and 4, for anxiety scores. The increase in anxiety scores between stage 2a and 
stage 4 was 0.43, and did not linearly increase across stages (Figure 8-6). 
Figure 8-6. Mean HADS anxiety scores by clinical stage, showing p-values as asterisks. 
** p < 0.01 
*  p < 0.05 
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ALS stage 
Anxiety Scores 
Change in Anxiety scores when moving to ALS stage 
Stage 2b Stage 3 Stage 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 4·00 3·47 4·54 -0·13 -0·63 0·38 -0·08 -0·60 0·45 0·43 -0·15 1·00 
2b 3·88 3·43 4·33    0·05 -0·37 0·47 0·55* 0·05 1·05 
3 3·93 3·49 4·36       0·51* 0·04 0·97 
4 4·43 3·91 4·95          
 
Table 8-5. Comparing differences in HADS depression scores across ALS clinical stage using MLE regression 
** p < 0.01 
*   p < 0.05 
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8.4 Discussion 
We have shown that ALS clinical stage corresponds in a predictable and linear manner to 
differences in HRQoL as assessed by EQ-5D visual analogue and utility scores, and depression 
scores as assessed by HADS, validating the staging system used, and supporting the use of ALS 
clinical staging in clinical trials and for allocation of health resources and treatments. The utility 
estimates at each stage can also be used in models to estimate cost-effectiveness of new 
therapies for ALS in clinical trials. The reduction in EQ-5D utility and VAS scores with increasingly 
advanced clinical stage corresponds with similar studies using a functional health state scale368 
and a functional score163. However, while previous studies have measured HRQoL in ALS361, 368-
372, the variability of scales used and lack of consensus on what constitutes decline make 
comparisons difficult. The use of clinical stage overcomes these issues as disease progression 
is defined rather than a functional proxy. Moreover, this is the largest cohort of individuals with 
ALS to have been longitudinally assessed against different health states using the EQ-5D scale 
and thus provides robust progression data. 
We modelled ALS clinical stage and disease factors as predictors of EQ-5D health utility, finding 
that clinical stage was the only significant independent predictor. There are aspects of the EQ-5D 
measure that limit the amount of testable variance caused by ALS disease progression. First, EQ-
5D only measures 5 dimensions of health; thus, symptoms that significantly impact wellbeing, and 
are present in ALS, such as fatigue, cognitive changes, mood, pain and acute exacerbations are 
not effectively measured by the EQ-5D scale373, 374. Second, the rapid progression of ALS coupled 
with poor therapeutic options explain why age at onset, sex and disease onset site do not 
independently influence HRQoL, as quality of life is generally reduced. Third there is a floor effect, 
with a majority of mid- to late-stage patients scoring in the lower brackets of the individual EQ-5D 
dimensions, something seen in similar studies361, 368. Thus, quantifying the HRQoL of ALS patients 
using the EQ-5D may be limited by the poor sensitivity in the latter stages of the disease.  
Analysis of the individual dimensions of EQ-5D show the greater impact of ALS severity on the 
‘physical health’ metrics compared to ‘mental health’ metrics. Predictably, ALS clinical stage was 
much more effective at predicting the Self Care, Mobility and Usual Activities dimensions than the 
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Pain/Discomfort, and Anxiety/Depression dimensions of EQ-5D. This is consistent with both 
studies assessing HRQoL in ALS368, and a plethora of other neuromuscular disorders, such as 
fascioscapulohumoral dystrophy and myasthenia gravis 361, 375. Interestingly, this is in contrast to 
the significant mental health impact of neurodegenerative disorders, such as Parkinson’s, or 
Huntington’s disease, and despite the fact that subclinical frontotemporal dysfunction may be 
present in up to 50% of those with ALS 376, 377. However, using the ALS-specific HADS tool to 
measure mental health, we found depression significantly increased with clinical stage. Research 
examining the effects of ALS disease progression on mood has also provided conflicting evidence 
for378 and against379 an increase in depression and is entangled with frontotemporal dementia 
(FTD) related apathy380, 381, the neurodegenerative companion of ALS. 
There are a number of limitations to this study. First, there were two factors acting to reduce 
statistical power: loss of patients through death, and slow progressing patients who did not reach 
later disease stages.  Nevertheless, by using a longitudinal study we have been able to show 
unique temporal changes in HRQoL that would not be seen in a cross-sectional study. Second, 
there is potential for confounding bias, as many variables were not accounted for in the model; 
for example, we did not include comorbidities, depression, fatigue, or chronic pain as influencers 
of HRQoL.  Third, we did not collect clinical stage prospectively but derived it from existing data. 
Our own analyses suggest a greater than 92% correlation between actual stage and stage 
estimated from ALSFRS-R, and it is possible some patients may have been misclassified as a 
result. A small misclassification rate is unlikely to impact the overall findings.  
Using data from a large, multicentre clinical trial, we have shown that clinical stage can be used 
to model the cost-effectiveness of ALS therapies. The study has acted as a further validation of 
the King's ALS Staging System, showing that EQ-5D and visual analogue scores differ 
significantly between stages 2a, 2b, 3 and 4, with more advanced disease stages corresponding 
to poorer quality of life. The study of longitudinal changes in EQ-5D in patients with ALS provides 
a framework for health economics analysis of ALS clinical trials data. 
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Chapter 9 Final Discussion 
9.1 Summary of findings 
The genotype analyses compared allele frequencies between ALS cases and controls, using 
logistic and linear regression for genotypes, AOO and survival. The major finding from the 
genotype analyses was a significant genome-wide association of a C9ORF72 haplotype with 
ALS, after cases with the C9ORF72 hexanucleotide mutations were removed. I labelled this the 
residual association as it identifies disease-causing genetic variation unexplained by the known 
hexanucleotide mutation and which arises from a haplotype distinct from the hexanucleotide-
mutation-related haplotype. 
Using a genome-wide association study approach, certain genes became statistically significant 
once ALS was stratified by onset location (limb/bulbar/respiratory). One gene that significantly 
associated with limb onset cases had a significant epistatic relationship with the C9ORF72 
hexanucleotide mutation. 
The genotype analyses also confirmed the association of a previously identified 15-SNP ATXN2 
haplotype, in UK and Netherland ALS populations. In thesis’ dataset I was able to find a more 
statistically significant haplotype consisting of 47 SNPs associated with ALS. Analyses of PLCD1 
did not identify a polymorphism or haplotype that associated with the gene, despite increasing 
evidence that it is involved in ALS (see section 8.3). 
Using the bioinformatic tool ACTA I estimated that a significant proportion of the AOO variance 
(in the international dataset) and survival (in the UK dataset) can be explained by genetics. I found 
a SNP significantly predicted AOO in the UK using linear regression, after adjusting for multiple-
testing. The four most significant SNPs had an interesting epistatic relationship with an intergenic 
SNP on chromosome 7. Survival and onset location did not reveal a SNP that showed a 
statistically significant association with ALS after adjusting for multiple-testing, but did reveal 
interesting epistasis interactions. The gene FAM195A significantly associated with limb-onset and 
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has been previously implicated in ALS. Furthermore, we found that it has a significant interaction 
with the C9ORF72 hexanucleotide mutation. 
The gene expression analyses compared spinal regions between ALS cases and controls 
stratified by anatomy, disease spread for upper limb onset cases, and pathological severity. 
Expression analyses by anatomy identified several known functional pathological pathways in 
ALS. The most significant of these were glycosylation and transmembrane activity, calcium 
binding, regulation of muscle contraction, response to external stimulus & apoptosis, 
oxidoreductase and flavoproteins, and regulation of insulin, peptide and hormone secretion. I also 
identified symporter activity, glycan metabolic processes, and pleckstrin homology, as important 
pathological indicators in the gene expression data. Many of these functions have been previously 
implicated in ALS pathology. 
 
I applied the same methods to examine gene expression by spread and pathological severity. 
Using histological and historical clinical data I was able to establish that for four upper-limb cases 
the disease began in the cervical spinal section and moved caudally quicker than rostrally. 
However, the gene expression analyses failed to show convincing differences in gene expression 
profiles although one gene (SLC1A7) consistently differentially expressed across the spinal cord 
regardless of disease stage. The SLC1A7 protein function is as a glutamate transporter and may 
relate to the excitotoxicity pathology of ALS.   
Analysis looking at gene expression across categories of pathological severity did reveal 
differences in profile. The pathologically affected region defined as mild-moderate exhibited 
differentially expressing genes that largely fell into one of three clusters; (a) angiogenesis and 
blood vessel development function, (b) glycoprotein-based membrane activity, and (c) leukocyte 
response. Examination of these clusters in increasingly severe pathological categories showed 
that their enrichment score (representing the presence of that functional pathway) diminished over 
time. On deeper qualitative inspection however it appears that immune responses are more 
present in comparison to glycoprotein activity. 
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Analysing patterns of change in gene expression across categories of pathological severity 
revealed four genes in which their expression statistically changed. It also replicated two genes 
previously identified in having putative involvement in ALS. One of these genes may have an 
interesting interactive relationship with ANGPT2, also implicated in the gene expression analyses, 
which may be important to ALS. Cluster analyses of the gene expression based on their patterns 
of change revealed several interesting functional categories, the two most interesting perhaps is 
an up-down change in leukocyte response which follows closely an up-down change in 
transcription activity, indicating that the two functions may influence one another 
 
Using non-genetic methods, I tested the hypothesis that clinical staging can be a predictor of 
disease progression. In this instance disease progression was measured using health utility, 
health-related quality of life, depression and anxiety. We found that staging ALS is more predictive 
of measuring disease progression in comparison to using absolute time. This means that ALS 
progresses at predictable stages when time is standardised. However while this is true 
statistically, there is much variability between patients in terms of disease time that is unaccounted 
for. 
 
9.2 Genetic and spread 
A major objective of this thesis was to examine two major characteristics of the ALS, its focal 
genetic pathogenesis and its widespread pathological spread, and analyse how they are linked. 
These are its (A) genetic basis and (B) its seemingly radial spread from a focal onset location. It 
is very likely that genetics affect spread because there are genetic modifiers that hasten AOO 
and increase the belligerence of the disease, if the belligerence of the disease can be defined as 
the speed and extent of spread. Here I would define AOO not as the age at which the disease 
ignites but rather when it first becomes noticeable. If ALS spread is a key factor of severity and it 
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is progressive before the disease becomes symptomatic, then this spread should affect AOO as 
well as survival.  
As we see in Chapter 8, the stages of ALS disease progression are relatively predictable within a 
standardised timeframe. We are also able to conclude that if disease progresses quickly from one 
onset location to a second, then the disease will be quick throughout its entire course. 
Alternatively, if it is slow to begin with then it will have a slow course. In this UK dataset examined 
here I identified several polymorphisms which seem to aggravate the disease towards death. I 
also reviewed genetic findings which support the evidence of disease modifying genes quickening 
the time between stages of ALS.  
Analysing the effects of genetics on ALS survival time and AOO, I found several interesting 
epistatic relationships between SNPs and the most prevalent genetic mutation known to ALS, the 
C9ORF72 hexanucleotide repeat. Complete functional annotation of the C9ORF72 gene is yet 
incomplete so I am unable to speculate whether or how these interactions are real. But I also 
found a residual association with ALS at the C9ORF72 locus which predicts greater than 2 repeat 
lengths for the C9ORF72 hexanucleotide repeat. Either >2 repeats is a part of residual disease-
associating haplotype, or there is a separate unexplained pathological mechanism caused by 
repeat, for example an alternative repeat sequence or bi-allelic homozygosity >2 repeats. It is 
interesting that an alternative C9ORF72 repeat may be dose-dependent on the number of repeats 
(previously thought to be non-pathogenic). Taken together with the now known somatic 
heterogeneity of C9ORF72, it acts as a good example of how a genetic mutations’ variability can 
cause variation in disease spread and perhaps even lead to focal onset by manifesting strong 
dosage in a particular weak-spot of the spinal cord or motor cortex. 
To examine the seeming dualistic discrepancy of a genetic but focal-onset disease I aimed to 
analyse the interaction between genetics and spread using gene expression analyses. My 
objective was to identify abnormal gene expression in a spinal region that progressively changed 
throughout disease spread and severity. This region could be seen as weak-spots, defined as 
cells and/or regions that are less protected against a specific genetic mutation(s), or possible 
‘external factors’ of toxins or antigens, that facilitate the activation of ALS at a specific location(s) 
in the spinal cord or motor cortex.  
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The gene expression analyses identified many genes that abnormally expressed at different 
pathological stages of the disease, including genes that showed evidence of dose-dependent 
changes as the disease moved from mild to severe. The genes and functions identified replicated 
known pathways in ALS disease. Moving from mild to severe pathological categories, the 
expression profiles changed from very definitive very significant functional categories implicating 
many genes, towards more ill-defined small gene-number categories. Patterns of gene 
expression change supported pre-existing hypothesis of how some of these function may have 
toxic gain-of-function to begin with, which eventually become under-regulated. Furthermore I was 
able to identify functional overlap between the three major profiles identified; angiogenesis, 
glycoproteins and immune response, the latter showing a statistically definitive pattern of change 
as a consequence of increasing pathological severity. 
The following is a simplistic example but the findings allow speculation on the manifestation of 
ALS. Say a person inherits a genetic mutation affecting either angiogenesis or glycoproteins. This 
elicits an immune response but not one that requires a strong presence in the C.N.S. As age 
increases immunocompetence declines and the genetic mutations compromises both aberrant 
blood brain barrier (BBB) signalling and muscle atrophy, causing an increased amount of 
leukocytes bypass the BBB into the C.N.S. Initially these are beneficial but overtime, and likely 
influenced by an array genetic variation in a person, the activity of leukocytes become toxic. These 
cause an array of cytotoxic events eventually killing motor neurons leading to the fast cascading 
disease of ALS. 
The concept of genes has moved away from them being stationary coding units. Analysing the 
interactions between genetics, RNA, and pathology, may unveil hidden mechanisms of disease 
causation and manifestation in ALS. We know they play a definitive role in the onset of ALS and 
it is likely they will influence its spread in terms of time and severity. 
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9.3 Genetic candidates 
Genes C9ORF72 and SLC1A7 have already been discussed as gene candidates above. PLCD1 
is a strong candidate for ALS despite not finding a haplotype associated with the disease in this 
dataset. Papers show its association with ALS and that its ablation worsens SOD1-related ALS 
phenotypes. In the gene expression analysis genes of the same family showed significant 
differential expression especially mild to moderate stages of the disease. These were PLCD3, 
PLCD4, and PLCXD3. 
CTBP2 may modulate ALS survival; it is known to suppress transcription exposing a possible 
route of pathogenesis.  FAM19A5 and LOC284993 were found to be interesting as their 
association with ALS significantly increased when only limb-onset patients were examined, and 
was statistically related to the C9ORF72 repeat mutation. These genes are functionally 
uncharacterised. 
Other genes from the gene expression analysis were MSRA which showed a network relationship 
with KIF3A, and PLCD3 showing a network relationship with ALS gene ITPR1. MSRA is involved 
in suloxide reductase whereas PLCD3 is likely to be involved in responses to extracellular stimuli. 
The gene ADA showed a functional relationship with the ALS2 gene. ADA contributes to cellular 
signalling responses, which are somewhat already implicated in ALS pathology.  UFD1L also 
showed a showed a protein interaction relationship with ALS VCP. The CYB5R1 also differentially 
expresses and interacts with ubiquitin proteins, which may group UFD1L, VCP, CYB5R1 and 
UBQLN under the same ALS pathological pathway. 
Gene expression by pathology revealed several interesting candidates. Genes TMEM132E, 
HAMP, ZKSAN1 and REM1 all showed changes in expression as the disease progressed. Genes 
SUSD1, CRIM1, KDR, and RAMP3 have all been previously implicated in ALS research and I 
found them to differentially expression when just taking hold of a spinal region. GEMIN5, involved 
in pre-mRNA splicing, is a good candidate as interacts with SMN1 and was found to differentially 
express in moderately effected spinal regions. 
- 214 - 
ANGPT2 has a very close relationship with ALS gene VEGFA, in that its immune-based activity 
depends on VEGFA activity. This was most salient at the most severest stage of the disease, 
suggesting ANGPT2’s candidacy as survival modifier. 
 
9.4 Research obstacles and future direction 
Using genotypes from blood samples does not allow anatomical specificity. Therefore it does not 
allow me to determine which genetic mutations or risk variants are important where. We can infer 
this using expression data and location but the activity of these regions are not often well 
categorised. For large effect size mutations, such as the C9ORF72 hexanucleotide mutation, it 
would be useful for studies to examine DNA from multiple anatomical regions involved in ALS. 
This is important for this thesis, as I am unable to confidently conclude whether the residual 
association at C9ORF72 was not the consequence of the somatic heterogeneity of the mutation. 
Although, this is unlikely as the residual association is a distinct haplotype background to that of 
the mutation.  
I identified that a significant proportion of survival variance in ALS can be accounted for by 
genetics. I did not find the same for AOO. It may be that survival in ALS is always modulated by 
genetic variance, whereas AOO can be. In a large population AOO genetic variance as whole did 
not show significant association with, but we are able identify specific nucleotide polymorphisms 
in certain patients. Further annotation of the genes associated with AOO (for example the 
statistical interaction between FAM195A and C9ORF72) are required to construct a hypothesis 
on why and how this relationship is important in ALS. 
The extent to which genotype analyses will have utility in complex neurodegenerative diseases is 
becoming increasingly questioned.  I believe using haplotype association testing in relation to 
ATXN2 and PLCD1 was a good method to substantiate their association with ALS, primarily 
because their underlying effects are believed to genetic, in the form a nucleotide repeat. Repeats 
can arise from haplotypic inheritance, which I aimed to identify here. But this method relies on the 
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premise that common variants identify underlying somewhat complex haplotypes, which may not 
be true. To counteract this, a method utilising rare variants allowing for haplotype variation across 
populations may have utility when dealing with mutations of low penetrance. 
The problem of genetic variance hidden in genotype analyses was somewhat tackled using the 
RNA-seq dataset, in an attempt to identify variation within known ALS genes that could help in 
future research, where common variant genotyping has been unsuccessful. ELP3 for example 
shows complex transcript variation, which has been a focus of our collaborators. Knowing that 
ELP3 association is unlikely to be due to a significant DNA mutation and gene expression 
analyses do not show it to be abnormally expressed but that protein expression of ELP3 is 
significantly reduced in ALS patients, warrants further examination into this transcript variation.  
The Illumina BeadChip platform examines transcript variation to some extent but is not as detailed 
as RNA-seq. This in itself is a disadvantage of using gene expression to examine genetic 
mutations. Gene expression informs us on which genes are abnormally activated (or deactivated) 
in relation to ALS but does not inform us on whether a genetic abnormality is due to gene or 
transcript mutation, or whether it is responding to a pathological environment. The combination 
of contextually using gene expression to identify gene candidates and then RNA-seq to deepen 
the perspective on those candidates may be a beneficial approach in the future. 
In ALS there is an added problem in using gene expression, as RNA from motor neurons, when 
the disease is at its most severe, should be almost not existent. It is questionable how informative 
gene expression analysis is at these stages. The most informative pathological stage in my 
analysis was when the disease was just beginning to take hold of a spinal region. Future gene 
expression research should take this into account when simply comparing across spinal 
segments. Bringing in eQTL data across spinal cord levels would also be informative and may 
clarify some of the SNPs which are associated with ALS. 
The clinical staging of ALS is not informed by genetic information. This is currently being 
developed. It would be interesting to include genes that we know create severe or mild ALS 
phenotypes and analyse how these change the time a patient stays in each stage. Onset-location 
is currently included in the clinical staging model, differentiating between limb and bulbar onset. 
- 216 - 
However it could be informative of how ALS spreads, if we analysed staging times by imposing 
on the model an onset location and perhaps clinical symptomatological progression. A direction 
in which clinical staging could be taken therefore is to stratify populations by genetic mutation, 
onset-location and spread, which may allow a greater level of specificity in predicting a patient’s 
course of disease. 
 
9.5 Final summary 
This thesis examined the genetics and spread of ALS. Its findings supported the association of 
individual genes implicated in the disease, and found no evidence for others. I found that a 
significant proportion of survival in ALS can be accounted for by genetics, and identified SNPs 
which predict AOO and survival.  I identified a residual association at C9ORF72 that is not due to 
the known hexanucleotide repeat mutation, and that this residual association also predicts greater 
than two hexanucleotide repeats. Furthermore, we identified a gene that shows statistical 
epistasis with the known C9ORF72 hexanucleotide repeat. A gene expression analysis by spinal 
cord anatomy, spread and pathology, identified profiles of genes strongly implicating blood vessel 
development and angiogenesis, glycoprotein activity, and leukocyte migration. Some gene 
expression profiles were consistent throughout the course of the disease, while others changed 
in agreement with predictions of how cell function may alter as a consequence of ALS 
involvement. This thesis also examined disease progression, a putative indicator of spread, with 
the King’s ALS Clinical Staging system, finding that it predicted changes in health utility, motor 
function and psychometric function, over time.  
The overall finding of thesis is that spread in ALS predictably affects not only physiology but gene 
expression, and that this likely to be modulated by genetic mutations.  
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Table A1. Most significant ATXN2 haplotype in the UK dataset (χ²=13.04; adjusted p = 1) and for 







Chi Square p-value 
SH2B3/rs2239194 G 0.921, 0.867 3.457 0.063 
SH2B3/rs3184504 A 0.396, 0.394 0.001 0.98 
SH2B3/rs739496 G 0.329, 0.298 0.49 0.4838 
ATXN2/rs10849949 G 0.330, 0.298 0.54 0.4623 
ATXN2/rs2073950 A 0.281, 0.239 1.03 0.3102 
ATXN2/rs2301621 A 0.283, 0.239 1.127 0.2884 
ATXN2/rs10774625 A 0.409, 0.399 0.043 0.8358 
ATXN2/rs10849952 A 0.952, 0.940 0.308 0.5791 
ATXN2/rs6490162 G 0.281, 0.239 1.03 0.3102 
ATXN2/rs628825 A 0.319, 0.294 0.327 0.5677 
ATXN2/rs630512 A 0.322, 0.294 0.416 0.5187 
ATXN2/rs16941541 G 0.948, 0.945 0.018 0.8927 
ATXN2/rs7969300 G 0.952, 0.940 0.308 0.5791 
ATXN2/rs616513 A 0.322, 0.284 0.738 0.3903 
ATXN2/rs12369009 C 0.307, 0.280 0.397 0.5284 












Bulbar 174 63.49 159 15 
Limb 364 59.01 343 21 
Respiratory 15 66.46 15 - 
Mixed 28 57.11 26 2 
Total or Mean 581 60.45 543 38 
 
Table A2. Number of cases by limb onset showing AOO and mutation status 
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Chr SNP Base Position Odds Ratio  Allele SE P-Value 
9 rs10967976 27534943 1.41 G 0.06349 6.16E-08 
9 rs903603 27519316 0.7098 A 0.06375 7.55E-08 
9 rs10812611 27532261 1.403 G 0.06347 9.82E-08 
6 rs1361121 50032029 0.5254 C 0.1314 9.67E-07 
9 rs774359 27551049 1.394 G 0.06842 1.23E-06 
9 rs10812605 27500360 1.355 G 0.06437 2.38E-06 
9 rs3849942 27533281 1.385 A 0.06996 3.28E-06 
11 rs1522659 80518746 0.7222 A 0.07065 4.10E-06 
9 rs2814707 27526397 1.375 A 0.06971 5.00E-06 
9 rs774357 27549835 1.373 A 0.06983 5.61E-06 
8 rs7003470 19386565 1.472 A 0.08526 5.68E-06 
4 rs2866197 101325339 0.685 G 0.0834 5.74E-06 
2 rs2177083 202669910 0.7547 G 0.06227 6.18E-06 
10 rs951030 107579349 1.427 A 0.0794 7.53E-06 
10 rs11192617 107572237 1.427 A 0.07949 7.58E-06 
12 rs10849295 5543688 0.7077 A 0.07893 1.18E-05 
9 rs774352 27506590 1.339 G 0.06707 1.34E-05 
9 rs774351 27506640 1.339 C 0.06708 1.36E-05 
9 rs1982915 27569560 0.762 A 0.06286 1.53E-05 
9 rs7046653 27480967 1.333 A 0.06661 1.56E-05 
8 rs1494913 108957826 0.7496 G 0.06675 1.58E-05 
4 rs11734827 101327031 0.7002 C 0.08256 1.58E-05 
8 rs1389976 108959180 0.7512 G 0.06668 1.79E-05 
9 rs10757665 27547919 0.712 G 0.07949 1.92E-05 
9 rs12349820 27543876 0.7132 G 0.07947 2.10E-05 
5 rs1423515 82098300 1.651 A 0.1192 2.57E-05 
4 rs17575890 37005907 1.315 G 0.06532 2.73E-05 
19 rs11669124 44315092 0.7529 A 0.06786 2.88E-05 
9 rs2073817 135549281 0.7575 A 0.06653 3.00E-05 
7 rs2293629 129144534 1.299 G 0.06288 3.11E-05 
22 rs138705 37463749 1.318 A 0.06636 3.19E-05 
9 rs2453556 27576162 1.298 G 0.06295 3.39E-05 
8 rs2941627 106352206 0.642 G 0.1071 3.53E-05 
22 rs6004919 24785216 1.525 A 0.1021 3.58E-05 
16 rs8053509 8769772 1.418 C 0.8465 3.70E-05 
7 rs3736626 129137406 1.296 C 0.6286 3.73E-05 
3 rs4684627 9231398 0.7414 G 0.07265 3.80E-05 
9 rs129901 135542084 0.7551 G 0.06821 3.83E-05 
6 rs9342307 92699953 0.7653 A 0.0651 3.99E-05 
9 rs886016 135545450 0.763 G 0.06591 4.07E-05 
22 rs6008748 47287746 0.7032 G 0.08603 4.25E-05 
11 rs669565 93175487 0.6189 A 0.1174 4.33E-05 
21 rs9983113 39237186 1.287 A 0.06182 4.37E-05 
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7 rs17556430 129133526 1.293 A 0.0629 4.42E-05 
5 rs2048213 66312660 1.694 A 0.1291 4.43E-05 
2 rs3769185 173721745 0.7704 A 0.06395 4.53E-05 
17 rs11655490 68625159 1.337 A 0.07145 4.76E-05 
22 rs4823800 47302439 0.6935 C 0.09016 4.92E-05 
2 rs17014873 127546689 1.538 C 0.1062 5.01E-05 
20 rs6128206 55868747 1.375 G 0.07848 5.03E-05 
 
Table A3. Top 50 SNPs taken from GWAS of All Cases vs. Controls 
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Chr SNP Base Position Odds Ratio Allele SE P-Value 
6 rs1361121 50032029 0.512 C 0.137 1.02E-06 
11 rs1522659 80518746 0.7143 A 0.07299 4.03E-06 
12 rs10849295 5543688 0.6932 A 0.0819 7.69E-06 
4 rs2866197 101325339 0.6847 G 0.08603 1.07E-05 
2 rs2177083 202669910 0.7548 G 0.06405 1.12E-05 
16 rs8053509 8769772 1.459 C 0.08646 1.24E-05 
7 rs10243139 30832290 1.509 G 0.09486 1.46E-05 
9 rs903603 27519316 0.7561 A 0.06533 1.87E-05 
22 rs6004919 24785216 1.561 A 0.1042 1.91E-05 
9 rs2073817 135549281 0.7463 A 0.0687 2.05E-05 
5 rs2048213 66312660 1.747 A 0.1313 2.12E-05 
4 rs17575890 37005907 1.33 G 0.06713 2.20E-05 
4 rs11734827 101327031 0.6972 C 0.08524 2.32E-05 
10 rs10996409 66862396 0.6226 G 0.1135 2.99E-05 
5 rs1173485 157502407 1.31 G 0.06483 3.18E-05 
4 rs2054684 173475020 1.515 A 0.09993 3.24E-05 
7 rs2293629 129144534 1.308 G 0.06478 3.35E-05 
6 rs9398002 150827248 1.424 G 0.08549 3.50E-05 
10 rs951030 107579349 1.404 A 0.08204 3.55E-05 
10 rs11192617 107572237 1.404 A 0.08214 3.56E-05 
8 rs1494913 108957826 0.7528 G 0.06873 3.61E-05 
2 rs17238525 156527831 1.304 G 0.06434 3.62E-05 
9 rs10967976 27534943 1.309 G 0.06522 3.63E-05 
11 rs10833748 22344321 1.309 A 0.06538 3.87E-05 
9 rs10816767 110822491 0.7646 G 0.06524 3.87E-05 
7 rs3736626 129137406 1.305 C 0.06477 3.99E-05 
8 rs1389976 108959180 0.7544 G 0.06866 4.07E-05 
9 rs129901 135542084 0.7494 G 0.07038 4.17E-05 
9 rs886016 135545450 0.7577 G 0.06796 4.45E-05 
9 rs1537431 110828049 1.3 G 0.06448 4.79E-05 
7 rs17556430 129133526 1.301 A 0.0648 4.80E-05 
12 rs2970809 4434874 1.333 A 0.07078 4.83E-05 
12 rs11051642 31916867 1.355 G 0.07486 4.95E-05 
9 rs10812611 27532261 1.303 G 0.0652 5.02E-05 
15 rs4932583 90230093 0.7604 G 0.06756 5.04E-05 
16 rs11074843 26997812 1.3 A 0.06512 5.53E-05 
8 rs7003470 19386565 1.428 A 0.08847 5.60E-05 
2 rs10196846 38232614 1.407 A 0.0849 5.69E-05 
5 rs1173472 157488401 1.383 A 0.08067 5.76E-05 
21 rs9983113 39237186 1.292 A 0.06363 5.78E-05 
4 rs7681336 7296855 1.568 A 0.1121 5.98E-05 
6 rs9377684 105552057 0.7029 G 0.08788 6.03E-05 
14 rs1420813 86546345 1.301 A 0.06559 6.15E-05 
2 rs3769185 173721745 0.7681 A 0.0659 6.23E-05 
5 rs1614336 157484446 1.297 C 0.06501 6.25E-05 
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15 rs7175096 90231631 0.723 G 0.08112 6.39E-05 
6 rs9384533 150817371 1.415 A 0.08736 7.00E-05 
8 rs7827583 128131764 1.403 A 0.08523 7.03E-05 
6 rs9342307 92699953 0.7663 A 0.06706 7.20E-05 
18 rs1517166 59848277 0.7761 G 0.06392 7.31E-05 
 








Position Beta Allele SE P-Value 
9 rs774357 27549835 5.724 A 0.233 7.67E-85 
9 rs2814707 27526397 5.711 A 0.2337 3.02E-84 
9 rs3849942 27533281 5.711 A 0.2337 3.02E-84 
9 rs774359 27551049 5.496 G 0.2462 1.29E-74 
9 rs774352 27506590 5.219 G 0.2604 3.93E-64 
9 rs774351 27506640 5.219 C 0.2604 3.93E-64 
9 rs7046653 27480967 5.219 A 0.2611 6.86E-64 
9 rs10812605 27500360 5.216 G 0.2828 7.93E-57 
9 rs10967976 27534943 5.857 G 0.3308 1.72E-53 
9 rs10812611 27532261 5.835 G 0.3335 1.50E-52 
9 rs10511816 27458461 3.943 A 0.3384 1.44E-27 
9 rs2453556 27576162 3.987 G 0.3438 2.35E-27 
9 rs4879515 27472235 4.019 A 0.3589 8.33E-26 
9 rs903603 27519316 -2.937 A 0.3496 5.98E-16 
9 rs2282241 27562255 -2.825 A 0.3568 1.94E-14 
9 rs11792285 27509173 -2.491 A 0.3395 1.04E-12 
9 rs2282240 27562634 -2.467 A 0.3476 5.00E-12 
9 rs1982915 27569560 -2528 A 0.3615 1.00E-11 
9 rs10967952 27464214 -2..439 G 0.3589 3.49E-11 
9 rs10967959 27472967 -2.544 A 0.3801 6.58E-11 
9 rs10967958 27471905 -2.411 A 0.3616 7.77E-11 
9 rs12349820 27543876 -2038 G 0.361 2.94E-08 
9 rs10757665 27547919 -2.038 G 0.361 2.94E-08 
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9 rs1977661 27492986 -2.651 A 0.4708 3.20E-08 
9 rs1822723 27468052 -1.934 A 0.3472 4.37E-08 
 









Ratio Allele SE P-Value 
9 rs3849942 27533281 4.898 A 0.1144 1.35E-43 
9 rs2814707 27526397 4.846 A 0.1139 1.95E-43 
9 rs774357 27549835 4.863 A 0.1142 2.03E-43 
9 rs774359 27551049 4.786 G 0.1137 6.62E-43 
9 rs7046653 27480967 4.09 A 0.1107 6.67E-37 
9 rs774352 27506590 4.047 G 0.1103 1.34E-36 
9 rs774351 27506640 4.047 C 0.1103 1.35E-36 
9 rs10812605 27500360 3.516 G 0.1107 9.75E-30 
9 rs10967976 27534943 3.16 G 0.1154 2.69E-23 
9 rs10812611 27532261 3.119 G 0.1154 7.88E-23 
9 rs903603 27519316 0.3509 A 0.1166 3.28E-19 
9 rs10511816 27458461 2.547 A 0.1071 3.08E-18 
9 rs4879515 27472235 2.558 A 0.1095 1.16E-17 
9 rs2282241 27562255 0.3978 A 0.1198 1.67E-14 
9 rs1565948 27549733 0.4259 A 0.1118 2.70E-14 
9 rs2453556 27576162 2.096 G 0.1038 1.19E-12 
9 rs11792285 27509173 0.4815 A 0.1215 1.97E-09 
9 rs1982915 27569560 0.5284 A 0.1068 2.59E-09 
9 rs2282240 27562634 0.4178 A 0.1501 6.65E-09 
9 rs1822723 27468052 0.4748 A 0.1393 9.70E-08 
9 rs10967959 27472967 0.3496 A 0.1987 1.32E-07 
9 rs10757665 27547919 0.4618 G 0.1491 2.38E-07 
9 rs12349820 27543876 0.4626 G 0.1491 2.53E-07 
9 rs10967952 27464214 0.4418 G 0.1656 8.66E-07 
18 rs1517166 59848277 0.5999 G 0.1037 8.88E-07 
 
Table A6. Top 25 significant SNPs from GWAS of cases with 7-23 repeats (n=208) vs. controls 
(n=4142) 
  







Ratio Allele SE P-Value 
9 rs10967976 27534943 2.818 G 0.08569 1.19E-33 
9 rs10812611 27532261 2.781 G 0.08562 696E-33 
9 rs903603 27519316 0.3854 A 0.08628 2.21E-28 
9 rs774359 27551049 2.244 G 0.0817 4.48E-23 
9 rs10812605 27500360 2.194 G 0.07978 6.75E-23 
9 rs2453556 27576162 2.149 G 0.7923 4.62E-22 
9 rs774352 27506590 2.144 G 0.0803 2.10E-21 
9 rs774351 27506640 2.144 C 0.08031 2.13E-21 
9 rs7046653 27480967 2.123 A 0.08001 5.05E-21 
9 rs3849942 27533281 2.175 A 0.08267 5.44E-21 
9 rs2814707 27526397 2.157 A 0.08232 1.00E-20 
9 rs774357 27549835 2.157 A 0.08245 1.15E-20 
9 rs1982915 27569560 0.4897 A 0.0817 2.35E-18 
9 rs11792285 27509173 0.4639 A 0.09217 7.81E-17 
9 rs4879515 27472235 1.793 A 0.07818 8.10E-14 
9 rs2282240 27562634 0.4456 A 0.1097 1.76E-13 
9 rs10511816 27458461 1.768 A 0.07776 2.31E-13 
9 rs10757665 27547919 0.4827 G 0.1098 3.28E-11 
9 rs12349820 27543876 0.4836 G 0.1098 3.63E-11 
9 rs2477518 27589746 1.674 G 0.07852 5.37E-11 
22 rs138705 37463749 1.525 A 0.07969 1.18E-07 
5 rs3806873 5515607 4.413 G 0.3026 9.32E-07 
5 rs3806874 5515620 4.328 A 0.3017 1.20E-06 
9 rs10967958 27471905 0.5708 A 0.116 1.35E-06 
9 rs10122902 27546780 1.523 A 0.08761 1.55E-06 
 
Table A7. Top 25 significant SNPs from GWAS of cases with >2 repeats (n=385) vs. controls 
(n=4142) 
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SLC1A7 0.27 9.16E-19 SHROOM2 0.60 9.40E-08 ARL6IP1 0.98 4.65E-17 SLC1A7 0.26 1.54E-06 QPRT 1.93 6.82E-08 
NCRNA00095 0.31 1.49E-13 NT5C 1.78 7.87E-06 SLC1A7 0.29 9.20E-05 IL7R 3.23 3.51E-05 IL7R 3.00 3.26E-07 
MCM3APAS 3.07 1.19E-08 ADH5 1.71 3.73E-05 NCRNA00095 0.31 4.07E-04 SPRY3 2.02 1.48E-03 SLC1A7 0.23 5.05E-06 
C21orf62 2.82 4.36E-07 SULT1B1 0.45 3.73E-05 APLN 1.55 1.17E-03 STAT4 1.69 4.52E-03 NT5C 1.80 1.24E-03 
CD38 2.08 6.11E-07 SYNC 1.94 7.27E-05 IGFBP3 0.42 2.60E-03 TUFT1 1.63 4.77E-03 FAM162A 1.60 3.59E-03 
QPRT 1.80 6.08E-06 SCP2 1.51 4.74E-04 PPEF1 0.74 6.04E-03 CHST9 2.12 6.27E-03 DHFRL1 1.64 4.82E-03 
CHST9 1.93 3.53E-05 ZFP36L2 1.60 9.08E-04 PTGS2 0.63 6.27E-03 IGFBP3 0.44 1.16E-02 SLC36A1 1.73 5.25E-03 
C8orf34 2.23 2.77E-04 DACT2 0.44 1.21E-03 RASL11A 0.67 1.11E-02 C21orf62 3.71 1.37E-02 RCVRN 0.43 6.10E-03 
PJCG6 0.53 3.00E-04 FZD6 0.68 1.21E-03 POTEB 2.08 1.64E-02 GRAMD1C 2.16 1.60E-02 C14orf149 1.76 6.99E-03 
PPP1R1A 1.75 5.19E-04 MORC2 0.56 1.21E-03 TNNC1 0.44 2.81E-02 FBXO34 1.52 3.06E-02 ACADSB 1.71 9.70E-03 
ACSM5 2.38 9.72E-04 SLC1A7 0.25 1.28E-03 ADA 0.56 2.97E-02 HERC6 1.55 3.06E-02 CYB5R1 1.85 1.11E-02 
SHE 0.61 1.16E-03 ZFP1 0.67 1.44E-03 LOC645296 0.62 2.97E-02 LOC595101 0.51 3.29E-02 C17orf91 1.81 1.12E-02 
SULT1B1 0.53 1.58E-03 SHE 0.50 1.71E-03     EGFL8 0.43 3.60E-02 GPR27 0.38 1.12E-02 
GPR27 0.58 2.24E-03 ANKRD6 1.39 1.87E-03     HIST1H4B 0.44 3.60E-02 NCRNA00095 0.27 1.12E-02 
TMEM200A 1.90 3.41E-03 C9orf103 1.51 2.05E-03     MIR555 2.02 3.60E-02 DNAJC27 1.64 1.22E-02 
GSTT1 2.24 3.62E-03 EML3 1.38 2.05E-03     SNTB1 1.86 3.79E-02 WDR19 1.49 1.63E-02 
LMO2 0.68 3.62E-03 MGEA5 0.63 2.05E-03     TMEM106A 0.43 3.79E-02 MCM3APAS 3.87 2.09E-02 
MTBP 1.70 3.62E-03 SERPINF1 1.70 2.75E-03     ADCY8 2.22 3.80E-02 C14orf104 1.69 2.37E-02 
ZNF322B 0.46 3.62E-03 LILRB3 1.43 2.78E-03     UFD1L 1.26 3.85E-02 ACPL2 2.08 2.92E-02 
KAL1 1.83 4.08E-03 HTT 0.69 2.94E-03     FAM46C 1.69 3.99E-02 PRODH 2.13 3.46E-02 
RCVRN 0.46 4.08E-03 LMO2 0.53 2.94E-03         PLEKHG3 1.68 3.53E-02 
F5 1.75 4.35E-03 RETSAT 1.52 2.94E-03         SPATA20 1.59 3.65E-02 
SNTB1 1.52 4.43E-03 SCUBE2 1.64 2.94E-03         TRUB1 1.75 3.65E-02 
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FFAR3 0.49 5.40E-03 FBXL17 1.59 3.22E-03         MFN1 1.51 4.04E-02 
S100A3 2.01 5.94E-03 RNASET2 1.55 3.22E-03         CYB5D2 1.58 4.35E-02 
CCDC102B 1.36 5.99E-03 MARVELD2 0.59 3.40E-03         FRMD4A 1.47 4.35E-02 
GALM 1.66 6.06E-03 C1orf115 0.55 4.16E-03         LOC401152 0.57 4.35E-02 
SYNC1 1.30 6.06E-03 CLCA2 0.64 4.98E-03         PLEKHH2 1.57 4.35E-02 
APLN 1.60 6.41E-03 C12orf5 1.48 5.76E-03         ACAP2 1.45 4.90E-02 
DCT 1.67 6.41E-03 GLT25D2 0.69 6.28E-03            
FAM21A 0.43 6.41E-03 DKFZP564J102 1.67 6.72E-03            
IFI27L1 1.30 6.41E-03 ENOX1 0.60 6.94E-03            
LOC731486 2.07 6.41E-03 SIX4 0.52 7.00E-03            
EFCAB2 1.35 6.78E-03 QPRT 1.97 7.13E-03            
ID4 1.31 7.09E-03 INADL 1.64 7.56E-03            
CMTM8 0.74 7.54E-03 RFX4 1.76 7.63E-03            
IGFBP3 0.50 7.65E-03 FAM188A 0.71 7.86E-03            
FMN2 1.45 9.13E-03 CRELD2 0.69 8.15E-03            
KNTC1 1.51 9.35E-03 C21orf56 0.68 8.29E-03            
CD48 2.24 1.00E-02 MSRA 1.33 8.37E-03            
C9orf43 1.58 1.07E-02 ACO2 1.39 8.40E-03            
FHL1 1.38 1.07E-02 PZP 0.53 8.40E-03            
GPR107 0.58 1.07E-02 PFKFB2 1.61 9.40E-03            
LILRA2 1.67 1.07E-02 CMTM8 0.67 9.81E-03            
NT5C 1.59 1.07E-02 STK17B 1.53 9.99E-03            
WDR19 1.34 1.09E-02 CCDC68 0.59 1.03E-02            
IL7R 2.39 1.15E-02 
STON1-
GTF2A1L 1.35 1.10E-02            
C1orf94 1.83 1.18E-02 MTHFD1L 1.35 1.17E-02            
CMBL 1.42 1.18E-02 KIAA1009 0.69 1.31E-02            
FSBP 1.52 1.18E-02 WDR49 1.34 1.35E-02            
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MSRA 1.45 1.18E-02 NOTCH2NL 1.48 1.50E-02            
TMEM204 0.63 1.20E-02 ADA 0.53 1.54E-02            
GADD45G 1.78 1.23E-02 TARP 0.67 1.57E-02            
PFKFB2 1.42 1.25E-02 C20orf191 0.67 1.74E-02            
SLC36A1 1.35 1.27E-02 AQP4 1.34 1.87E-02            
ADH5 1.51 1.29E-02 HYOU1 0.74 1.89E-02            
GRAMD4 1.53 1.31E-02 UBE2Q1 0.68 1.94E-02            
CENPK 1.68 1.34E-02 NFATC2 1.73 2.00E-02            
CBWD1 1.28 1.36E-02 FZD8 0.67 2.06E-02            
RAMP2 0.72 1.36E-02 LRRC25 2.40 2.17E-02            
CDKN3 1.60 1.39E-02 PRKCDBP 0.71 2.51E-02            
ADAMTS5 1.54 1.44E-02 GPKOW 0.59 2.54E-02            
PCDHB16 1.66 1.44E-02 SPATA4 1.55 2.94E-02            
LOC595101 0.64 1.46E-02 YJEFN3 0.59 2.94E-02            
GPNMB 2.09 1.49E-02 MCM3APAS 3.03 3.01E-02            
TFCP2L1 1.72 1.50E-02 PTPRB 0.77 3.01E-02            
CENPP 1.53 1.51E-02 MED17 0.67 3.05E-02            
LOC645296 0.73 1.51E-02 LOC440396 0.75 3.05E-02            
FOXF2 0.68 1.53E-02 ZNF341 0.75 3.05E-02            
MSLN 2.28 1.54E-02 GPR62 0.61 3.21E-02            
PLCXD3 1.41 1.55E-02 AP2A2 0.48 3.25E-02            
C19orf18 1.69 1.57E-02 CCDC102B 1.42 3.25E-02            
TSPAN6 1.41 1.61E-02 ACSM5 2.99 3.26E-02            
IL18RAP 1.62 1.68E-02 FAM149A 1.45 3.26E-02            
TDRD9 1.89 1.69E-02 GNG12 1.43 3.26E-02            
C12orf73 0.65 1.78E-02 RAB12 1.64 3.26E-02            
DNASE2 1.42 1.85E-02 RNASEH1 0.68 3.26E-02            
THSD1 0.64 1.91E-02 TMEM204 0.63 3.26E-02            
- 266 - 
MARVELD2 0.66 1.93E-02 GEM 1.92 3.30E-02            
TAS2R43 0.52 1.96E-02 RREB1 1.44 3.35E-02            
FUT9 1.40 2.04E-02 PLTP 2.02 3.36E-02            
SNORD54 1.66 2.04E-02 LILRA2 2.35 3.39E-02            
PALB2 1.36 2.07E-02 PDIA4 0.64 3.39E-02            
PROK2 1.94 2.07E-02 RPS6KA1 1.56 3.48E-02            
SEPT3 1.30 2.09E-02 LCA5L 1.71 3.54E-02            
ELTD1 0.75 2.09E-02 LOC54103 1.49 3.61E-02            
MAMLD1 1.41 2.09E-02 IGFBP6 0.71 3.63E-02            
SLC41A1 1.37 2.16E-02 TTC32 1.39 3.67E-02            
GAN 1.43 2.24E-02 MPP6 1.49 3.75E-02            
C4orf19 1.78 2.25E-02 C20orf54 0.71 3.77E-02            
DCLRE1B 1.49 2.25E-02 HAPLN2 0.61 3.77E-02            
SAP30BP 0.73 2.25E-02 SMARCAD1 0.71 3.77E-02            
HS2ST1 1.30 2.28E-02 PODN 0.68 3.81E-02            
FLJ10357 1.34 2.40E-02 JUNB 1.83 3.89E-02            
DDIT4L 1.42 2.42E-02 GPR85 0.68 3.91E-02            
ADCY8 1.51 2.43E-02 FANCE 0.76 3.95E-02            
S100A4 1.44 2.51E-02 PUS7 0.76 4.08E-02            
FLJ22536 1.34 2.52E-02 LOC113386 0.64 4.10E-02            
EAF2 1.29 2.53E-02 INTS7 0.74 4.11E-02            
HLA-A29.1 0.49 2.59E-02 CRTAP 1.37 4.27E-02            
CDC42EP4 1.27 2.69E-02 CBX5 1.28 4.37E-02            
MTFR1 1.43 2.72E-02 BTNL9 0.69 4.39E-02            
FBXL17 1.39 2.72E-02 SLC22A23 0.76 4.39E-02            
PPP4R4 1.47 2.73E-02 TAS2R46 0.67 4.50E-02            
ZNF323 0.72 2.75E-02 CLPTM1L 0.60 4.51E-02            
PLK4 1.51 2.75E-02 CD38 2.01 4.70E-02            
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CHRNA1 4.32 2.76E-02 ZIC4 0.61 4.72E-02            
C1orf110 1.51 2.77E-02 RAMP2 0.64 4.76E-02            
LOC644928 0.61 2.84E-02 MEF2C 1.57 4.77E-02            
ANO6 1.32 2.90E-02 SFMBT2 1.52 4.81E-02            
RPESP 1.75 2.90E-02 CEBPA 1.76 4.83E-02            
SERPINE1 1.88 2.90E-02 NEUROD2 0.44 4.83E-02            
FDX1 1.37 2.94E-02 TAS2R43 0.43 4.83E-02            
TRIM22 1.52 2.94E-02 ANKAR 0.79 4.92E-02            
CPA4 0.64 2.94E-02 FLJ13614 1.50 4.99E-02            
NDUFA7 1.74 3.00E-02                
DPEP3 2.02 3.06E-02                
C9orf103 1.44 3.08E-02                
C2 1.59 3.08E-02                
C4orf31 1.54 3.09E-02                
C4orf16 1.38 3.14E-02                
C2orf40 1.57 3.15E-02                
MMRN1 0.64 3.15E-02                
PCDHB7 1.44 3.16E-02                
C6orf192 1.25 3.18E-02                
SLC15A3 1.53 3.18E-02                
KLRB1 1.90 3.34E-02                
PLCD3 1.43 3.36E-02                
SLC15A2 1.36 3.49E-02                
OSBPL3 1.53 3.50E-02                
COBL 0.75 3.52E-02                
SSPN 1.23 3.62E-02                
MS4A14 1.90 3.69E-02                
GZMK 1.97 3.74E-02                
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RPL29 0.70 3.76E-02                
DDX49 0.68 3.79E-02                
C14orf149 1.35 3.91E-02                
WASF2 0.79 4.01E-02                
C3orf51 0.66 4.02E-02                
LOC283932 0.76 4.06E-02                
LRRC25 1.96 4.07E-02                
PAPSS2 0.68 4.08E-02                
KIAA0182 1.39 4.24E-02                
ZNF7 1.77 4.28E-02                
PRODH 1.67 4.36E-02                
C8orf40 1.40 4.47E-02                
CDNF 1.62 4.47E-02                
CYB5R1 1.49 4.47E-02                
SMAD6 0.73 4.47E-02                
USP37 0.78 4.47E-02                
ZDHHC1 1.54 4.47E-02                
C11orf92 1.48 4.58E-02                
CHSY3 1.52 4.68E-02                
GJA1 1.25 4.68E-02                
RPE65 2.02 4.69E-02                
HERC2P2 0.71 4.71E-02                
LOC442582 0.67 4.71E-02                
BTNL9 0.71 4.71E-02                
IGSF5 1.51 4.78E-02                
MIR575 0.72 4.78E-02                
TUBGCP3 1.45 4.78E-02                
ABCC9 1.34 4.86E-02                
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FMO4 1.54 4.90E-02                
IL3RA 0.58 4.92E-02                
ANKRD13B 0.73 4.93E-02                
FLJ33360 0.70 4.96E-02                
NOL12 0.78 4.96E-02                
 
Table A8. All significantly differentially expressing genes by anatomical region 
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SLC36A1 1.35 0.01 SLC36A1 1.35 0.01 C4ORF31 1.54 0.03 S100A4 1.44 0.03 
CYB5R1 1.49 0.04 SLC15A2 1.36 0.03 MSRA 1.45 0.01 S100A3 2.01 0.01 
SLC15A2 1.36 0.03 SLC1A7 0.27 0.00 CHST9 1.93 0.00 PCDHB7 1.44 0.03 
ADCY8 1.51 0.02 SLC15A3 1.53 0.03 GSTT1 2.24 0.00 F5 1.75 0.00 
WASF2 0.79 0.04      PAPSS2 0.68 0.04 PCDHB16 1.66 0.01 
TSPAN6 1.41 0.02      HS2ST1 1.30 0.02 SNTB1 1.52 0.00 
GJA1 1.25 0.05           PLCD3 1.43 0.03 
RPE65 2.02 0.05           EFCAB2 1.35 0.01 
HS2ST1 1.30 0.02           ELTD1 0.75 0.02 
C8ORF40 1.40 0.04           RCVRN 0.46 0.00 
CD48 2.24 0.01           ANO6 1.32 0.03 
LILRA2 1.67 0.01              
SLC1A7 0.27 0.00              
DPEP3 2.02 0.03              
ELTD1 0.75 0.02              
CHRNA1 4.32 0.03              
ANO6 1.32 0.03              
KLRB1 1.90 0.03              
RAMP2 0.72 0.01              
ZDHHC1 1.54 0.04              
PCDHB7 1.44 0.03              
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TMEM204 0.63 0.01              
BTNL9 0.71 0.05              
IL18RAP 1.62 0.02              
TMEM200A 1.90 0.00              
SSPN 1.23 0.04              
LRRC25 1.96 0.04              
IGSF5 1.51 0.05              
CD38 2.08 0.00              
CHSY3 1.52 0.05              
CHST9 1.93 0.00              
SLC41A1 1.37 0.02              
C6ORF192 1.25 0.03              
FUT9 1.40 0.02              
FFAR3 0.49 0.01              
IL7R 2.39 0.01              
GRAMD4 1.53 0.01              
FMO4 1.54 0.05              
DCT 1.67 0.01              
MARVELD2 0.66 0.02              
GPR27 0.58 0.00              
PCDHB16 1.66 0.01              
MSLN 2.28 0.02              
TAS2R43 0.52 0.02              
USP37 0.78 0.04              
GPNMB 2.09 0.01              
GPR107 0.58 0.01              
IFI27L1 1.30 0.01              
ABCC9 1.34 0.05              
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THSD1 0.64 0.02              
CMTM8 0.74 0.01              
C19ORF18 1.69 0.02              
SLC15A3 1.53 0.03              
C11ORF92 1.48 0.05              
MS4A14 1.90 0.04              
IL3RA 0.58 0.05              
 
Table A9. Differentially expressing genes by functional cluster comparing cases and controls  
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Regulation of insulin, peptide and hormone secretion 
Gene Fold Change Difference P-Value 
CD38 2.01 0.05 
PFKFB2 1.61 0.01 
MGEA5 0.63 0.00 
ADH5 1.71 0.00 
GNG12 1.43 0.03 
JUNB 1.83 0.04 
 
Table A10. Differentially expressed genes by functional cluster comparing cases and controls 
medulla samples 
 
Regulation of muscle contraction, response to external stimulus & 
apoptosis 
Gene Fold Change Difference P-Value 
PTGS2 0.63 0.01 
PPEF1 0.74 0.01 
TNNC1 0.44 0.03 
SLC1A7 0.29 0.00 
POTEB 2.08 0.02 
IGFBP3 0.42 0.00 
ADA 0.56 0.03 
 
Table A11. Differentially expressed genes by functional cluster comparing cases and controls 
cervical samples 
 
Conjugation pathway & catabolic processes 
Genes Fold Change Difference P-value 
UFD1L 1.26 0.04 
HERC6 1.55 0.03 
FBXO34 1.52 0.03 
 
Table A12. Differentially expressed genes by functional cluster comparing cases and controls 
thoracic samples 
 
- 274 - 
Flavoproteins and oxidoreductase Pleckstrin homology 
Gene Fold Change Differential P-Value Gene Fold Change 
Differential P-
Value 
ACADSB 1.71 0.01 PLEKHG3 1.68 0.04 
CYB5R1 1.85 0.01 PLEKHH2 1.57 0.04 
DHFRL1 1.64 0.00 FRMD4A 1.47 0.04 
PRODH 2.13 0.03 ACAP2 1.45 0.05 
 
Table A13. Differentially expressed genes by functional cluster comparing cases and controls 
lumbar samples 
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SLC1A7 0.20 6.15E-04 SLC1A7 0.22 1.90E-06 SLC1A7 0.15 2.89E-10 FAM43A 0.55 2.11E-04 
POTEB 2.26 1.12E-02 IL7R 2.92 7.30E-04 IL7R 3.17 3.11E-07 MCM3APAS 3.34 1.06E-03 
        QPRT 1.94 4.68E-06 SHROOM2 0.63 9.60E-03 
        ACSM5 2.56 4.28E-05 SOX17 0.60 9.60E-03 
        NT5C 1.92 1.50E-04 SULT1B1 0.46 1.34E-02 
        ACER2 0.44 1.14E-02 CENPV 0.60 3.26E-02 
        DHFRL1 1.68 1.40E-02    
        C14orf104 1.75 4.53E-02    
        RCVRN 0.47 4.69E-02    
 
Table A14. All significantly differentially expressing genes by disease spread 
 
Mild-Moderate Moderate Moderate-Severe Severe 
Gene Symbol Fold Change P-Value 
Gene 
Symbol 
Fold Change P-Value 
Gene 
Symbol 
Fold Change P-Value Gene Symbol Fold Change P-Value 
NCRNA00095 0.19 2.16E-33 SLC1A7 0.26 2.96E-05 SLC1A7 0.15 2.16E-33 ANGPT2 0.36 1.55E-13 
FAM21A 0.08 9.50E-19 LGI4 0.58 1.04E-04 PJCG6 0.44 2.85E-06 ELSPBP1 3.44 2.43E-08 
HLA-DRB4 0.09 2.56E-15 HLA-A29.1 0.17 3.36E-04 MTBP 1.92 7.74E-06 INPP4B 1.68 2.50E-07 
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MCM3APAS 3.54 8.81E-11 GEMIN5 0.62 2.05E-03 HAPLN3 0.46 6.73E-05 PJCG6 0.43 4.87E-07 
SOX18 0.41 4.16E-10 CPA4 0.45 2.53E-03 ADA 0.50 7.24E-04 TKTL1 2.03 1.53E-06 
CH25H 2.47 4.85E-08 TLE2 0.50 2.53E-03 RCVRN 0.41 8.77E-04 HIVEP3 0.51 4.18E-06 
CMTM8 0.58 6.07E-08 LOC440248 0.38 3.57E-03 A2LD1 1.70 8.77E-04 MCM3APAS 4.15 5.41E-06 
QPRT 2.02 4.82E-07 NCRNA00095 0.37 7.31E-03 CCDC102B 1.43 1.14E-03 SLC1A7 0.34 6.19E-06 
ADCY8 2.02 1.34E-06 GPR107 0.46 7.31E-03 TMEM204 0.57 1.20E-03 QDPR 0.46 1.75E-05 
TBC1D2B 1.85 4.98E-06 BTN3A2 1.64 7.31E-03 MSRA 1.56 1.38E-03 GALNT6 0.25 2.35E-05 
DACT2 0.31 6.25E-06 SULT1B1 0.45 7.35E-03 BTNL9 0.59 1.52E-03 ADA 0.43 3.12E-05 
CCDC68 0.38 7.52E-06 TMEM139 0.50 7.35E-03 C9orf103 1.56 2.57E-03 PTGS2 0.40 3.14E-05 
CD38 2.39 8.55E-06 GPR27 0.47 8.46E-03 NT5C 1.63 3.72E-03 RCVRN 0.36 4.87E-05 
ROBO4 0.36 1.01E-05 ZNF385C 0.47 1.13E-02 ALPL 0.72 5.97E-03 CNKSR1 0.48 9.21E-05 
RAMP2 0.54 1.51E-05 
RP5-
1022P6.2 0.68 1.17E-02 C4orf33 1.41 7.66E-03 LOC645296 0.57 1.25E-04 
KAL1 2.53 1.94E-05 RAMP2 0.65 1.28E-02 THSD1 0.59 7.82E-03 ZNF135 1.64 3.24E-04 
TNFSF10 0.35 2.92E-05 LOC442582 0.52 1.36E-02 GPNMB 2.50 8.13E-03 NOS1AP 0.62 3.31E-04 
IRF5 2.56 3.09E-05 C1orf110 1.71 1.53E-02 C10orf107 1.58 9.26E-03 ZSCAN12L1 0.56 3.31E-04 
PIM1 2.07 3.73E-05 PRPF6 0.61 1.67E-02 LILRA2 1.77 9.26E-03 RPE65 2.64 3.83E-04 
SLC25A34 0.53 4.65E-05 SHE 0.64 2.17E-02 DCHS1 0.63 1.10E-02 FLJ16165 0.39 4.87E-04 
SULT1B1 0.37 5.42E-05 CFH 0.57 2.32E-02 TOMM20L 1.58 1.10E-02 QPRT 1.93 5.42E-04 
AEBP1 1.87 7.70E-05 DDIT4L 1.60 2.54E-02 QPRT 1.79 1.10E-02 IGSF1 1.84 9.51E-04 
CHST9 2.38 8.23E-05 FFAR3 0.48 2.96E-02 ANGPT2 0.50 1.10E-02 SCUBE2 1.64 1.04E-03 
GPR27 0.54 1.01E-04 WIZ 0.54 2.96E-02 SLC19A3 0.67 1.16E-02 PLCD3 1.59 1.08E-03 
PRRX1 1.64 1.17E-04 S100P 0.42 2.96E-02 CD38 2.17 1.16E-02 SHROOM4 0.25 1.12E-03 
DNASE2 1.69 1.61E-04 ODF3L2 0.60 3.16E-02 SLC5A6 0.73 1.30E-02 PUS7 0.69 1.16E-03 
DDIT4L 1.79 1.61E-04 ADCY4 0.59 3.18E-02 NOL12 0.68 1.31E-02 ACSM5 2.56 1.18E-03 
LOC645296 0.57 1.70E-04 HLA-C 2.51 3.18E-02 CEBPA 1.50 1.35E-02 CYP3A5 1.74 1.34E-03 
TMEM2 0.59 2.02E-04 PADI4 0.48 3.64E-02 FFAR3 0.52 1.38E-02 ADAL 0.59 1.67E-03 
C19orf18 2.01 2.11E-04 BGLAP 0.60 3.90E-02 LYRM2 1.58 1.38E-02 CCDC33 2.76 1.70E-03 
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EMX2OS 0.34 2.13E-04 MIR575 0.67 4.88E-02 FSBP 1.60 1.38E-02 FBXL16 0.46 1.73E-03 
GPR116 0.65 2.15E-04 HLA-H 0.60 4.88E-02 SERPINE1 2.06 1.53E-02 C1orf110 1.94 1.91E-03 
ABO 0.40 2.77E-04 RCVRN 0.49 4.97E-02 C19orf18 1.82 1.65E-02 ZNF323 0.67 2.05E-03 
PIRT 1.62 2.84E-04 LOC595101 0.62 4.97E-02 HLA-A29.1 0.21 1.67E-02 FAM21A 0.38 2.24E-03 
HSPA12B 0.56 2.98E-04     HERC2P2 0.64 1.67E-02 DCT 1.92 2.62E-03 
GPR124 0.53 3.16E-04     SNORD54 1.65 1.67E-02 GADD45G 2.22 2.83E-03 
PTPRB 0.67 3.80E-04     PCDHGB5 0.71 1.68E-02 YPEL3 0.47 2.83E-03 
GSTT1 2.28 3.92E-04     OSGIN2 1.35 1.68E-02 TCTN2 1.62 2.83E-03 
ABCC3 3.11 4.39E-04     MSLN 2.30 1.68E-02 DNASE2B 2.00 2.90E-03 
NRG3 1.68 5.13E-04     C14orf149 1.44 1.69E-02 PCDHB16 1.91 3.01E-03 
SHE 0.51 6.64E-04     APLN 1.82 1.74E-02 LOC441743 0.65 3.01E-03 
CMBL 1.62 6.91E-04     ABHD7 0.71 1.76E-02 SPATA5L1 0.69 3.50E-03 
IL17RB 1.80 7.12E-04     ZIC3 0.55 1.84E-02 ZNF642 0.57 3.51E-03 
OXTR 0.63 7.65E-04     PFKFB2 1.44 2.04E-02 CDC42EP4 1.38 3.55E-03 
LMO2 0.57 7.75E-04     DACT2 0.52 2.12E-02 WDR27 1.57 3.55E-03 
DKFZp451A211 0.33 7.75E-04     ZNF322B 0.39 2.16E-02 SLC16A9 1.38 3.55E-03 
SHROOM4 0.23 8.43E-04     PDE10A 0.54 2.16E-02 DNAH2 2.47 3.55E-03 
PRODH 2.42 8.57E-04     SHE 0.61 2.16E-02 CHRNA1 2.90 3.56E-03 
RGMA 1.72 9.04E-04     EPB42 0.55 2.17E-02 MASP1 1.85 3.99E-03 
SLC1A7 0.36 9.20E-04     FUT9 1.38 2.17E-02 FFAR3 0.48 4.00E-03 
CHST6 1.56 9.20E-04     ACADSB 1.45 2.20E-02 SPOCK3 0.47 4.00E-03 
C1QTNF5 1.61 9.20E-04     LOC54103 1.52 2.29E-02 KLHL2 0.72 4.00E-03 
ANKRD38 0.62 9.56E-04     CD34 0.73 2.32E-02 ZNF785 0.60 4.16E-03 
CYYR1 0.68 1.14E-03     LOC728323 1.63 2.39E-02 GSTM5 1.81 4.16E-03 
PLA1A 0.63 1.19E-03     LMO2 0.66 2.50E-02 GSTM2 1.65 4.27E-03 
LOC731486 2.41 1.37E-03     CMTM1 1.29 2.51E-02 C17orf75 1.41 4.33E-03 
IGDCC4 1.67 1.42E-03     ADH5 1.61 2.53E-02 LOC644928 0.55 4.70E-03 
C20orf160 0.61 1.44E-03     VEGFC 0.54 2.54E-02 ZUFSP 0.70 5.12E-03 
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BEGAIN 0.46 1.48E-03     C9orf43 1.73 2.54E-02 STON2 1.54 5.17E-03 
LOC401233 2.48 1.48E-03     AHSP 0.53 2.56E-02 C7orf50 1.36 5.34E-03 
C6orf48 0.74 1.49E-03     ZWINT 1.51 2.61E-02 SNORD49A 0.66 5.51E-03 
NTNG1 1.53 1.50E-03     KANK3 0.59 2.63E-02 OR4F21 1.63 5.51E-03 
FOXQ1 0.69 1.69E-03     IL27RA 0.65 2.63E-02 NT5C 1.61 6.42E-03 
SNX24 0.67 1.69E-03     CA1 0.30 2.67E-02 SNTB1 1.52 6.55E-03 
AFAP1L2 0.61 1.71E-03     LOC731486 2.23 2.67E-02 TIPIN 1.40 6.62E-03 
GRAMD4 1.71 1.73E-03     CMTM8 0.71 2.71E-02 ENTPD2 2.15 6.64E-03 
TRIL 1.48 1.73E-03     RAB11FIP4 0.63 2.76E-02 METTL8 0.69 6.68E-03 
C21orf62 3.74 1.99E-03     PLK4 1.62 2.76E-02 ZNF441 1.64 6.70E-03 
KCNA5 1.67 2.19E-03     C21orf62 2.67 2.76E-02 LIAS 0.72 6.80E-03 
GRASP 0.47 2.22E-03     MTHFD2L 0.74 2.78E-02 GRAMD4 1.59 6.91E-03 
CABC1 1.72 2.24E-03     FOXF2 0.63 2.82E-02 CCDC37 2.17 7.23E-03 
TDRD10 0.36 2.30E-03     C1orf94 2.02 2.90E-02 C16orf62 0.66 7.88E-03 
ABCG2 0.61 2.33E-03     POFUT2 1.03 2.90E-02 C14orf79 1.66 8.04E-03 
PAX6 1.82 2.39E-03     FBXL17 1.42 2.91E-02 CHSY3 1.48 8.34E-03 
JAG1 0.65 2.55E-03     RAMP2 0.74 2.91E-02 POLR2D 0.74 8.50E-03 
F5 2.35 2.65E-03     GAN 1.51 2.91E-02 SNORD54 1.62 8.52E-03 
NAPB 3.26 2.69E-03     RHOXF1 0.45 2.93E-02 IRX3 1.47 8.52E-03 
BMP8B 0.43 2.74E-03     EMR4 2.17 3.12E-02 C3orf51 0.54 9.09E-03 
TDH 1.98 2.77E-03     ACER2 0.57 3.17E-02 LRAT 1.38 9.09E-03 
RPESP 1.83 2.81E-03     IL3RA 0.54 3.21E-02 SNTA1 1.45 9.09E-03 
NKD1 0.65 2.86E-03     LRP8 0.76 3.23E-02 ACSL1 0.67 9.33E-03 
ST14 2.34 2.91E-03     PXMP3 1.34 3.45E-02 GIMAP7 0.71 9.89E-03 
UBQLNL 0.43 2.99E-03     DHDH 1.37 3.45E-02 IL7R 2.25 9.95E-03 
MTBP 1.84 3.11E-03     MRS2 1.54 3.48E-02 GZMK 1.81 9.96E-03 
KNTC1 1.65 3.15E-03     FBXO36 1.38 3.49E-02 CES7 0.36 9.96E-03 
ABCB1 0.69 3.26E-03     DCT 1.82 3.50E-02 RHBDL1 0.48 9.97E-03 
- 279 - 
GJA1 1.44 3.31E-03     ECSIT 0.63 3.50E-02 TUBAL3 0.42 1.10E-02 
HERC2P4 0.59 3.36E-03     PRELID1 0.65 3.50E-02 ECT2 0.72 1.12E-02 
MYO1F 1.94 3.46E-03     GGT5 0.71 3.51E-02 DBI 1.54 1.13E-02 
TBX2 0.56 3.56E-03     EVI1 0.72 3.53E-02 BRF2 0.65 1.13E-02 
TC2N 1.86 3.67E-03     PLCD3 1.57 3.56E-02 NCRNA00095 0.32 1.14E-02 
ZNF771 0.55 3.67E-03     DEGS2 0.62 3.63E-02 ADRA1A 1.73 1.16E-02 
ANKRD13B 0.51 3.76E-03     DDX49 0.66 3.63E-02 COL5A2 1.46 1.21E-02 
MARVELD2 0.48 3.79E-03     FMO4 1.65 3.63E-02 FMO4 1.82 1.25E-02 
LEPR 0.57 3.87E-03     MARVELD2 0.62 3.69E-02 USMG5 0.36 1.25E-02 
PAFAH1B3 1.54 4.29E-03     VTA1 1.50 3.83E-02 SNORD94 4.59 1.25E-02 
BTNL9 0.66 4.30E-03     PDIA4 0.71 3.86E-02 SERPINE1 1.73 1.28E-02 
FCGRT 1.59 5.23E-03     ZNF7 1.84 3.89E-02 RPL29 0.65 1.32E-02 
VIL2 1.41 5.26E-03     MFSD2 0.65 3.90E-02 KCND1 1.77 1.32E-02 
NAGLU 1.73 5.26E-03     ADAMTS5 1.51 3.90E-02 PCSK7 0.69 1.32E-02 
LOC440563 0.45 5.35E-03     GSTT1 2.55 3.90E-02 ABHD12B 0.58 1.33E-02 
TRAPPC2P1 1.63 5.41E-03     KNTC1 1.56 3.96E-02 STC1 0.54 1.34E-02 
ADCY4 0.65 5.41E-03     ABCG2 0.73 4.00E-02 CENPN 0.70 1.38E-02 
PLCXD3 1.80 5.85E-03     HBD 0.27 4.02E-02 TXNDC3 0.58 1.39E-02 
PPP4R4 1.80 6.44E-03     PCDHB16 1.63 4.02E-02 LOC442245 2.12 1.48E-02 
HRK 0.42 6.56E-03     TARP 0.69 4.13E-02 LRRC58 0.72 1.50E-02 
IFI27L1 1.42 6.75E-03     FOXQ1 0.69 4.13E-02 C2orf70 1.74 1.55E-02 
CHPF 1.86 6.78E-03     KCND1 1.55 4.13E-02 CACNA1B 0.50 1.55E-02 
LOC440248 0.42 6.78E-03     BRCC3 1.59 4.13E-02 SNAPC3 0.50 1.66E-02 
DCLK2 1.88 6.99E-03     TMEM55A 1.60 4.13E-02 DKFZp434I1020 1.68 1.66E-02 
CXCL14 0.53 7.39E-03     TTC32 1.59 4.17E-02 HSD11B1 0.53 1.70E-02 
MIF 1.57 7.39E-03     TPH1 1.59 4.18E-02 HMGCR 0.66 1.72E-02 
DEGS2 0.58 7.67E-03     C1orf69 0.62 4.20E-02 WNK2 1.71 1.75E-02 
TSSC1 0.68 8.18E-03     PAPSS2 0.61 4.21E-02 ATP13A4 1.44 1.76E-02 
- 280 - 
SLC41A1 1.56 8.55E-03     ZFHX2 0.63 4.21E-02 ZNF519 1.35 1.88E-02 
IGFBP3 0.46 8.57E-03     INO80B 1.43 4.21E-02 ACACB 1.39 1.91E-02 
SNTB1 1.58 9.69E-03     S100A3 1.94 4.30E-02 MICAL2 0.58 1.93E-02 
REM1 0.51 9.69E-03     PKN3 0.61 4.33E-02 SSH2 0.62 1.93E-02 
TOMM34 0.67 1.01E-02     TDRD10 0.48 4.39E-02 APLN 1.61 1.94E-02 
PLA2G15 1.53 1.01E-02     IFRD2 0.72 4.39E-02 CLASP1 0.68 1.94E-02 
PIPOX 1.57 1.03E-02     SIAH2 0.74 4.40E-02 FOSL1 2.10 1.94E-02 
C6orf192 1.40 1.06E-02     VWA2 0.63 4.47E-02 GBP5 1.60 1.94E-02 
C4orf31 1.93 1.09E-02     DBI 1.44 4.64E-02 KIAA0773 0.71 1.97E-02 
ID4 1.42 1.15E-02     CBWD1 1.30 4.70E-02 ZNF7 1.85 2.01E-02 
HLA-DRB1 2.72 1.17E-02     ARHGEF15 0.64 4.79E-02 FUT11 0.67 2.01E-02 
F3 1.67 1.17E-02     ALDH7A1 1.36 4.79E-02 DKFZP564O0523 0.74 2.01E-02 
LOC401152 0.44 1.17E-02     FAM131C 2.06 4.80E-02 IGFBP3 0.38 2.02E-02 
CFH 0.63 1.19E-02     MORC2 0.66 4.81E-02 CAMK2G 1.35 2.04E-02 
OLFML2A 0.62 1.20E-02     KIF26A 0.58 4.84E-02 ZNF322B 0.28 2.07E-02 
CENPK 1.95 1.22E-02     EGFL7 0.63 4.86E-02 ZNF284 2.05 2.17E-02 
OTOS 3.44 1.22E-02     WDR19 1.35 4.89E-02 SFTPD 1.85 2.17E-02 
GIMAP7 0.75 1.24E-02     UBE2QP2 0.74 4.91E-02 CA1 0.32 2.22E-02 
CD44 1.23 1.24E-02     C12orf5 1.43 4.91E-02 CYP4F3 1.98 2.23E-02 
ZNF785 0.53 1.25E-02     GORASP1 1.44 4.91E-02 ALDH5A1 1.39 2.35E-02 
TEK 0.69 1.25E-02     GRAMD4 1.52 4.91E-02 VPS37D 0.65 2.35E-02 
HBQ1 0.44 1.25E-02     HFM1 1.56 4.91E-02 CUTA 0.93 2.35E-02 
CLIC5 0.42 1.25E-02     DENND1C 1.62 4.91E-02 AGFG2 1.52 2.36E-02 
C9orf61 1.76 1.25E-02     HMG20A 1.39 4.97E-02 SMA5 0.89 2.42E-02 
STXBP2 1.96 1.25E-02         TASP1 1.39 2.42E-02 
ZNF507 0.52 1.26E-02         TTC21A 1.40 2.61E-02 
TMEM204 0.47 1.29E-02         WDR31 1.53 2.71E-02 
EDN1 0.56 1.30E-02         LRFN1 0.56 2.76E-02 
- 281 - 
DCT 1.77 1.31E-02         LRFN4 0.62 2.77E-02 
SELP 0.38 1.33E-02         LOC220594 0.60 2.80E-02 
MS4A14 2.22 1.33E-02         ZMYND19 0.76 2.86E-02 
APLN 1.68 1.42E-02         SVOPL 2.07 2.88E-02 
CENPP 1.85 1.42E-02         GIMAP8 0.71 2.89E-02 
NUDT16 0.73 1.42E-02         PPP1R3C 0.76 2.89E-02 
MIR575 0.65 1.43E-02         C1orf158 2.30 2.90E-02 
YDJC 1.65 1.43E-02         SIX4 0.47 3.02E-02 
ITGB2 1.48 1.44E-02         COBL 0.73 3.02E-02 
PFKFB2 1.52 1.47E-02         HERC6 1.37 3.02E-02 
C9orf103 1.54 1.49E-02         GATS 0.77 3.02E-02 
FOXF2 0.60 1.49E-02         CELSR3 0.70 3.02E-02 
SIRPB1 1.83 1.49E-02         RAB17 0.65 3.02E-02 
ACVRL1 0.63 1.51E-02         AMOT 1.40 3.06E-02 
IL6 2.04 1.51E-02         SYNC1 1.33 3.14E-02 
LOC100129550 1.66 1.57E-02         CRYGS 0.50 3.14E-02 
ELTD1 0.64 1.57E-02         AGAP11 1.60 3.14E-02 
USP37 0.72 1.61E-02         GPR3 0.46 3.17E-02 
37865 1.45 1.62E-02         ASXL2 0.70 3.21E-02 
LILRA2 2.00 1.65E-02         PTPN20A 0.39 3.21E-02 
LOC285016 1.85 1.69E-02         FLJ42957 1.44 3.23E-02 
EDN3 0.48 1.75E-02         FNBP1L 1.31 3.25E-02 
SUSD1 1.55 1.76E-02         ARPC5L 0.74 3.25E-02 
FMN2 1.56 1.81E-02         CCBP2 1.56 3.32E-02 
DNAJC1 1.50 1.81E-02         ZDHHC1 1.55 3.36E-02 
SLC4A11 1.89 1.82E-02         NDUFB1 0.60 3.37E-02 
MALAT1 0.48 1.83E-02         C7orf10 1.37 3.37E-02 
NAALADL1 0.62 1.83E-02         LCA5L 1.98 3.44E-02 
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SH3PXD2A 0.74 1.83E-02         WDSOF1 0.69 3.45E-02 
TRIM47 1.45 1.86E-02         IFT122 1.39 3.53E-02 
MTFR1 1.55 1.88E-02         LOC731486 2.02 3.60E-02 
CNTNAP1 1.52 1.99E-02         H1F0 1.38 3.61E-02 
MS4A7 1.85 2.00E-02         SGTB 1.90 3.61E-02 
AOAH 1.75 2.02E-02         KPNA1 0.75 3.66E-02 
EFCAB3 2.21 2.09E-02         C12orf39 1.75 3.68E-02 
TCTEX1D2 1.37 2.11E-02         PROK2 3.10 3.74E-02 
FOXC1 0.67 2.11E-02         PLK5P 0.61 3.74E-02 
CCL2 1.63 2.12E-02         NAPB 2.34 3.78E-02 
SERPINA3 1.50 2.12E-02         PLCB3 1.43 3.78E-02 
PTPRO 1.78 2.28E-02         CTDSPL 1.40 3.78E-02 
DGKE 0.66 2.29E-02         PPP1R13L 1.34 3.79E-02 
C4orf19 2.01 2.29E-02         MYOZ1 1.35 3.82E-02 
TCF15 0.50 2.29E-02         CALR 0.65 3.83E-02 
C12orf39 1.77 2.35E-02         LOC440563 0.61 3.84E-02 
C6orf114 0.67 2.35E-02         NOTCH2NL 1.44 3.85E-02 
LOC441743 0.68 2.39E-02         PDE10A 0.57 3.93E-02 
ZSCAN23 0.52 2.39E-02         SLC25A19 0.71 3.94E-02 
C2orf40 1.66 2.42E-02         C15orf63 0.62 3.94E-02 
POMC 0.58 2.42E-02         C15orf52 1.33 4.02E-02 
S100A4 1.53 2.43E-02         GNAO1 1.05 4.13E-02 
NET1 0.79 2.45E-02         KIAA1324L 0.77 4.17E-02 
PLCD3 1.49 2.49E-02         SETD7 1.37 4.21E-02 
HBA1 0.36 2.49E-02         LOC162632 0.74 4.23E-02 
MIR320B2 0.55 2.49E-02         FLJ10357 1.45 4.26E-02 
AGXT2L1 1.38 2.50E-02         MRPL34 0.69 4.39E-02 
TACSTD1 0.55 2.61E-02         C11orf92 1.81 4.39E-02 
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FGF11 1.38 2.67E-02         MICALL1 0.75 4.42E-02 
AGFG2 1.64 2.67E-02         USP37 0.72 4.54E-02 
ARSG 0.60 2.73E-02         ACSF2 0.68 4.55E-02 
RAB40AL 0.65 2.73E-02         UTRN 1.40 4.61E-02 
ZBTB7B 1.76 2.73E-02         C1orf192 1.55 4.69E-02 
FGD5 0.57 2.73E-02         NR2C2AP 0.76 4.82E-02 
KIAA1009 0.52 2.73E-02         FAM73A 0.70 4.91E-02 
PTPRZ1 1.49 2.73E-02            
GAN 1.55 2.80E-02            
VANGL1 0.46 2.82E-02            
EDC4 0.60 2.82E-02            
ZNF280D 0.62 2.84E-02            
TMEM45B 0.56 2.91E-02            
PCDHGB5 0.71 2.93E-02            
FHL1 1.39 2.97E-02            
AFG3L1 0.79 2.97E-02            
MOAP1 1.41 2.98E-02            
EMCN 0.62 2.99E-02            
WDR19 1.39 2.99E-02            
EI24 0.71 3.00E-02            
CDCA7 2.23 3.00E-02            
CYP2S1 1.98 3.04E-02            
HYI 1.53 3.07E-02            
NCAPD3 1.66 3.07E-02            
APEH 1.46 3.07E-02            
DCLK1 1.42 3.08E-02            
HLF 0.74 3.09E-02            
CACNA1B 0.53 3.10E-02            
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RNF5 0.60 3.10E-02            
APOB48R 2.00 3.10E-02            
FLJ12684 0.47 3.10E-02            
GGT5 0.66 3.10E-02            
SMAD6 0.70 3.10E-02            
SLC38A1 1.45 3.11E-02            
DCLRE1B 1.60 3.16E-02            
IL3RA 0.50 3.16E-02            
PDXDC2 1.34 3.16E-02            
SLC39A14 1.39 3.16E-02            
PRKCDBP 0.68 3.16E-02            
ATP13A4 1.48 3.16E-02            
CD48 2.37 3.16E-02            
TRIM26 0.76 3.16E-02            
ZNF219 1.74 3.20E-02            
HGF 1.69 3.26E-02            
CNOT6L 0.75 3.32E-02            
ANO6 1.39 3.36E-02            
GSPT1 0.46 3.36E-02            
MIR325 0.48 3.36E-02            
COL5A3 1.37 3.36E-02            
ZNF326 0.68 3.38E-02            
ZNF287 0.74 3.40E-02            
NBPF20 0.59 3.41E-02            
BBS10 0.58 3.45E-02            
SLC44A3 1.35 3.46E-02            
PMS2L4 0.76 3.51E-02            
CDKN3 1.81 3.55E-02            
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TUBAL3 0.45 3.61E-02            
FAM113B 1.58 3.62E-02            
DNHD1 1.58 3.67E-02            
EPAS1 0.77 3.67E-02            
SNORA5C 0.33 3.67E-02            
SBNO2 1.60 3.67E-02            
NRCAM 1.36 3.72E-02            
PTER 1.75 3.80E-02            
RALB 0.76 3.81E-02            
TRPV2 1.45 3.81E-02            
FLJ20309 0.74 3.81E-02            
C1orf69 0.57 3.89E-02            
ADH4 0.69 3.91E-02            
NCF1 1.83 3.94E-02            
TTC32 1.60 3.95E-02            
TSPAN6 1.51 3.96E-02            
GORASP1 1.44 4.01E-02            
FLJ10781 1.38 4.04E-02            
NOTCH3 0.68 4.04E-02            
ABCA6 0.62 4.05E-02            
CROCCL2 0.68 4.10E-02            
FHL5 0.60 4.11E-02            
ALDH5A1 1.37 4.12E-02            
EVI1 0.71 4.14E-02            
HIST1H2BJ 0.61 4.14E-02            
NDUFB11 1.63 4.14E-02            
TMEM132E 1.87 4.18E-02            
STX17 0.65 4.19E-02            
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HMGCR 0.63 4.21E-02            
PAPSS2 0.56 4.21E-02            
C12orf5 1.48 4.22E-02            
MAGEF1 1.66 4.22E-02            
ARHGAP19 0.70 4.24E-02            
C9orf43 1.79 4.27E-02            
ODZ4 1.34 4.31E-02            
FHOD3 1.50 4.32E-02            
OSBPL3 1.71 4.33E-02            
ZSCAN2 0.64 4.38E-02            
CD24 1.66 4.39E-02            
DGCR6 1.56 4.39E-02            
SLFN13 0.60 4.40E-02            
C7orf64 0.74 4.43E-02            
STAG3L1 0.76 4.44E-02            
USP49 0.66 4.44E-02            
GRAMD1C 1.55 4.45E-02            
SYNM 1.03 4.48E-02            
ZKSCAN1 0.63 4.53E-02            
CCDC85A 1.37 4.53E-02            
ZNF322B 0.46 4.58E-02            
CD34 0.66 4.60E-02            
MT1F 1.42 4.67E-02            
LRRC37B2 0.74 4.67E-02            
RNF138P1 0.71 4.69E-02            
KIF2A 0.49 4.69E-02            
UAP1 1.55 4.78E-02            
HTRA4 2.10 4.78E-02            
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LOC283932 0.61 4.80E-02            
PHF10 0.72 4.80E-02            
HAMP 1.71 4.80E-02            
GGH 1.36 4.80E-02            
FAHD2B 1.91 4.83E-02            
FBP1 1.88 4.83E-02            
FCGR2B 2.17 4.83E-02            
GMPR 1.45 4.86E-02            
STXBP5L 1.92 4.89E-02            
LYZ 1.90 4.91E-02            
C10orf33 1.35 4.97E-02            
LIAS 0.74 4.99E-02            
 




Blood vessel development Glycoprotein signalling Glycoproteins & membrane activity Fibronectin 
Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value 
SELP 0.38 1.33E-02 IGDCC4 1.67 1.42E-03 ADCY4 0.65 5.41E-03 NRCAM 1.36 3.72E-02 
EMCN 0.62 2.99E-02 ADCY4 0.65 5.41E-03 SLC44A3 1.35 3.46E-02 PTPRB 0.67 3.80E-04 
ACVRL1 0.63 1.51E-02 AEBP1 1.87 7.70E-05 GPR124 0.53 3.16E-04 IGDCC4 1.67 1.42E-03 
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LMO2 0.57 7.75E-04 NRG3 1.68 5.13E-04 HMGCR 0.63 4.21E-02 PTPRZ1 1.49 2.73E-02 
EPAS1 0.77 3.67E-02 ACVRL1 0.63 1.51E-02 ADCY8 2.02 1.34E-06 F3 1.67 1.17E-02 
LEPR 0.57 3.87E-03 SLC44A3 1.35 3.46E-02 TSPAN6 1.51 3.96E-02 LEPR 0.57 3.87E-03 
EDN1 0.56 1.30E-02 ARSG 0.6 2.73E-02 JAG1 0.65 2.55E-03 KAL1 2.53 1.94E-05 
PRRX1 1.64 1.17E-04 ADCY8 2.02 1.34E-06 IL17RB 1.8 7.12E-04 TEK 0.69 1.25E-02 
JAG1 0.65 2.55E-03 HMGCR 0.63 4.21E-02 NRCAM 1.36 3.72E-02 ROBO4 0.36 1.01E-05 
CD44 1.23 1.24E-02 GPR124 0.53 3.16E-04 CD48 2.37 3.16E-02 PTPRO 1.78 2.28E-02 
PLCD3 1.49 2.49E-02 TRPV2 1.45 3.81E-02 LILRA2 2 1.65E-02 IL3RA 0.5 3.16E-02 
ROBO4 0.36 1.01E-05 LEPR 0.57 3.87E-03 CD44 1.23 1.24E-02    
FOXC1 0.67 2.11E-02 SUSD1 1.55 1.76E-02 CH25H 2.47 4.85E-08    
SOX18 0.41 4.16E-10 TSPAN6 1.51 3.96E-02 RALB 0.76 3.81E-02    
   JAG1 0.65 2.55E-03 ELTD1 0.64 1.57E-02    
   SIRPB1 1.83 1.49E-02 DNAJC1 1.5 1.81E-02    
   IL17RB 1.8 7.12E-04 ODZ4 1.34 4.31E-02    
   NRCAM 1.36 3.72E-02 MS4A7 1.85 2.00E-02    
   CD48 2.37 3.16E-02 TMEM204 0.47 1.29E-02    
   C4ORF31 1.93 1.09E-02 VANGL1 0.46 2.82E-02    
   LILRA2 2 1.65E-02 FAM21A 0.08 9.50E-19    
   CD44 1.23 1.24E-02 PIM1 2.07 3.73E-05    
   CH25H 2.47 4.85E-08 TMEM132E 1.87 4.18E-02    
   AOAH 1.75 2.02E-02 PTPRO 1.78 2.28E-02    
   SLC1A7 0.36 9.20E-04 CD38 2.39 8.55E-06    
   ROBO4 0.36 1.01E-05 SLC25A34 0.53 4.65E-05    
   SERPINA3 1.5 2.12E-02 CD34 0.66 4.60E-02    
   CFH 0.63 1.19E-02 CHPF 1.86 6.78E-03    
   PLA1A 0.63 1.19E-03 F3 1.67 1.17E-02    
   CNTNAP1 1.52 1.99E-02 ST14 2.34 2.91E-03    
   ELTD1 0.64 1.57E-02 SLC38A1 1.45 3.11E-02    
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   ANO6 1.39 3.36E-02 EMCN 0.62 2.99E-02    
   ODZ4 1.34 4.31E-02 HLA-DRB1 2.72 1.17E-02    
   RAMP2 0.54 1.51E-05 FCGRT 1.59 5.23E-03    
   BTNL9 0.66 4.30E-03 ITGB2 1.48 1.44E-02    
   TMEM204 0.47 1.29E-02 NAPB 3.26 2.69E-03    
   OLFML2A 0.62 1.20E-02 KCNA5 1.67 2.19E-03    
   TMEM132E 1.87 4.18E-02 ABCA6 0.62 4.05E-02    
   PTPRO 1.78 2.28E-02 GORASP1 1.44 4.01E-02    
   PCDHGB5 0.71 2.93E-02 GPR27 0.54 1.01E-04    
   CD38 2.39 8.55E-06 STX17 0.65 4.19E-02    
   F5 2.35 2.65E-03 TEK 0.69 1.25E-02    
   CD34 0.66 4.60E-02 HLA-DRB4 0.09 2.56E-15    
   CHST6 1.56 9.20E-04 DNHD1 1.58 3.67E-02    
   CHPF 1.86 6.78E-03 ABCB1 0.69 3.26E-03    
   CHST9 2.38 8.23E-05 TRIL 1.48 1.73E-03    
   F3 1.67 1.17E-02 IFI27L1 1.42 6.75E-03    
   ST14 2.34 2.91E-03 ABCG2 0.61 2.33E-03    
   SLC38A1 1.45 3.11E-02 ATP13A4 1.48 3.16E-02    
   SLC39A14 1.39 3.16E-02 NOTCH3 0.68 4.04E-02    
   NAGLU 1.73 5.26E-03 GGT5 0.66 3.10E-02    
   EMCN 0.62 2.99E-02 EI24 0.71 3.00E-02    
   CCL2 1.63 2.12E-02 TNFSF10 0.35 2.92E-05    
   HLA-DRB1 2.72 1.17E-02 SLC4A11 1.89 1.82E-02    
   OXTR 0.63 7.65E-04 RNF5 0.6 3.10E-02    
   ITGB2 1.48 1.44E-02 LRRC37B2 0.74 4.67E-02    
   FCGRT 1.59 5.23E-03 C19ORF18 2.01 2.11E-04    
   KCNA5 1.67 2.19E-03 BEGAIN 0.46 1.48E-03    
   NAALADL1 0.62 1.83E-02 ABO 0.4 2.77E-04    
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   POMC 0.58 2.42E-02 IL3RA 0.5 3.16E-02    
   ABCA6 0.62 4.05E-02 MS4A14 2.22 1.33E-02    
   DCT 1.77 1.31E-02 CACNA1B 0.53 3.10E-02    
   RGMA 1.72 9.04E-04 IGDCC4 1.67 1.42E-03    
   C1QTNF5 1.61 9.20E-04 NRG3 1.68 5.13E-04    
   GPR27 0.54 1.01E-04 ACVRL1 0.63 1.51E-02    
   KAL1 2.53 1.94E-05 TRPV2 1.45 3.81E-02    
   TEK 0.69 1.25E-02 LEPR 0.57 3.87E-03    
   HLA-DRB4 0.09 2.56E-15 CYP2S1 1.98 3.04E-02    
   CD24 1.66 4.39E-02 SUSD1 1.55 1.76E-02    
   PTPRB 0.67 3.80E-04 GJA1 1.44 3.31E-03    
   SELP 0.38 1.33E-02 SIRPB1 1.83 1.49E-02    
   IL6 2.04 1.51E-02 STXBP5L 1.92 4.89E-02    
   PLA2G15 1.53 1.01E-02 APOB48R 2 3.10E-02    
   PTPRZ1 1.49 2.73E-02 SLC1A7 0.36 9.20E-04    
   GGH 1.36 4.80E-02 SNTB1 1.58 9.69E-03    
   NTNG1 1.53 1.50E-03 CNTNAP1 1.52 1.99E-02    
   ABCB1 0.69 3.26E-03 ANO6 1.39 3.36E-02    
   HBA1 0.36 2.49E-02 TOMM34 0.67 1.01E-02    
   HGF 1.69 3.26E-02 RAMP2 0.54 1.51E-05    
   COL5A3 1.37 3.36E-02 NDUFB11 1.63 4.14E-02    
   TRIL 1.48 1.73E-03 BTNL9 0.66 4.30E-03    
   TMEM2 0.59 2.02E-04 CYYR1 0.68 1.14E-03    
   ABCG2 0.61 2.33E-03 PCDHGB5 0.71 2.93E-02    
   NOTCH3 0.68 4.04E-02 CHST6 1.56 9.20E-04    
   DNASE2 1.69 1.61E-04 CHST9 2.38 8.23E-05    
   GGT5 0.66 3.10E-02 CLIC5 0.42 1.25E-02    
   SLC4A11 1.89 1.82E-02 SLC41A1 1.56 8.55E-03    
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   FCGR2B 2.17 4.83E-02 GRAMD1C 1.55 4.45E-02    
   ABCC3 3.11 4.39E-04 C6ORF192 1.4 1.06E-02    
   LRRC37B2 0.74 4.67E-02 DEGS2 0.58 7.67E-03    
   ABO 0.4 2.77E-04 GRASP 0.47 2.22E-03    
   IGFBP3 0.46 8.57E-03 SLC39A14 1.39 3.16E-02    
   BMP8B 0.43 2.74E-03 NKD1 0.65 2.86E-03    
   IL3RA 0.5 3.16E-02 OXTR 0.63 7.65E-04    
   CACNA1B 0.53 3.10E-02 NAALADL1 0.62 1.83E-02    
   GPR116 0.65 2.15E-04 GRAMD4 1.71 1.73E-03    
      DCT 1.77 1.31E-02    
      RGMA 1.72 9.04E-04    
      C1QTNF5 1.61 9.20E-04    
      DGKE 0.66 2.29E-02    
      MARVELD2 0.48 3.79E-03    
      PLCD3 1.49 2.49E-02    
      CD24 1.66 4.39E-02    
      PTPRB 0.67 3.80E-04    
      SELP 0.38 1.33E-02    
      PIRT 1.62 2.84E-04    
      TMEM45B 0.56 2.91E-02    
      PTPRZ1 1.49 2.73E-02    
      NTNG1 1.53 1.50E-03    
      TMEM2 0.59 2.02E-04    
      RAB40AL 0.65 2.73E-02    
      FCGR2B 2.17 4.83E-02    
      ABCC3 3.11 4.39E-04    
      CMTM8 0.58 6.07E-08    
      GPR116 0.65 2.15E-04    
- 292 - 
            
Leukocyte migration & cell motility 
Leukocyte migration & response to 
external stimuli Defence response Surface antigen & binding 
Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value 
SELP 0.38 1.33E-02 EDN3 0.48 1.75E-02 SELP 0.38 1.33E-02 SELP 0.38 1.33E-02 
EDN3 0.48 1.75E-02 SELP 0.38 1.33E-02 IL6 2.04 1.51E-02 EMCN 0.62 2.99E-02 
IL6 2.04 1.51E-02 SBNO2 1.6 3.67E-02 CCL2 1.63 2.12E-02 ACVRL1 0.63 1.51E-02 
CCL2 1.63 2.12E-02 IL6 2.04 1.51E-02 NCF1 1.83 3.94E-02 ABCB1 0.69 3.26E-03 
ACVRL1 0.63 1.51E-02 AOAH 1.75 2.02E-02 LYZ 1.9 4.91E-02 IL17RB 1.8 7.12E-04 
HMGCR 0.63 4.21E-02 F3 1.67 1.17E-02 MYO1F 1.94 3.46E-03 NRCAM 1.36 3.72E-02 
PAX6 1.82 2.39E-03 EDN1 0.56 1.30E-02 AFAP1L2 0.61 1.71E-03 CD48 2.37 3.16E-02 
ITGB2 1.48 1.44E-02 CD24 1.66 4.39E-02 ITGB2 1.48 1.44E-02 CD38 2.39 8.55E-06 
NRCAM 1.36 3.72E-02    IL17RB 1.8 7.12E-04 RGMA 1.72 9.04E-04 
CD44 1.23 1.24E-02    MIF 1.57 7.39E-03 CD44 1.23 1.24E-02 
CD34 0.66 4.60E-02    CD48 2.37 3.16E-02 CD34 0.66 4.60E-02 
KAL1 2.53 1.94E-05    LILRA2 2 1.65E-02 KAL1 2.53 1.94E-05 
FOXC1 0.67 2.11E-02    CD44 1.23 1.24E-02 F3 1.67 1.17E-02 
CD24 1.66 4.39E-02    HAMP 1.71 4.80E-02 CD24 1.66 4.39E-02 
DCLK1 1.42 3.08E-02    AOAH 1.75 2.02E-02    
      F3 1.67 1.17E-02    
      HIST1H2BJ 0.61 4.14E-02    
      SERPINA3 1.5 2.12E-02    
      CFH 0.63 1.19E-02    
      CD24 1.66 4.39E-02    
            
Extracellular region Plasma membrane 
Leukocyte migration & response to 
bacterial molecule Phosphate activity 
Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value Gene Fold Change P-value 
- 293 - 
EDN3 0.48 1.75E-02 EMCN 0.62 2.99E-02 EDN3 0.48 1.75E-02 PTPRB 0.67 3.80E-04 
AEBP1 1.87 7.70E-05 NRG3 1.68 5.13E-04 SELP 0.38 1.33E-02 PTPRZ1 1.49 2.73E-02 
EMCN 0.62 2.99E-02 ACVRL1 0.63 1.51E-02 IL6 2.04 1.51E-02 PFKFB2 1.52 1.47E-02 
NRG3 1.68 5.13E-04 SHROOM4 0.23 8.43E-04 CCL2 1.63 2.12E-02 FBP1 1.88 4.83E-02 
CCL2 1.63 2.12E-02 HLA-DRB1 2.72 1.17E-02 CD34 0.66 4.60E-02 C12ORF5 1.48 4.22E-02 
LEPR 0.57 3.87E-03 TRPV2 1.45 3.81E-02 ITGB2 1.48 1.44E-02 CDKN3 1.81 3.55E-02 
EDN1 0.56 1.30E-02 OXTR 0.63 7.65E-04 CD24 1.66 4.39E-02 PTPRO 1.78 2.28E-02 
JAG1 0.65 2.55E-03 GJA1 1.44 3.31E-03       
POMC 0.58 2.42E-02 FCGRT 1.59 5.23E-03       
OTOS 3.44 1.22E-02 ITGB2 1.48 1.44E-02       
MIF 1.57 7.39E-03 JAG1 0.65 2.55E-03       
IL17RB 1.8 7.12E-04 KCNA5 1.67 2.19E-03       
APOB48R 2 3.10E-02 SIRPB1 1.83 1.49E-02       
C4ORF31 1.93 1.09E-02 IL17RB 1.8 7.12E-04       
C1QTNF5 1.61 9.20E-04 CD48 2.37 3.16E-02       
CD44 1.23 1.24E-02 NRCAM 1.36 3.72E-02       
HAMP 1.71 4.80E-02 CD44 1.23 1.24E-02       
KAL1 2.53 1.94E-05 GORASP1 1.44 4.01E-02       
DGCR6 1.56 4.39E-02 MARVELD2 0.48 3.79E-03       
CFH 0.63 1.19E-02 TEK 0.69 1.25E-02       
SERPINA3 1.5 2.12E-02 SNTB1 1.58 9.69E-03       
PLA1A 0.63 1.19E-03 RALB 0.76 3.81E-02       
HTRA4 2.1 4.78E-02 HLA-DRB4 0.09 2.56E-15       
APLN 1.68 1.42E-02 CNTNAP1 1.52 1.99E-02       
SELP 0.38 1.33E-02 CD24 1.66 4.39E-02       
IL6 2.04 1.51E-02 DCLK1 1.42 3.08E-02       
PLA2G15 1.53 1.01E-02 TOMM34 0.67 1.01E-02       
PTPRZ1 1.49 2.73E-02 PTPRB 0.67 3.80E-04       
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NTNG1 1.53 1.50E-03 RAMP2 0.54 1.51E-05       
GGH 1.36 4.80E-02 SELP 0.38 1.33E-02       
LYZ 1.9 4.91E-02 IL6 2.04 1.51E-02       
OLFML2A 0.62 1.20E-02 TMEM204 0.47 1.29E-02       
HGF 1.69 3.26E-02 PTPRZ1 1.49 2.73E-02       
COL5A3 1.37 3.36E-02 NCF1 1.83 3.94E-02       
C2ORF40 1.66 2.42E-02 NTNG1 1.53 1.50E-03       
TNFSF10 0.35 2.92E-05 ABCB1 0.69 3.26E-03       
CXCL14 0.53 7.39E-03 PTPRO 1.78 2.28E-02       
F5 2.35 2.65E-03 RAB40AL 0.65 2.73E-02       
C12ORF39 1.77 2.35E-02 NOTCH3 0.68 4.04E-02       
CHST9 2.38 8.23E-05 TNFSF10 0.35 2.92E-05       
F3 1.67 1.17E-02 SLC4A11 1.89 1.82E-02       
ST14 2.34 2.91E-03 CD34 0.66 4.60E-02       
CMTM8 0.58 6.07E-08 F3 1.67 1.17E-02       
ABO 0.4 2.77E-04 ST14 2.34 2.91E-03       
IGFBP3 0.46 8.57E-03 ABCC3 3.11 4.39E-04       
BMP8B 0.43 2.74E-03 SYNM 1.03 4.48E-02       
   GRASP 0.47 2.22E-03       
   CACNA1B 0.53 3.10E-02       
            
Leukocyte migration & chemotaxis EGF-like domain 
Gene Fold Change P-value Gene Fold Change P-value 
EDN3 0.48 1.75E-02 DCT 1.77 1.31E-02 
IL6 2.04 1.51E-02 NOTCH3 0.68 4.04E-02 
CCL2 1.63 2.12E-02 SELP 0.38 1.33E-02 
CXCL14 0.53 7.39E-03 NRG3 1.68 5.13E-04 
HMGCR 0.63 4.21E-02 SUSD1 1.55 1.76E-02 
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ADCY8 2.02 1.34E-06 TEK 0.69 1.25E-02 
LEPR 0.57 3.87E-03 NTNG1 1.53 1.50E-03 
KAL1 2.53 1.94E-05 CNTNAP1 1.52 1.99E-02 
CMTM8 0.58 6.07E-08 ELTD1 0.64 1.57E-02 
OXTR 0.63 7.65E-04 ITGB2 1.48 1.44E-02 
ITGB2 1.48 1.44E-02 JAG1 0.65 2.55E-03 
TCF15 0.5 2.29E-02 ODZ4 1.34 4.31E-02 
 
Table A16. List of differentially expressing genes by functional cluster for spinal regions showing mild-moderate pathology 
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Glycosylation 
Gene Fold Change P-value 
SLC1A7 0.26 2.96E-05 
LGI4 0.58 1.04E-04 
CPA4 0.45 2.53E-03 
BTN3A2 1.64 7.31E-03 
GPR107 0.46 7.31E-03 
GPR27 0.47 8.46E-03 
RAMP2 0.65 1.28E-02 
CFH 0.57 2.32E-02 
FFAR3 0.48 2.96E-02 
ADCY4 0.59 3.18E-02 
HLA-C 2.51 3.18E-02 
HLA-H 0.60 4.88E-02 
 
Table A17. List of differentially expressing genes by functional cluster for spinal regions showing 
moderate pathology  
Metabolic and biosynthetic processes 
Gene Fold Change P-value 
GGT5 0.71 3.51E-02 
MSRA 1.56 1.38E-03 
MTHFD2L 0.74 2.78E-02 
GSTT1 2.55 3.90E-02 
SLC19A3 0.67 1.16E-02 
PAPSS2 0.61 4.21E-02 
 
Table A18. List of differentially expressing genes by functional cluster for spinal regions showing 
moderate-severe pathology  
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UTRN 1.40 4.61E-02 DCT 1.92 2.62E-03 ACSL1 0.67 9.33E-03 
MYOZ1 1.35 3.82E-02 FMO4 1.82 1.25E-02 PTGS2 0.40 3.14E-05 
CHRNA1 2.90 3.56E-03 CYP3A5 1.74 1.34E-03 ALDH5A1 1.39 2.35E-02 
SNTA1 1.45 9.09E-03 PPP1R3C 0.76 2.89E-02 CYP4F3 1.98 2.23E-02 
    LRAT 1.38 9.09E-03 ACACB 1.39 1.91E-02 
    ACSL1 0.67 9.33E-03 ACSF2 0.68 4.55E-02 
    PTGS2 0.40 3.14E-05 ACSM5 2.56 1.18E-03 
    HMGCR 0.66 1.72E-02    
    CYP4F3 1.98 2.23E-02    
    CALR 0.65 3.83E-02    
    FOSL1 2.10 1.94E-02    
 
Table A19. List of differentially expressing genes by functional cluster for spinal regions showing severe pathology  
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Probe Gene P-value Adj. P F Statistic 
6510307 ST5 3.88E-08 7.78E-04 46.68845 
4260424 PARD3B 2.18E-07 2.19E-03 36.52398 
510669 CNTFR 3.75E-06 2.18E-02 23.90182 
2750139 RNF216L 4.34E-06 2.18E-02 23.36336 
1190082 C6ORF48 2.24E-05 8.96E-02 17.98008 
3940309 CDAN1 4.23E-05 1.41E-01 16.16605 
7610189 ZNF706 6.03E-05 1.73E-01 15.21642 
4150537 ZNF331 8.38E-05 2.00E-01 14.37108 
540706 HLF 0.000101 2.00E-01 13.91797 
4230021 NCK2 0.000108 2.00E-01 13.75316 
7000736 MLC1 0.00011 2.00E-01 13.70059 
1570687 IFT122 0.000127 2.03E-01 13.35793 
670326 ABI2 0.000132 2.03E-01 13.26287 
380224 FADS2 0.000153 2.13E-01 12.91631 
4900670 COX5A 0.00016 2.13E-01 12.81235 
460577 STON2 0.000178 2.23E-01 12.55788 
430546 HIST1H2BG 0.000266 3.07E-01 11.66773 
1570767 HOMER2 0.000311 3.07E-01 11.32783 
7150349 TPD52L1 0.000329 3.07E-01 11.21263 
3370136 ACAD11 0.000338 3.07E-01 11.1518 
5550500 MXRA7 0.000355 3.07E-01 11.05158 
3130669 SATB1 0.000357 3.07E-01 11.03642 
5820681 PBX2 0.000358 3.07E-01 11.02964 
2760678 RCVRN 0.000406 3.07E-01 10.76943 
2320750 MRVI1 0.000414 3.07E-01 10.7303 
6770131 OLFM4 0.000419 3.07E-01 10.70203 
7560136 WDR92 0.000441 3.07E-01 10.59726 
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6940348 TIPIN 0.000456 3.07E-01 10.5314 
6330168 EVC 0.000511 3.07E-01 10.30169 
3290400 CUTA 0.000528 3.07E-01 10.23488 
3520750 SPOCK3 0.000569 3.07E-01 10.08545 
1340685 PLEC1 0.000572 3.07E-01 10.07721 
6060358 ATG4A 0.000593 3.07E-01 10.0031 
6560167 DIAPH3 0.000594 3.07E-01 10.00103 
3930008 RPL14 0.000603 3.07E-01 9.972876 
4480767 NUP98 0.000611 3.07E-01 9.945566 
6110095 CCDC15 0.000617 3.07E-01 9.926901 
3360291 TICAM1 0.000649 3.07E-01 9.826936 
4220731 P4HA1 0.000681 3.07E-01 9.732617 
3310167 SDF4 0.000712 3.07E-01 9.647009 
1740471 TINF2 0.000717 3.07E-01 9.633339 
5340414 LGTN 0.000727 3.07E-01 9.606422 
6840494 CYP4F3 0.000752 3.07E-01 9.542619 
5130551 SOX6 0.000779 3.07E-01 9.47462 
4610136 GPATCH4 0.00079 3.07E-01 9.447991 
6330133 BPGM 0.000794 3.07E-01 9.438416 
6590731 DTNBP1 0.000807 3.07E-01 9.40863 
2900593 VEGFA 0.000821 3.07E-01 9.374119 
3520196 LIG4 0.000828 3.07E-01 9.35835 
3930603 RPL23AP53 0.000845 3.07E-01 9.320729 
4050368 AGFG2 0.00087 3.07E-01 9.265605 
6580524 KIAA1161 0.000879 3.07E-01 9.246611 
130669 BAG5 0.000883 3.07E-01 9.238592 
6510093 PPARA 0.0009 3.07E-01 9.202857 
7380167 C21ORF69 0.000901 3.07E-01 9.20069 
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3830682 TTC9C 0.000901 3.07E-01 9.199352 
3990070 PCDHGA5 0.000909 3.07E-01 9.182836 
270204 RFNG 0.000913 3.07E-01 9.175077 
4050593 MRC2 0.000924 3.07E-01 9.152795 
5560474 RAMP2 0.00094 3.07E-01 9.121292 
4200093 MRO 0.000944 3.07E-01 9.113269 
7650070 RAMP2 0.000955 3.07E-01 9.090783 
4920747 ZNF823 0.000966 3.07E-01 9.069866 
 
 
Table A20. Genome-wide One-Way ANOVA of gene expression changes by severity level
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Chapter 8  
 
 
 EQ-5D Utility VAS Scores 








Stage 2a 139 65% 139 65% 
Stage 2b 89 41·6% 89 41·6% 
Stage 3 71 33·2% 72 33·6% 
Stage 4 147 68·7% 147 68·7% 
  
Table A21. Missing values for EQ-5D Utility and VAS scores 214 LiCALS patients  
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ALS stage 
Mobility 
Change in Mob when moving to ALS stage 
2b 3 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·63 1·54 1·73 0·16** 0·07 0·25 0·37** 0·27 0·46 0·53** 0·42 0·63 
2b 1·80 1·72 1·88    0·21** 0·13 0·28 0·36** 0·27 0·45 
3 2·00 1·93 2·08       0·16** 0·07 0·24 
4 2·16 2·07 0·25          
ALS stage 
Self-Care 
Change in SC when moving to ALS stage 
2b 3 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·65 1·53 1·77 0·25** 0·14 0·37 0·50** 0·38 0·63 0·77** 0·63 0·91 
2b 1·91 1·80 2·01    0·25** 0·15 0·35 0·52** 0·40 0·63 
3 2·16 2·06 2·25       0·26** 0·15 0·37 
4 2·42 2·31 2·54          
ALS stage 
Usual Activity 
Change in UA when moving to ALS stage 
2b 3 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·90 1·79 2·01 0·20** 0·09 0·31 0·36** 0·25 0·47 0·60** 0·47 0·73 
2b 2·09 2·00 2·16    0·16** 0·07 0·25 0·40** 0·29 0·51 
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3 2·26 2·17 2·34       0·24** 0·14 0·34 
4 2·50 2·39 2·60          
ALS stage 
Pain/Discomfort 
Change in PD when moving to ALS stage 
2b 3 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·37 1·26 1·47 0·18** 0·07 0·29 0·24** 0·13 0·35 0·20** 0·07 0·33 
2b 1·55 1·46 1·63    0·06** -0·03 0·15 0·02** -0·08 0·13 
3 1·60 1·53 1·68       -0·04** -0·13 0·06 
4 1·57 1·47 1·67          
ALS stage 
Anxiety/Depression 
Change in AD when moving to ALS stage 
2b 3 4 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
2a 1·32 1·22 1·42 0·13** 0·02 0·23 0·11** 0·00 0·22 0·24** 0·12 0·36 
2b 1·45 1·37 1·53    -0·02** -0·01 -0·07 0·11** 0·00 0·21 
3 1·43 1·36 1·50       0·13** 0·03 0·22 
4 1·56 1·46 1·65          
 
Table A22. Comparing differences in EQ-5D dimension scores across ALS clinical stage using MLE regression 
*  p < ·05 
** p < ·01 
 





Figure A1. LocusZoom Manhattan plot of imputed SNPs in and around PLCD1 for the 
international dataset. The heat scale represents linkage disequilibrium. Bonferroni-correction 
alpha value was at 2.82x10-5. 
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Figure A2: GWAS of All Cases (599) vs. Controls (4136). Red line is genome correction threshold 
(5 x 10-8) and blue line is bonferroni threshold (1.13 x 10-7). 
 
Figure A3. GWAS of mutation cases removed (560) vs. controls (4136). Red line is genome 
correction threshold (5 x 10-8) and blue line is bonferroni threshold (1.13 x 10-7). 
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Figure A4. Q-Q Plot for GWAS comparing non-repeat mutation cases (560) vs. controls (4136) 
 
 
Figure A5. Manhattan plot of GWAS comparing repeat mutation cases (39) vs. controls (4136). 
Red line is genome correction threshold (5 x 10-8) and blue line is bonferroni threshold (1.13 x 10-
7). 
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Figure A6. Q-Q Plot for GWAS comparing repeat mutation cases (39) vs. controls (4136) (λGC of 
1.02). 
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79-SNP Mutation-Specific Haplotype 11-SNP Residual Haplotype 
Haplotype association analysis of mutation cases 
(39) vs. controls (1182): χ² = 64.62; p = 9.08 x 10-
14 
Haplotype association analysis of non- 
mutation cases (560) vs. controls (1182): 
χ² = 15.58; p = 7.90 x 10-5 
Figure A7. 79-SNP haplotype for cases with the pathological expansion (left) and an 11-SNP 
haplotype for those without (right).  
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Figure A8. Relative frequency of non-mutation cases and controls by the largest repeat length 
 
Figure A9. Relative frequency of non-repeat mutation cases (n = 239) and controls (n = 357) by 
repeat length as an additive model 
 
 
Figure A10. AFLP of example case showing homozygosity for five repeats 
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Data Analysis Appendix 
Chapter 3 
 
The Kruskal-Wallis test was used to examine the effect of mutation status on site of symptom 
onset. Age of symptom onset and the effect of onset location on age of onset were examined 
under one-way ANOVA, with Welch’s F correction for lack of homogeneity.  
Clinical information was available for 581 cases (Table S1). There was no effect of mutation status 
on site of onset or on age of onset. There was a significant effect of site of onset by age of onset 
(F = 8.642 (3), p < 0.001), consistent with previous studies.S1. 
 
Data Analysis D1. Patient Characteristic Analyses 
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Chapter 2 & 3 
 
--bfile example_file 
 --maf 0.002 
 --hwe 0.00001 
 --geno 0.05 




 --out  example_file_QC 
 --noweb 
 
Script A1. Typical Plink script for quality control. 
 
 
This protocol is based on the ENIGMA imputation protocol 
http://enigma.loni.ucla.edu/protocols/genetics-protocols/) and has been modified by Dr Caroline 
Johnston, a bioinformatician at the Institute of Psychiatry, and myself. 
 
Step 1. Download extra files for crossover: 
  wget "http://enigma.loni.ucla.edu/wp-
content/uploads/2012/04/v2.20101123.ENIGMA2.EUR.autosomes.vcf.tgz" 
  wget "http://enigma.loni.ucla.edu/wp-
content/uploads/2012/04/v2.20101123.ENIGMA2.EUR.autosomes.extras.tgz" 
  tar -xvzf v2.20101123.ENIGMA2.EUR.autosomes.vcf.tgz 
  tar -xvzf v2.20101123.ENIGMA2.EUR.autosomes.extras.tgz 
  gzip -d 1kgp.*.gz 
 
Step 2. Data Quality Control 
This steps removes strand ambiguous SNPs, controls for low minor allele frequency, 
missingness, HWE, and SNP duplications. 
 
  awk '{ if (($5=="T" && $6=="A")||($5=="A" && $6=="T")||($5=="C" && $6=="G")||($5=="G" && 
$6=="C")) print $2, "ambig" ; else print $2 ;}' Test.bim | grep ambig > ambig.list 
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  plink --bfile Test --exclude ambig.list --make-founders --out lastQC --maf 0.01 --geno 0.05 --mind 
0.05 --hwe 0.000001 --make-bed --noweb 
  plink --bfile lastQC --exclude duplicated.list --make-bed --noweb --make-founders --out lastQC2 
--maf 0.01 --geno 0.05 --mind 0.05 --hwe 0.000001 
 
 
Step 3. Shift pedigree file to NCBI build 37 and flip strand 
This step updates the pedigree file to NCBI build 37 and flips strand ready for the 1000 genomes 
reference panel 
 
  awk '{print $2,$1,$3,$4,$5,$6}' lastQC.bim > tempQC.bim 
  awk 'NR==FNR{s=$1;a[s]=$0;next} a[$1]{print $0 " "a[$1]}' tempQC.bim 1kgp.alleles > 
merged.alleles 
  awk '{ if ($2!=$8 && $2!=$9) print $1}' merged.alleles > flip.list 
  plink --bfile lastQC --extract 1kgp.snps --update-map 1kgp.chr --update-chr --flip flip.list --make-
bed --out temp --noweb 
  plink --bfile temp --update-map 1kgp.bp --make-bed --out lastQCb37 --noweb 
  
Step 4. Calculating how many SNPs have been lost by the leftover 
  wc -l lastQCb37.bim 
  # 475120 lastQCb37.bim 
  wc -l Test.bim 
  # 488434 Test.bim 
 
Step 5. Reformat the dat files 
Recode QC’d pedigree file by –recode. 
awk '{ print "M", $1 ":" $4}' lastQCb37.map > ready4mach.dat 
I will replace the first column with the SNPs from original map file; this will mean the output will 
correspond with rs numbers rather than a Variant Call Format (VCF).  
To remove the phenotype column (incompatible with MACH and minimac imputation): 
awk '{$6=""; print $0}' lastQCb37.ped | sed 's/\ \ /\ /' > ready4mach.ped 
 
 
Step 6. Phasing 
mach1 -d  lastQCb37.dat.gz –p lastQCb37.ped.gz –prefix lastQCb37 –rounds 20 –states –phase 
–sample 5 > lastQCb37.mach.log 
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Step 7. Imputation using MACH (good for GenGen and Plink) or minimac (faster imputation, 
mach2dat and ProbABEL) 
Using MACH: 
awk '{ if ($1 == "M") print $2; }' < lastQCb37.dat > lastQCb37.snps 
mach1 -d lastQCb37.dat -p lastQCb37.ped -s lastQCb37.snps -h lastQCb37.hap --crossover 
lastQCb37.rec --errormap lastQCb37.erate --autoFlip --greedy --mle --mldetails --prefix 
imputation > imputation.log 
 
Using Minimac: 
minimac --vcfReference --rounds 5 --states 200 --refHaps 
chr9.phase1_release_v3.20101123.snps_indels_svs.genotypes.refpanel.ALL.vcf –haps 
lastQCb37 –snps lastQCb37.snps –autoClip lastQCb37.dat –prefix lastQCb37_imputed > 
lastQCb37_minimac.log 
 
 Optional Step 8: GenGen 
sed -n '/rs_example_SNP1/,/ rs_example_SNP2/p' chr_example.legend > 
chr_example_out.legend  
/.../convert_mach.pl lastQCb37.mlgeno lastQCb37.mlinfo lastQCb37 -legend 
chr_example_out.legend --chr example -ped ready4mach.ped -prefix imputed_gengen 
Update disease status using Plink, as it would have been set to none (-9).  
 
Script A2. Imputation and GenGen protocol using 1000 genomes. 
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Step 1. Create Convertf parameter file  
genotypename: example.ped 
snpname:  example.map         
indivname:       example.ped 
outputformat:    EIGENSTRAT 
genotypeoutname: example.eigenstratgeno 
snpoutname:      example.snp 
indivoutname:    example.ind 
familynames:     NO 
 
Step 2. Convert Pedigree files for Eigenstrat 
$parfile="par.PED.EIGENSTRAT"; 
system("/.../eigensoft_3.0/bin/convertf -p par.EIGENSTRAT.PED") 
 













Step 4. Eigenstrat 
/.../bin/eigenstrat -i example.eigenstratgeno -j example.pheno -p example.pca -l 10 –o 
eigenstrat_out  
 
Script A3. Smart PCA and Eigenstrat scripts for identifying sub-population structure 
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--bfile example_file 
 --covariates eigenstrat_out 
 --maf 0.002 
 --hwe 0.00001 
 --geno 0.05 




 --out  example_file_logistic 
 --noweb 
 
Script A4. Example Plink analysis comparing allele frequency between cases and controls using 
logistic regression, with quality control measures. 
 
 
plink --file example --hap-assoc --hap-window 
2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,3
5,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50 --out windows_out --noweb  
 
plink plink –bfile example -hap-snps 
rs2239194,rs3184504,rs739496,rs10849949,rs2073950,rs2301621,rs10774625,rs6490162,rs6
28825,rs630512,rs16941541,rs616513,rs12369009 --chap --out chap_out --noweb 
 
Script A5. Example Plink analysis for sliding window analyses and haplotype association test 
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Convert Illumina to Sanger 
maq ill2sanger INPUT.illumina.fastq OUTPUT.sanger.fastq 
 
Alignment to reference transcriptome using TopHat 
/.../bin/tophat -F 0.10 -a 5 -p 1 -o /.../output/ sequence.fastq 
 
Sort bam and index file 
/.../bin/samtools sort accepted_hits.bam sorted.bam 
 
/.../samtools index sorted.bam 
 
Add header to bam file, convert to SAM file, and isolate region of interest 
/.../samtools view -b –S -h –o chr8_sort.bam sort.bam chr8:27,502,505-27,533,066 
 
Identify SNPs and Indels  using SAMtools, bcf and vcf tools, or GATK 
/.../samtools mpileup -ugf /.../bowtie/indexes/hg18.fa chr8_sort.bam > rawhits.bcf 





java -Xmx4g -jar /.../GenomeAnalysisTK.jar -R /.../bowtie/indexes/hg18.fa fa -T UnifiedGenotyper 
-I chr8_sort.bam > GATK.vcf -D /.../dbsnp_129_hg18.rod -stand_call_conf 30.0 -stand_emit_conf 
10.0 -dcov 50 --platform SOLEXA 
 
Estimate and test for differential expression comparing it to reference transcriptome 
cufflinks -b /.../bowtie/indexes/hg18.fa chr8_sort.bam -o /.../cufflinks/ 
 
cuffcompare transcripts.gtf -r reference_genome/hg18.UCSCknowngene.isoforms.gtf -o 
/.../cuffcompare/ 
 
Using MISO to identify alternative transcripts 
python run_miso.py --summarize-samples SE/control/ SE/control/ 
 
Using SpliceMap to identify novel spice junctions 
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/.../runSpliceMap /.../run.cfg 
 





# This cofiguration file contains all settings for a run 
# of SpliceMap. 
# 
# lines begining with '#' are comments 











# Directory of the chromosome files in FASTA format 
# Each chromosome should be in a separate file (can be concatenated) 
# ie. chr1.fa, chr2.fa, ... 
# (single value) 
 
genome_dir = /scratch/project/groupammar/Ash/SpliceMap/ChromosomesHG18/ 
 
## 
# These are the two lists of sequencer reads files.  
# "reads_list2" can be commeted out if reads are not paired-end. 
# Make sure the order of both lists are the same! 
# Also, "reads_list1" must be the first pair.  
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# Note: pair-reads should be in the "forward-reverse" format.  












# Format of the sequencer reads, also make sure reads are  
# not split over multiple lines. 
# Choices are: FASTA, FASTQ, RAW 
# (single value) 
 
read_format = FASTQ 
 
## 
# Format of the quality string if FASTQ is used 
# Choices are:  
#   phred-33 -- Phred base 33 (same as Sanger format) [default] 
#   phred-64 -- Phred base 64 (same as Illumina 1.3+) 
#   solexa   -- Format used by solexa machines 
# (single value) 
 
 




# The short reads mapper used 
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# choices are "bowtie", "eland" or "seqmap" 
# Bowtie is recommended 
# this can be commented out if the mapping has already been done and the  
# appropriate ".t" files exist in the temp directory [advanced].  
# (single value) 
 










# these are annotations used to find novel junctions, in ref or bed format.  
# (optional) 
# (single value) 
 
annotations = /scratch/project/groupammar/Ash/SpliceMapExample/all.gene.refFlat.txt 
 
## 
# Directory name of the directory that stores temporary files 
# (optional) Default = temp 
# (single value) 
 




# Directory name of the directory that stores the output files 
# (optional) Default = output 
# (single value) 
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# Maximum intron size, this is absolute 99th-percentile maximum. 
# Introns beyond this size will be ignored.  
# (optional) If you don't set this, we will assume a mamalian genome (400,000) 
# (single value) 
 





# 25-th intron size, this is the lower 25th-percentile intron size 
# This is not the smallest size that SpliceMap will search. That is about ~25bp.  
# (optional) If you don't set this, we will assume a mammalian genome (20,000) 
# (single value) 
 




# Maximum number of multi-hits 
# If a 25-mer seed has more than this many multi-hits, it will be discarded. 
# (optional) Default is 10 
# (single value) 
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## 
# Full read length 
# SpliceMap will only use the first "full_read_length" bp for mapping. 
# If the read is shorter than "full_read_length", the full read will be used before head clip.  
# If you comment this out SpliceMap will use as many as possible. 
# This is for the case where the reads might have N's at the end.  
# It is always desireable to cut off the N's 
# (optional) 
# (single value) 
 





# Number of bases to clip off the head of the read 
# This clipping is applied after "full_read_length" 
# (optional) 
# (single value) 
 





# Number of mismatches allowed in half-seeding 
# Choices are 0,1(default) or 2 
# (optional) 
# (single value) 
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# Maximum number of mismatches allowed in entire read 
# No limit on value, however SpliceMap can only identify reads with 
# a maximum of 2 mismatches per 25bp.  
# Default is 2.  
# (optional) 
# (single value) 
 




# Maximum number of bases allowed to be soft clipped from the ends of reads during 
# alignment. This is required as mismatches near junctions could cause parts of a 
# a read to not map.  
# Default is 40. 
# (optional) 
# (single value) 
 






# Generate a SAM file 
# choices are 
#   "cuff" -- Generate Cufflinks compatible SAM file 
#   "sam"  -- Generate regular SAM file 
# 
# If this is commented out, no SAM file will be generated 
# (optional) 
# (single value) 
 
sam_file = cuff 




# Generate separate coverage for non-uniquely mappable reads 
# choices are 
#   "yes" -- Generate it [This requires 15G+ of memory for 23 million reads] 
#   "no"  -- don't generate it [default] 
# (optional) 
# (single value) 
 





# Name of the chromosome file with wildcards 
# If none is given the default of "chr*.fa" will be used [this is compatible with the UCSC genome 
files] 
# If your genome file is concatenated just type the file name here 
# (optional) 
# (single value) 
 
#chromosome_wildcard = chr*.fa 
 
## 
# Number of chromosomes to process at once, to take advantage of multi-core systems. 
# This is not threading, so it will take extra memory. However, running 2 at a time should be fine. 
# (optional) Default = 1 
# (single value)  
 








#  Bowtie specific options 











# Base of bowtie index, this should be the same genome as the 
# chromosome files 
# eg. if you bowtie files are "genome/hg18/genome.1.ewbt", É 
# then your base dir is "genome/hg18/genome" 
# (single value) 
 









# Number of threads to use for mapping (SpliceMap may use this option in future) 
# Default value is 2 
# (optional) 
# (single value) 
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# Try hard? 
# choices are "yes" or "no" 
# Default value is yes. (it is not much slower, about 15%) 
# I'm unsure if this is required, feel free to try with  
# this option off and let me know your results.  
# (optional) 
# (single value) 
try_hard = yes 
 
Script A6. Scripts used for RNA-seq analyses. 
  




Touchdown PCR protocol 
95°C   3min  
94°C   1min  
75°C    1min; decreasing temperature each cycle  ‐ 1°C"             
68°C   2min  
 
94°C 30sec  
56°C  30sec       
72°C  1min  
72°C   5min 
-10°C  END 
 
Protocol P1. Rutherford NJB, DeJesus- Hernandez MBS, Baker MCB, Kryston TBMS, Brown 
PEMS, Lomen-Hoerth CMDP, et al. C9ORF72 hexanucleotide repeat expansions in patients with 
ALS from the Coriell Cell Repository. Neurology. 2012;79(5):482-3. 
 
 
Cycle  x 25 time  
 
ycle x 25 ti es  
Cycle x 25 times 
